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Cellular senescence is a permanent proliferative arrest of cells triggered by 
several different stress mechanisms. Senescent cells display an inflammatory 
phenotype termed the senescence-associated secretory phenotype (SASP), 
being IL-1 signalling one of its key signalling pathways. Full-length IL-1b is 
cleaved into its mature active form by caspase-1, core enzymatic protein of a 
cytosolic platform called the canonical inflammasome. In contrast, caspase-4, 
central to the non-canonical inflammasome by analogy, can not cleave IL-1b 
although it can regulate canonical inflammasome activity. Moreover, research 
findings in recent years have revealed that inflammatory caspases (i. e. caspase-
1 and caspase-4) are key mediators of a type of inflammatory cell death called 
pyroptosis. Although caspase-1 and 4 are crucial in inflammatory responses, the 
function of inflammatory caspases in senescence remained poorly studied. 
Thus, this research thesis was conducted to investigate the role of inflammatory 
caspases in oncogene-induced senescence (OIS). Caspase-4 expression was 
observed to be increased in RASG12V-induced senescence in human primary 
IMR90 fibroblasts. Depletion of caspase-4 in this model of OIS impacted on the 
inflammatory signature (including reduced expression of SASP members and 
regulation of IL-1b) as well as a partial bypass of the proliferation arrest. 
Activation of caspase-4 by intracellular lipopolysaccharide (LPS) induced not 
only cell death by pyroptosis but also a senescence phenotype in the fraction of 
cells surviving cell death. Finally, a protein-protein interaction study by a 
proximity biotinylation approach followed by mass spectrometry analysis was 
conducted to unravel potential interactors of inflammatory caspases in OIS. In 








In case of a threat, the cells in our body can detect the danger and respond to it. 
For example, if a protein that can eventually lead to an oncogenic process 
activates, the cell is able to detect this event and activate a state of proliferative 
arrest called senescence that prevents further cell division. Senescence is not a 
unique response in cancer, but it also happens in many other contexts such as 
age-related diseases or developmental processes. Because senescence cells are 
implicated in multiple pathological events, their targeting is appealing to 
therapeutic intervention, and understanding its fundamental molecular 
processes might help identify novel clinical targets. 
 
Senescent cells are distinctive from normal cells because, besides having 
stopped proliferating, they also exhibit inflammatory signals. These signals can 
have several different functions, some of which may be beneficial (such as 
promoting the neighbouring cells to become senescent) while others are 
detrimental (attracting immune system cells to kill and remove senescent cells) 
for senescence maintenance. Therefore, the senescence response as well as its 
derived inflammation is complex and needs of further investigation to be better 
understood. In this line, during my thesis I have studied a group of proteins 
called inflammatory caspases, that are involved in inflammatory processes. I 
have found a new role for these proteins in senescence in both the control of 
the production and secretion of inflammatory proteins as well as in the 
regulation of cell proliferation. As the inflammatory signature is a key feature of 
senescent cells, providing these new findings contributes to a better 
understanding of cellular senescence and may provide exploitable targets for 
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Chapter 1 - Introduction 
 
 
1.1 Cellular senescence 
 
1.1.1 Definition and general aspects 
 
Cellular senescence was first described by Leonard Hayflick in 1961, who observed that, 
after a certain number of passages in culture, human fibroblasts cease to divide thus 
entering a new non-proliferative state (1). Although the finding was not immediately 
accepted by the whole scientific community, the key importance of this restriction 
point, today called “Hayflick’s limit”, is now undeniable and has been thoroughly 
studied in many biology disciplines, from aging to cancer. 
 
Currently, cellular senescence is defined as “a state of permanent cell cycle arrest in 
response to different damaging stimuli” (2). Diverse senescence activation mechanisms 
exist, highlighting the complexity behind the acquisition of the senescence phenotype. 
These mechanisms are reviewed later in this chapter. 
 
The senescent phenotype is deeply heterogeneous and depends not only on the cause 
but also on the cellular and physiological context. Moreover, although there are some 
general phenotypical aspects which are commonly shared by most senescent cells, 
these are not exclusive of senescence (2, 3). Therefore, in the lack of a universal 
senescent marker, a combination of them is recommended to identify senescent cells 
(4). General aspects of senescent cells as well as some of the most widely used markers 









1.1.1.1 Morphological changes 
 
In vitro, senescent cells are enlarged, flat and have an altered shape compared to their 
proliferating counterparts (Figure 1.1). However, this morphology, which is easily 
observed in dish-cultured cells, is not discerned in vivo (5). 
 
1.1.1.2 Senescence-associated b-galactosidase activity 
 
In 1995, Dimri et al. described a protocol to detect b-galactosidase activity at pH 6.0 
that distinguished senescent cells from other phenotypes (6). The enhanced b-
galactosidase activity observed in senescent cells is the result of an increased lysosomal 
content (7). Despite the assay also detects non-senescent cells such as those undergoing 
cell contact inhibition due to excessive cellular confluence (8), senescence-associated 
b-galactosidase (SA-b-galactosidase) activity detection remains the most widely used 
senescence biomarker to date (5) (Figure 1.1). 
 
1.1.1.3 Cellular proliferation halt 
 
One of the hallmarks of senescence is cellular proliferation halt, which can be measured 
using various techniques, being two of the most popular the quantification of 5-bromo-
2-deoxyuridine (BrdU) incorporation and Ki-67 staining (9). Because BrdU is an 
analogue of thymidine, it is incorporated into newly synthesized DNA during the cell 
cycle S phase, thus BrdU labelling is used to identify proliferating cells (10) (Figure 1.1). 
Additionally, Ki-67 is an endogenous nuclear protein specifically expressed during 
mitosis (11). However, because both BrdU labelling and Ki-67 positive staining are 
proliferative markers, these assays also detect other non-proliferative states such as 
quiescence and therefore fail to be senescence-specific (12). In parallel, cell cycle arrest 
can also be monitored through the detection of increased levels of key cell cycle 
regulators such as p53, p21, p16 and p15, although, again, increased levels of these 
tumour suppressor genes are not indicators of cellular proliferation halt or senescence 






1.1.1.4 Nuclear changes 
 
Many changes occur in the nucleus of senescent cells. Senescence-associated 
heterochromatin foci (SAHF), which are dependent on the retinoblastoma protein 
(pRb) pathway, are chromatin rearrangements that result in dense aggregations visible 
upon 4ʹ,6-diamidino-2-phenylindole (DAPI) staining (14) (Figure 1.1). Another event 
that takes place is the reduction of the levels of lamin B1, a constituent protein of the 
nuclear lamina (15). These and other structural changes in the nucleus result in 
epigenetic remodelling and consequent modulation of gene expression (3). Additional 
nuclear alterations that senescent cells can present include an increased number and 
size of promyelocytic (PML) nuclear bodies (16, 17) and the emergence of DNA 
segments with chromatin alterations (DNA-scars) (18). 
 
1.1.1.5 The senescence-associated secretory phenotype 
 
The collective production and secretion of inflammatory cytokines, chemokines and 
other factors by senescent cells is known as the senescence-associated secretory 
phenotype (SASP) (19, 20). The SASP has a key regulator role in senescence and will be 
reviewed later. It is important to note that, because the transcriptional activation of 
some SASP-associated genes leads to a logarithmic increase of the mRNA and protein 
levels of these factors, their detection is also useful in the identification of senescent 
cells (21) (Figure 1.1). However, these factors can also be present in many other 
inflammatory contexts and, conversely, not all senescent cells present a SASP. For 
instance, overexpression of the key senescence cyclin regulators CDKN1A or CDKN2A 
induces cell cycle arrest without SASP expression (22). Nonetheless, the SASP is a 







Figure 1.1 Identifying senescent cells 
Because no universal senescence marker has been identified, a combination of techniques is 
used to detect senescent cells, some of which are shown in this figure. Proliferating (top) and 
oncogene-induced senescent (bottom) IMR90 human fibroblasts were stained to detect SA-b-
galactosidase activity (left). Note as well that a distinctive morphology can be observed in 
senescent cells: these are more enlarged and have lost the elongated shape of proliferating 
fibroblasts. Using immunofluorescence microscopy, it is also possible to detect BrdU 
incorporation (anti-BrdU (FITC); DAPI), SAHF formation (DAPI) and IL-1b production (anti-
IL-1b (FITC); DAPI), as shown in the figure from left to right. Arrows indicate SAHF. 
 
 
1.1.1.6 Resistance to apoptosis 
 
Resistance to apoptosis is a hallmark of senescent cells (23). Some stress inducers can 
trigger both apoptosis and senescence and, importantly, the mechanisms that 
determine which of these two responses is activated are not yet well understood (24). 
Nonetheless, senescent cells inhibit apoptosis through the upregulation of BCL-2 
proteins (25) and inhibition of this protein family triggers apoptosis in senescent cells 
(26); these findings have been of critical importance in the development of senolytic 
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Senescence is a metabolically highly active response. Increased AMP:ATP and 
ADP:ATP ratios due to augmented glycolysis in senescent cells are sensed by AMP-
activated protein kinase (AMPK) (27). Activation of AMPK contributes to cell cycle 
arrest through two described mechanisms: [1] phosphorylation of p53 (28) and [2] 
inhibition of Hu antigen R (HuR)-dependent degradation of p21 and p16-coding mRNAs 
(29). 
 
Importantly, mitochondrial mass is increased in senescent cells (30, 31) as a 
consequence of reduced mitophagy (32). Because mitochondria generate reactive 
oxygen species (ROS), accumulation of mitochondria has been linked to the increased 
levels of ROS found in senescent cells (33). In addition, mitochondrial dysfunction is 
commonly observed in senescent cells, independently of the triggering stimulus (33). 
Moreover, Correia-Melo et al. showed that depletion of mitochondria by E3 ligase 
Parkin-induced mitophagy prevents senescence, demonstrating the essential 
requirement of mitochondria for the induction and establishment of the senescent 
phenotype (34). 
 
Many studies link autophagy perturbation and senescence and, specifically, increased 
macroautophagy has been broadly described in senescent cells (27). Induction of 
autophagy and autophagy malfunctioning have been shown to promote a senescence 
response (35, 36). Nonetheless, loss of autophagy has also been described to act as a 
pro-senescence mechanism through stabilization of the levels of the transcription 
factor GATA4 (37). One proposed explanation for this opposite role of autophagy in 
senescence is that general autophagy might promote cellular senescence whereas 
selective autophagy may inhibit it (38). In addition, in a recent study, García-Prat et al. 
showed that an autophagy-dependent mechanism prevents senescence in muscle stem 
cells and, impairment of this mechanism results in mitochondrial dysfunction and 
cellular senescence (39). Autophagy and its crosstalk with mitochondrial metabolism 





Lipid content is also altered in cellular senescence. Because lipofuscin (fluorescent 
aggregates that contain lipids and highly oxidized proteins) accumulates in the 
cytoplasm of senescent cells (40), its detection is used to identify senescence by means 
of histochemical techniques such as Sudan Black B staining (41). Moreover, increased 
ROS can react with membrane lipids causing lipid peroxidation and the generation of 
free radical secondary messengers. Consequently, elevated lipid peroxidation and 
altered fatty acid catabolism result in metabolic alterations and changes in the lipid 
profile of senescent cells (42). In particular, ceramide levels are deregulated in 
senescent cells (43). Interestingly, a lipidomic study showed that the metabolic 




1.1.2 Types of cellular senescence 
 
The criteria used to distinguish between senescent phenotypes focuses on the origin, 




Figure 1.2 Schematic representation of several inducers of senescence 





1.1.2.1 Replicative senescence 
 
Cellular senescence as firstly described by Leonard Hayflick is nowadays termed 
replicative senescence and its cause is not strictly the passage of time but the number 
of rounds of DNA replication that have taken place (45). 
 
Telomeres are short DNA repeats found at the end of chromosomes that shorten at 
each DNA replication round. Historically, although telomeres were described as early 
as in the 1940s (46), it was not until the late 1980s that scientists observed different 
telomere lengths among different cell types (47) and shorter telomere lengths in 
senescent cells (48). Finally, in 1998, Bodnar et al. ectopically expressed telomerase (the 
enzyme responsible for telomere maintenance) in telomerase-deficient cell lines; as a 
consequence, telomerase-expressing cells continued to proliferate while the control 
telomerase-deficient cells underwent senescence, proving that telomere shortening is 
the main event leading to replicative senescence (49). Mechanistically, telomere 
uncapping activates the DNA damage response (DDR) which in turn promotes 
senescence induction. 
 
1.1.2.2 Genotoxic stress-induced senescence 
 
Damaged DNA in non-telomeric sites can also lead to a senescence response (50). 
Unrepaired DNA breaks caused by gamma radiation induce a potent senescence 
response (51). Non-ionizing radiation, such as ultraviolet (UV) rays, can also activate 
cellular senescence (52).  
 
Small molecule compounds including chemotherapy drugs such as etoposide (a DNA 
topoisomerase inhibitor), bleomycin (a DNA break inducer) or cisplatin (a DNA 
alkylating agent) also inflict DNA damage-induced senescence (53). Of note, many 
DNA damaging agents trigger an apoptotic response at high doses but the induction of 







1.1.2.3 Oxidative stress-induced senescence 
 
Reactive oxygen species (ROS) can trigger a senescence response by causing DNA 
damage (54, 55). ROS have also been shown to play a role in the establishment and 
maintenance of DNA damage-induced senescence through a p21-mediated positive 
feedback loop (56). ROS production is also increased in replicative senescence (30) and 
oncogene-induced senescence (OIS) (31, 57). Although addition of antioxidants has 
been shown to delay or prevent senescence onset in some contexts (57-59), the 
mechanisms of ROS as initiators and effectors of senescence programs remain to be 
further investigated (4, 60). In vitro, sublethal hydrogen peroxide (H2O2) treatment is 
widely used to induce senescence by oxidative stress (61).  
 
1.1.2.4 Oncogene-induced senescence 
 
Activation of more than 50 oncogenes can lead to a senescence response, known as 
oncogene-induced senescence (OIS) (62). The first observation of OIS was described 
by Serrano et al. after expression of oncogenic H-RASG12V in human fibroblasts (63). In 
contrast to replicative senescence, expression of telomerase does not hinder OIS (64). 
Genetic alterations leading to OIS include gain of function mutations (RAS, BRAF, 
AKT), gene amplification and gene overexpression (65). Activation of OIS prompts the 
engagement of different signalling pathways depending on the activated oncogene and 
cell type. Frequently, an initial hyper-replication phase induces DNA damage and 
increased ROS production that initiate positive feedback loops and will maintain OIS 
(5, 66, 67). Metabolic reprogramming also plays a key role in OIS; for instance, Kaplon 
et al. showed that activation of pyruvate dehydrogenase (PDH) by phosphorylation is 
indispensable for the development of OIS (68). Evidence for in vivo OIS has been widely 
reported (65). OIS has been proposed to be both a preventing and promoting 
mechanism of tumour progression (69).  
 
H-Ras, K-Ras and N-Ras are proto-oncogenic Ras proteins (a small family of GTPases) 
that have been used as prototypes in the study of the mechanisms triggered by OIS 
(70). Point mutations (generally located in amino acids 12, 13 or 61) in alleles of these 




oncogenic Ras proteins with enhanced guanosine triphosphate (GTP) binding affinity 
that alters the downstream signalling effector pathways (71, 72). Mechanistically, 
oncogenic Ras triggers senescence by activating the DNA damage response, leading to 
signalling transduction events through the p53/p21 axis, as well as activation of the 
INK4/ARF locus (73). In this thesis, overexpression of H-RASG12V in human fibroblasts 
is used as a model of OIS.  
 
Likewise, loss of a tumour suppressor can also induce senescence (62). In this context, 
the phosphatase and tensin homolog (PTEN) inactivation is the best characterized 
activation mechanism: loss of the tumour suppressor PTEN induces a cellular 
senescence response in vivo through activation of PI3K/Akt/mTOR signalling (74, 75). 
 
1.1.2.5 Mitochondrial dysfunction-associated senescence 
 
Recently, a distinct senescence response due to mitochondrial dysfunction, and 
thereby termed mitochondrial dysfunction-associated senescence (MiDAS), was 
described (76). In contrast to other senescent phenotypes, cells undergoing MiDAS 
display a mild SASP with no activation of IL-1 signalling. The authors also described 
that the mechanism behind MiDAS activation is independent of ROS and DNA damage 
and relies on a NAD-AMPK-p53-dependent signalling pathway. 
 
1.1.2.6 Paracrine senescence 
 
The soluble factors secreted by senescent cells can reinforce senescence in an autocrine 
manner by promoting positive feedback-loops. Mechanistically, autocrine senescence 
has been proved by showing no cellular growth arrest upon inhibition of IL-6R, IGFBP7 
or CXCR2 (77-79). Moreover, a senescent cell can also induce senescence in a neighbour 
non-senescent cell: a phenomenon known as paracrine senescence. The SASP mediates 
non-cell autonomous senescence through transforming growth factor-β (TGF-β) and 
IL-1 signalling (80, 81). Besides the SASP, senescent cells interact with surrounding cells 
in other ways including NOTCH signalling (82), production of ROS (83), cytoplasmic 





1.1.3 The signalling pathways behind cellular senescence 
 
Cellular senescence entails a highly complex and dynamic network of interacting 
molecular pathways. Next, key signalling pathways and their roles in cellular 
senescence are summarized. 
 
1.1.3.1 The DNA damage response 
 
When the DDR is activated, DNA damage sensor proteins at DNA damage foci recruit 
the Ataxia-telangiectasia-mutated (ATM) and ataxia telangiectasia and Rad3-related 
(ATR) kinases. ATM and ATR then phosphorylate the downstream signalling 
checkpoint kinases 1 (CHK1) and 2 (CHK2) causing [1] inhibition of CDC25 
phosphatases and [2] p53 phosphorylation and stabilization; thus limiting cellular 
proliferation (86) (Figure 1.3). The DDR does not only induce senescence; besides cell 
cycle arrest, it can also activate other programs, such as those related to DNA repair or 
apoptosis, depending on the context (87).  
 
1.1.3.2 p53 and p21 
 
The tumour suppressor p53 is also stabilized in senescence by ARF (encoded in the 
INK4/ARF locus); ARF inhibits MDM2, a p53-degrading protein (88, 89). P53 
stabilization results in increased expression of its downstream effector, the cyclin-
dependent kinase interacting protein (CIP) p21, also known as p21 or p21CIP (90) (Figure 
1.3). P21 is a cyclin-dependent kinase inhibitor (CDKI). In addition to p53-dependent 
signalling, p21 can be regulated in senescence by other transcriptional, post-
transcriptional and post-translational mechanisms including RNA binding proteins, 
binding of miRNAs, phosphorylation and proteosomal degradation (2). 
  
1.1.3.3 INK4/ARF locus 
 
The INK4/ARF locus contains the tumour suppressors genes CDKN2A and CDKN2B. 
CDKN2A encodes two transcripts which are translated into the functionally different 




encodes p15 (also known as p15INK4b) (88). In senescence, the loss of Polycomb-mediated 
silencing mechanisms in this locus leads to increased expression of its encoded genes 
(24). Functionally, ARF stabilizes p53 (as explained previously) whereas p16 and p15 are 
CDKIs (Figure 1.3). It has been suggested that p16 activation may be key for the 




Figure 1.3 Key signalling pathways controlling cell cycle arrest in senescence 
DNA damage sensing activates p53 and its downstream cell cycle regulator p21. Epigenetic 
remodelling of the INK4/ARF locus facilitates the transcription of its encoded genes. Both 
p53/p21 and p16 pathways converge in preventing pRb phosphorylation by inhibiting the 
formation of CDK-cyclin complexes. Consequently, hypophosphorylated pRb sequesters the 
transcription factor E2F and inhibits the transcription of its target genes, which are necessary 






1.1.3.4 Regulation of pRb phosphorylation and E2F targets expression 
 
CDKIs play a key role in senescence by inhibiting the formation of CDK-cyclin 
complexes. P21 inhibits the activity of CDK2-cyclin E complexes whereas p15 and p16 
inhibit the formation of CDk4/CDK6-cyclin D complexes (92). In proliferating cells, 
these complexes phosphorylate pRb which dissociates from the transcription factor 
E2F, allowing the transcriptional activation of essential genes for proliferation. In 
senescent cells, hypophosphorylated pRb prevents E2F from activating the expression 
of its target genes, thus halting cell cycle progression (5) (Figure 1.3). 
 
1.1.3.5 The senescence-associated secretory phenotype (SASP) 
 
The production and secretion from senescent cells of a myriad of soluble and insoluble 
factors, including cytokines (IL-1a, IL-1b, IL-6), chemokines (IL-8, GROa), proteases 
(MMP-1, MMP-3) and growth factors, is known as the SASP (19, 20, 93). The 
composition of the SASP and its function depends on the senescence stimulus, cell 
type, genetic status and neighbouring environment; however, it frequently includes a 
potent subset of proinflammatory molecules (24). Classically proposed as a strictly 
downstream mechanism of the DDR (94, 95), the SASP can also be activated by DDR-
independent mechanisms, such as p38/MAPK signalling (96) and the cGAS/STING 
pathway (97-99) (Figure 1.4). 
 
During infection, trigger detection by innate immune receptors is key in inducing 
cellular inflammatory responses that include the activation of transcriptional 
proinflammatory programs. These pathways are also activated and play master roles 
during sterile inflammation. Recently, a noteworthy mechanistic connection between 
an innate immune sensor system and the SASP has been made: cytosolic chromatin 
fragments in senescent cells activate the cGAS-STING DNA sensing innate immune 
pathway which in turn controls the transcription of SASP factors (97-99). Because 
innate immunity is crucial in the interplay between danger sensing and the 
inflammatory response, it is tempting to speculate that other innate immune pathways 






Figure 1.4 Key SASP signalling events 
Stress inducers activate the p38/MAPK, DDR and cGAS/STING pathways, leading to the 
transcription of NF-kB and C/EBPb target genes. SASP genes, such as IL8, IL6, IL1A and IL1B, 
are translated into SASP factors which are secreted to the extracellular space. There, SASP 
factors reinforce autocrine senescence and promote paracrine senescence among other 
functions as described in the main text. 
 
 
Many functions have been attributed to the SASP (Figure 1.5), with beneficial or 
detrimental consequences depending on the (patho)physiological context. Some of 
these biological functions and effects are summarized below: 
 
1. Reinforcement of autocrine senescence  
In OIS, positive feedback loops mediated by IL-6R, IGFBP7 or the IL-8 receptor 
CXCLR2 (77-79) have been shown to control cell cycle arrest in an autocrine 
fashion. Moreover, senescence-associated IL-6 and IL-8, which reinforce 
senescence through positive feedback loops that sustain NF-kB and C/EBPb-
dependent transcriptional activation, are upstream regulated by cell-surface bound 
IL-1a (100). 
 
2. Paracrine senescence 
Secreted SASP factors can induce senescence in surrounding non-senescent cells 
through the TGF-b and IL-1 signalling pathways (80, 81). Whereas TGF-b mainly 



















regulates paracrine senescence (through the induction of the NADPH-oxidase 
NOX4 in neighbouring cells), IL-1 signalling controls both autocrine and paracrine 
senescence. 
 
3. Promotion of tumorigenesis 
In contrast to the two above mentioned functions, paradoxically, the SASP can also 
promote cellular proliferation of surrounding cells, tumour growth, epithelial-to-
mesenchymal transition and invasion in tumorigenic contexts (19, 101-104).  
 
4. Recruitment of immune cells 
SASP-mediated recruitment of innate (NK cells, macrophages) and adaptive (T 
cells) immune cells contributes to beneficial tumour immunosurveillance as shown 
in in vivo studies (105-107). However, adverse tumorigenic effects of SASP-recruited 
immunosuppressive myeloid cells have also been recently described (108-110). 
 
5. Promotion of angiogenesis 
Senescent conditioned medium containing the SASP vascular endothelial growth 
factor (VEGF) stimulates the proliferation and invasion of endothelial cells (111). In 
a pathological context, detrimental SASP-induced neovascularization has been 
described in tumorigenesis as well as in retinopathy (112, 113). 
 
6. Tissue homeostasis 
SASP factors acutely secreted by senescent fibroblasts, such as CCN1 or PGDF-AA, 
remodel the extracellular matrix during optimal wound healing (114, 115). The SASP 
is also implicated in restricting fibrotic responses (116, 117). In addition, IL-6 
signalling from senescent cells facilitates in vivo cellular reprogramming after tissue 
damage (118). Moreover, acute SASP production may also contribute to tissue 
regeneration by promoting stemness (119). Nonetheless, remodelling of the 
extracellular matrix by secreted matrix metalloproteinases (MMPs) can also have 
deleterious effects in age-related diseases (120, 121). 
 
7. Chronic inflammation 
The SASP has been associated with low-level inflammation accumulating in aged 
tissues, a phenomenon also known as inflammaging (122). However, the specific 
contribution of the SASP to the detrimental effects of increased senescence in aged 






Figure 1.5 Functions and effects of the SASP 
The SASP can exert a plethora of distinct functions and effects. Green and red arrows symbolize 
functions for which mainly beneficial or detrimental effects have been suggested, respectively. 
A yellow arrow is used when both positive and negative consequences have been proposed. 
 
 
Because of its many potential roles, the SASP is tightly controlled. Activation of the 
transcription factors NF-kB and CCAAT/enhancer-binding protein-β (C/EBPb) boosts 
the transcription of SASP factors (78, 123). Epigenetic mechanisms such as fading of 
repressive marks, chromatin rearrangements and histone variants also regulate the 
transcription of SASP factors (2). Moreover, a recent study has shown a regulatory 
mechanism involving alternative splicing: the splicing factor PTBP1 is necessary for 
exon skipping during pre-mRNA processing of key genes involved in intracellular 
trafficking, one of which, the Exocyst complex component 7 (EXOC7), controls a 
particular subset of proinflammatory cytokines of the SASP (124). At the post-
transcriptional level, the mechanistic target of rapamycin (mTOR) controls the 
translation of SASP factors (125-127).   
 
Importantly, post-translational mechanisms also maintain, tune and amplify the 
inflammatory signalling. IL-1 signalling is a master regulator of the SASP: IL-1a 
depletion reduces NF-kB and C/EBPb activity (100) whereas blockage of the 




processing, blunts the SASP (80). Moreover, dynamic NOTCH1 activity can act as a 
switching mechanism between a TGF-b secretome in earlier stages of senescence and a 
subsequent C/EBPb-mediated SASP (82). Release to the extracellular space of some 
SASP factors depends on effective intracellular trafficking by specific proteins, such as 
the sheddase ADAM17 (128, 129), as well as exosome secretion (85, 130). In all, the 




1.1.4 Pathophysiology of cellular senescence 
 
Occurring cellular senescence has been described in a wide variety of physiological 
contexts, from embryonic development to disease (5). In particular, the role of cellular 
senescence has been and still is widely studied in cancer, ageing and age-related 
diseases, including cardiovascular diseases, metabolic diseases (such as type 2 diabetes) 
and other diseases that resemble or are linked to premature aging (chronic obstructive 
pulmonary disease (COPD), progeria). This subheading includes a summary of the key 
findings and current developments in cancer and ageing. 
 
1.1.4.1 The dual role of senescence in cancer 
 
Detection of senescence in pre-malignant human and mice tumours but not in their 
corresponding more advanced stages suggested a tumour suppressor role for 
senescence in cancer (74, 131-134). Genetic suppression of modulators of senescence 
concomitant to an oncogenic stress enhances tumour malignancy and accelerates 
progression, confirming a tumour suppressor role for senescence (74, 134). 
Mechanistically, activation of key tumour suppressors (such as p53 or 16) due to 
increased oncogenic signalling leads to the activation of a senescence response and 
consequent proliferation arrest (131). Mutations in these tumour suppressor genes, a 
common event in progressing human malignant tumours, block senescence-induced 
cell cycle arrest in favour of tumour progression (135). Noteworthy, reactivation of p53 
in some mouse models of in vivo tumorigenesis leads to tumour regression and/or 




apoptotic and senescent responses, its role as a tumour suppressor depends on its 
ability to prevent cellular proliferation rather than its apoptotic function (137). The 
SASP also promotes anti-tumorigenic proliferation arrest by reinforcing autocrine 
senescence and promoting paracrine senescence (77-79). 
 
Besides its intrinsic ability to halt proliferation, senescence can also exert a protective 
role in cancer by triggering the immune response through the SASP (138). Xue et al. 
described for the first time clearance of tumour senescent cells by recruitment of innate 
immune cells (neutrophils, macrophages and NK cells) to established H-RASG12V liver 
carcinomas (105). In mice with an intact adaptive immune system, this beneficial 
immunosurveillance program was conducted by CD4+ T lymphocytes and macrophages 
recruited to N-RASG12V pre-malignant senescent hepatocytes (106). SASP-mediated 
immunosurveillance, which results in the clearance of cells in the tumour 
microenvironment to limit tumorigenic progression, has thenceforth been confirmed 
in a number of in vivo studies (107). 
 
Despite abundant literature supporting a tumour suppressor role for senescence, there 
is also evidence that senescence can promote tumorigenesis (139). Indeed, several 
studies indicate that the SASP promotes cancerous invasiveness (94, 101), angiogenesis 
(111) and cellular proliferation (140), growth (103, 141) and dedifferentiation (102). 
Moreover, SASP-mediated recruitment of an immunosuppressive set of myeloid 
immune cells can cause an immunotolerant tumour environment that promotes 
tumour growth (108-110). In this scenario, one proposed hypothesis is that the SASP 
might prevent tumorigenesis in a p53-intact context but promote malignancy if p53 
signalling is impaired, i.e., the SASP might be protective in pre-malignant lesions but 
pro-tumorigenic in advanced tumours (110, 138, 142). 
 
In summary, the beneficial or detrimental role of senescence in cancer and, in 
particular, of the SASP, varies depending on the tissue, state of progression, immune 
landscape, genetic alterations and other characteristics of the tumour. Hence potential 
interventions exploiting/inhibiting senescence or/and the SASP are under investigation 





1.1.4.2 Ageing and age-related pathologies 
 
Accumulation of senescent cells during ageing, either by an accelerated increase in 
their presence or by malfunctioning of their clearance mechanisms, has been linked to 
organismal tissue decline (143, 144). Several senescent markers are progressively 
detected at higher levels in some aged tissues (145); among these, p16 has received much 
attention (146). In particular, a key study using an in vivo mouse model of progeria, a 
disease that mimics accelerated aging, showed that selective depletion of p16-
expressing cells ameliorates some ageing–related disorders of the phenotype (147). The 
authors used the same smart genetic approach, a drug-inducible apoptotic fusion 
protein under the p16 promoter, to later validate the beneficial effects of killing p16-
expressings cells during natural ageing in mice (148).  
 
Not all studies link senescence in ageing to detrimental effects. In fact, some studies 
show that increased levels of some tumour-suppressor genes can be protective during 
ageing and enhance lifespan (149, 150). A suggested explanation to our current 
knowledge is based on the concept of “antagonistic pleiotropy” (151): the acute presence 
of senescent cells promotes beneficial tissue homeostasis whereas chronic, persistent 
senescence weakens the tissue and increases its vulnerability to age-related disorders 
(144). 
 
Aged tissues present increased chronic low-inflammation levels, a circumstance that 
has been named inflammaging and is majorly linked with deleterious effects (122). It is 
thought that, because of its nature, the SASP may be key to inflammaging. Indeed, 
clearance of senescence cells in some aged tissues reduces inflammation (121, 148, 152). 
Moreover, some of the SASP factors have been functionally associated with age-related 
disorders (146) and targeted clearance of high-SASP senescent cells ameliorates kidney 
function in a fast-aging mice model (152). Inhibition of mTOR, which can promote the 
mRNA translation of many SASP factors, increases lifespan in mice (153). However, how 







1.1.4.3 Therapeutic implications of cellular senescence 
 
Because senescence can have beneficial and detrimental effects depending on the 
context, both pro-senescence and anti-senescence therapeutic approaches haven been 
explored. 
 
On the subject of pro-senescence strategical approaches, the term therapy-induced 
senescence (TIS) was coined to refer to the use of chemotherapeutical drugs to induce 
senescence and promote its potential beneficial tumour suppressor effect in cancer 
targeting (73, 154). For example, the FDA-approved drug for breast cancer treatment 
palbociclib induces senescence by inhibiting CDK4/CDK6 (155-157). Not all studies 
convey in the idea that promoting cellular senescence prevents tumour progression; in 
fact, although the SASP has been shown to enhance tumour chemosensitivity (158), 
senescence has also been associated with worse clinical outcome after chemotherapy, 
including increased tumour relapse (159, 160). 
 
On the other hand, two anti-senescence therapeutic approaches have been taken: [1] to 
attack a particular aspect of senescent cells (such as the SASP) and [2] to deplete 
senescent cells. Noteworthy, the recent advances in the development of senolytics have 
been of great importance for the later strategy. 
 
Although selective depletion of the SASP has been proposed as a mechanism to inhibit 
particular negative effects in some contexts such as ageing and OIS (161), targeting the 
SASP remains complex because of its numerous functions and therefore potential off-
target effects (162). To limit the later, specific SASP inhibitors that target particular 
SASP subsets have been investigated (163). For instance, rapamycin, an mTOR 
inhibitor, is a potent suppressor of the IL-1 arm (125, 126). Other evaluated SASP-
targeted strategies include NF-KB inhibitors, including glucocorticoids and metformin 
(164, 165), as well as the use of specific antibodies targeting selected secreted factors 
such as IL-6 (166). Nevertheless, a better understanding of the regulation and functions 
of the SASP is necessary for the identification of novel targets and development of 





As earlier mentioned, resistance to apoptosis is a hallmark of senescent cells. This 
apparent obstacle for their elimination has turned out to be its “Achilles’ Heel” as a 
number of compounds targeting the upregulated anti-apoptotic pathways have proven 
to specifically eliminate senescent cells (26, 167). Among these senolytic drugs, BCL-2 
family inhibitors have shown promising results both in vitro and in vivo in age-related 
disorders (167, 168). Treatment with senolytics can also inhibit tumour formation and 
metastatic spread (148, 159). In addition, to limit potential off-target effects, a combined 
strategy of chemotherapy followed by senolytics has been proposed (169, 170).  
Interestingly, a recent study has shown that senolytic strategies with already approved 
FDA-drugs can improve aging phenotypes in mice (171). Introducing a different 
targeted approach, Muñoz-Espín and colleagues showed that drugs with no preference 
for senescent cells could be specifically delivered to these cells by encapsulating the 
compounds with galacto-oligosaccharides; consequently, the content of these 
nanoparticles is distinctively released in senescent cells due to their increased 
lysosomal activity (172). In all, it is clear that numerous efforts are currently being made 



























1.2 Inflammatory caspases 
 
1.2.1 Caspase definition and general aspects 
 
To group the family of phylogenetically related proteins with endoprotease activity 
relying on [1] an own catalytic cysteine residue and [2] an aspartic acid residue on the 
substrate’s cleavage motif, the term caspase, i.e. cysteine-dependant aspartate-directed 
protease, was proposed in 1996 (173).  
 
1.2.1.1 Classification and function of caspases 
 
Caspases are classically divided in two major groups: those related to inflammation 
(caspase-1, -4, -5, -11 and -12) and those related to apoptosis (caspase-2, -3, -6, -7, -8, -9 
and -10) (Table 1.1) (174-176). Apoptotic caspases are further subdivided into initiators, 
which interact with upstream molecules, or effectors, i.e. downstream of the initiator 
caspases. Among apoptotic initiator caspases, caspase-8 mediates the extrinsic pathway 
of apoptosis (due to extracellular perturbation sensing) whereas caspase-9 mediates the 
intrinsic pathway of apoptosis (due to extra or intracellular stress); both active caspase-
8 or caspase-9 can cleave and activate the effector caspases-3, 6 and 7 (177). Caspase-14 
does not belong to any of the aforementioned groups and has a unique role in 
keratinocyte differentiation (178). This simplistic classification clashes with the real 
functions of caspases as caspases from both groups have been described to be involved 
in processes initially only attributed to the other subgroup (179-182). 
 
In terms of structure, caspases have an N-terminal pro-domain, generally involved in 
binding with signalling molecules, and a C-terminal proteolytic domain, where the 
active site lies (i.e. the catalytic cysteine residue). All inflammatory and some initiator 
apoptotic caspases have a caspase activation and recruitment domain (CARD) within 
the pro-domain. Beyond caspases, other key inflammatory and apoptotic proteins bear 
a CARD domain; in fact, CARD-CARD domain interactions among caspases and with 
other adaptor proteins are an essential part of multimeric assembly and signal 
transduction (183). Caspases with no CARD domain have either a death effector domain 





Table 1.1 Classification of caspases 
Caspases classified according to their role and host. A schematic representation of each 




Originally, mammalian caspases were identified as proteases whose function depends 
on the ability to cleave themselves, other caspases or other substrates (184, 185). In fact, 
most caspases are synthetized as full-length zymogens, and are active after 
dimerization and/or self-cleavage by auto-processing or external cutting by other 
proteases (186, 187). Cleavage after the pro-domain and within the catalytic domain (in 
the inter-subunit linker) leads to the generation of shorter active caspase forms that, in 
general, correspond to a large subunit and a small subunit, also known as p20 and p10 
respectively due to their molecular sizes (188). These subunits frequently dimerize to 
Caspase Type Organism Structure
1 Inflammatory M, H
2 Apoptotic (Initiator) M, H
3 Apoptotic (Effector) M, H
4 Inflammatory H
5 Inflammatory H
6 Apoptotic (Effector) M, H
7 Apoptotic (Effector) M, H
8 Apoptotic (Initiator) M, H
9 Apoptotic (Initiator) M, H
10 Apoptotic (Initiator) H
11 Inflammatory M
12 Inflammatory M, H






form active catalytic tetramers (189). However, many studies challenge these general 
observations by evidencing that [1] not all caspase functions depend on their catalytic 
activity (190, 191) and [2] dimerization but not processing, i.e. self-cleavage, is essential 
for activation of non-executioner caspases (192-196). 
 
Nonetheless, catalytic activities remain the best well-defined caspase functions at the 
mechanistic level. On one hand, a highly conserved cysteine residue is found in the 
active site of all caspases (188). On the other hand, all their substrates contain a caspase 
cleavage amino acid sequence (P4-P3-P2-P1-P1’-P2’-P3’-P4’, where each P is an amino 
acid and the cleavage takes place between P1 and P1’) that bears an aspartic acid (D) in 
the P1 position (197). Using in vitro approaches based on positional scanning synthetic 
combinatorial libraries, optimal amino acid identity for P4, P3 and P2 positions were 
described for each caspase (198, 199). Subsequently, the initial cleavage motifs have 
been confirmed or corrected using more advanced technologies (200-203); table 1.2 
describes the optimal peptide P4-P3-P2-P1 cleavage sequences agreed for inflammatory 
caspases. 
 
Some caspases have hundreds of identified substrates whereas others are known to 
cleave only one specific protein (197). Identifying caspase substrates presents several 
caveats: [1] caspases are known to be promiscuous, with overlapping substrate 
specificities; [2] predicted optimal cleavage motifs are sometimes distant from actual 
cleavage events, for instance, the optimal substrate cleavage sequence described for 
caspase-1 is WEHD (P4-P3-P2-P1) but caspase-1 cleaves human proIL-1b after YVHD 
(204) and gasdermin-D after FLTD (205); [3] substrate identification based on linear 
peptide sequence does not account for secondary structures, which limit caspase 
accessibility to their substrates, and [4] in vivo intracellular concentration and [5] 
catalytic efficiency, i.e. rate of substrate cleavage, can differ in logarithmic folds 
between caspases (200, 201, 206-208). As a result, in vitro biochemical assays may not 
reflect the biological relevance / implications of caspases in a cellular context. Taking 
into consideration all the above mentioned concerns, it is also important to note that 
reagents based on optimal cleavage peptide sequences lack specificity and, therefore, 
their use is not reliable to target one specific caspase in whole cells either for their study 






Table 1.2 Substrate specificity of inflammatory caspases 
Predicted optimal cleavage peptide sequences for caspase-1, -4 and -5 activity are described. The 
number of identified substrates for each caspase is based on the most recent degradomics and 




1.2.1.2 Inflammatory caspases 
 
Mammalian inflammatory caspases include caspase-1, -4, -5, -11 and -12. Interestingly, 
all inflammatory caspase genes cluster in the same region, located in chromosome 11 in 
humans or chromosome 9 in mice (210) (Figure 1.6). In fact, scientists that engineered 
the two initial CASP1 knockout mouse models by homologous recombination were 
unaware that the embryonic stem cells that they used to generate the mice belonged 
to a strain harbouring a CASP11 germline mutation that results in no caspase-11 protein 
expression; thus, the contribution of caspase-11 in these original studies was neglected 
(211, 212). Once researchers became aware of this fact (213), they also realized that 
segregation of the two genes and hence generation of single CASP1 knockout mice 
through thorough backcrossing was extremely unlikely because CASP1 and CASP11 
genes are only separated by around 1500 bp. The development of more efficient gene 
targeting techniques has enormously contributed to accurately generate single CASP1 
or CASP11 knockout models and revisit and reassess the previously overlooked function 








Key substrates with well-
defined roles
1 WEHD 50-100 IL-1b, GSDMD, cGAS
4 (W/L)EHD, LEVD 1-5 GSDMD, cGAS






Figure 1.6 Genomic location of inflammatory caspase genes 
Chromosomal organization of human (above) and mouse (below) inflammatory caspase genes. 
The schematically represented regions also encode other elements which have not been added 
for additional clarity. Of note, in humans this region also encodes a caspase pseudogene and 




Caspase-1 was the first ever identified caspase and was originally named IL-1 converting 
enzyme (ICE) under the observation of its ability to cleave inactive full-length proIL-1b 
into an active short fragment (184, 185). The function of caspase-1 will be described in 
section 1.2.2 The canonical inflammasome. 
 
Caspase-4 and -5 are the human orthologues of murine caspase-11 presumably as a 
consequence of a gene duplication event relatively recent in evolutionary terms (210) 
(Figure 1.6). However, caspase-4 and caspase-5 are not redundant: they are expressed 
in different tissues and each has distinctive functions. In fact, caspase-4 is expressed 
ubiquitously, in a similar fashion to caspase-1, whereas the detection of caspase-5 is 
limited to a restricted subset of myeloid cells; therefore, it has been suggested that 
caspase-4 has broader functions than caspase-5, the later having a functional role 
confined to restricted lineages (175, 216) (Figure 1.7). Moreover, functional observations 
on caspase-11 are not always translated to caspase-4 or/and -5 and vice versa, suggesting 
species-specific roles (217, 218). Caspase-4 and -5 will be further examined in section 














Figure 1.7 Expression of inflammatory caspases in human cells and tissues 
Differential analysis of caspase expression in various tissues and cell types reveals a distinctive 
expression pattern for caspase-1, -4 and -5. Data were obtained from the ensembl.org website: 
using the Ensembl regulatory build resources, CASP1, CASP4 and CASP5 promoter activity 
(active: red; inactive: blue) were predicted based on the epigenetic signatures around these 





Finally, the role of caspase-12 is poorly understood. Besides cleaving itself, and thus 
exerting an auto-processing role, no other substrates have been identified (220). 
Studies in mice proposing that caspase-12 is a negative regulator of caspase-1 have been 
contradicted and no clear function has been yet proposed for murine caspase-12 (221, 
222). Moreover, in humans, a frameshift mutation in the CASP12 gene anticipates a stop 
codon and generates a truncated caspase-12 with no proteolytic domain (223). In less 
than 1% of humans, an additional single nucleotide polymorphism reverts the 
premature stop codon allowing transcription of the full gene; however, the proteolytic 
domain of this protein is also catalytic inactive due to further mutations (224). 
Although some studies have investigated whether human CASP12 and its mutated 
variants can be linked to inflammatory disease susceptibility, weak associations have 
been reported and no physiological relevance of either truncated or full-length human 
caspase-12 has been yet described (175, 221, 225-228). Given that human caspase-12 has 
a highly limited expression profile and its acquired host-specific mutations question its 











































































































































































































































































































































1.2.2 The canonical inflammasome 
 
Inflammasomes are multimeric protein cytosolic complexes that serve as platforms for 
the recruitment and activation of inflammatory caspases and subsequent processing of 
their substrates (229). Their main role is to integrate external and internal stimuli into 
innate immune responses. Inflammatory caspases are the core enzymatic units of 
inflammasomes; hence inflammasomes are divided into two subtypes: [1] canonical and 
[2] non-canonical, depending on the presence of caspase-1 or caspase-4/-5/-11 
respectively. 
 
1.2.2.1 Canonical inflammasomes: types and functions 
 
The principal function of canonical inflammasomes is to channel the recognition of a 
stimulus into an inflammatory response through caspase-1-mediated activation of IL-
1b (230). Although inflammasomes have been extensively studied since their discovery 
fifteen years ago (229), there is a lack of consensus regarding their dynamics, including 
their activation and regulation (192). This fact might be explained by the abundance 
and complexity of mechanisms described, highlighting the versatility of the 
inflammasome in integrating immune responses. In this sub-section, a brief summary 
of the molecular mechanisms involved in canonical inflammasome activation, function 
and regulation is presented. 
 
Inflammasome activation is initiated when exogenous or self-originated molecules, 
termed pathogen-associated molecular patterns (PAMPs) or damage-associated 
molecular patterns (DAMPs) respectively, are detected by cytosolic pattern recognition 
receptors (PRRs) (231). Examples of PAMPs include microbial nucleic acids and 
secretion systems or cell wall components. In contrast, DAMPs are molecules, such as 
uric acid crystals, ATP or heat-shock proteins, derived from the host and, therefore, can 
mediate inflammasome activation also during sterile inflammation (232). Besides 
recognizing PAMPs and DAMPs, PRRs can also detect the loss of cellular homeostasis 
(for instance, altered production of ROS); these broader processes were recently 









Figure 1.8 Canonical inflammasomes integrate innate immune sensing mechanisms to 
activate IL-1b  and other cytokines 
The schematic representation of canonical inflammasome assembly reflects its general 
mechanistic pattern: [1] a DAMP or PAMP is recognised either directly or indirectly by a specific 
PRR; [2] the different sensing mechanisms converge in the formation of a multimeric cytosolic 
platform that recruits caspase-1 through homotypic interactions with its CARD domain 
(depicted as dark green circles); the prototypical NLRP3 inflammasome is shown as an example; 
CARD caspase-1 proteolytic domain PYD LRRNATCH




[3] the final canonical inflammasome activates cytokines such as IL-1b or IL-18. NLRP1, NLRP3 
and NLRC4 are all NLR proteins. *The NLRP1 receptor senses the anthrax lethal factor in mice; 
however, its ligand in humans remains unknown, although well-characterized single 
mucleotide polymorphism (SNP) mutations of its gene are associated with some auto-




Some of the best studied PRRs are: the nucleotide-binding oligomerization domain 
(NOD) leucine-rich repeat (LRR) containing receptors (NLRs), the absent in melanoma 
2 receptor (AIM-2) and the pyrin receptor (234, 235). Each of these PRRs specifically 
can detect one or several danger molecules or ligands and in turn interacts with specific 
mediator/adaptor proteins to activate the assembly of the inflammasome. Some of the 
better characterized sensing mechanisms including the respective PRRs involved are 
depicted in Figure 1.8.  
 
Independently of the upstream activation signal, most PRRs oligomerize (through 
homo-domain protein-protein contacts) and generate nucleating surfaces where 
further interactions occur with other mediating proteins, such as the key apoptosis-
associated speck-like protein containing a CARD domain (ASC) (235). Recruited ASC 
proteins also oligomerize through their homotypic domains and polymerize into linear 
filaments which, in turn, aggregate into macromolecular specks, contributing to the 
signal’s amplification (236). Finally, ASC recruits caspase-1 through the interaction of 
their CARD domains. Subsequent local accumulation of caspase-1 facilitates its 
dimerization, indispensable for caspase-1 activation, the key objective of canonical 
inflammasome assembly (175, 192, 237). 
 
It is widely accepted that active IL-1b-cleaving caspase-1 is found as a tetramer 
consisting of two p20 and two p10 subunits (p20/p1o) (188). However, Boucher et al. 
have recently challenged this model and described that, in fact, active caspase-1 is found 
in either dimerized p45 (full-length) or p33/p10 tetramers, where p33 is a fragments that 
corresponds to the CARD domain plus the p20 subunit. Interestingly, these authors 
also propose that the p33/p10 processing into p2o/p10 (the original described active 




inactive (192). Nevertheless, active caspase-1 located at the inflammasome site 
processes several precursor pro-inflammatory interleukins, such as IL-1b and IL-18, into 
their active secreted forms (204). 
 
In summary, inflammasome assembly results in the activation of pro-inflammatory 
cytokines, amongst which, the master signalling cytokine IL-1b. IL-1b, which lacks a 
signal secretion sequence, is released from cells through a not yet fully understood 
unconventional secretion pathway (238). Once released, IL-1b binds to the extracellular 
side of the transmembrane protein type 1 IL-1 receptor (IL-1R1). Although they only 
share a 26 % amino acid homology (239), IL-1b and IL-1a have very similar secondary 
structures and share biological functions such as binding to IL-1R1 in its extracellular 
domain. In contrast to IL-1b, IL-1a [1] is not cleaved by caspase-1 (but by extracellular 
proteases which are not related to the inflammasome), [2] is an active molecule in its 
precursor form (although less bioactive than cleaved) and [3] it is a “dual-function 
cytokine”: acts both as a transcription factor in the nucleus (where it can induce the 
expression of IL-8, for instance) and a signalling molecule secreted or bound to the 
extracellular membrane (240, 241). Although IL-1a is not processed by caspase-1, in the 
absence of caspase-1 IL-1a production is greatly reduced, suggesting that IL-1b controls 
Il-1a expression (211). 
 
Binding of extracellular IL-1b or IL-1a to the IL-1R1 induces a conformational change in 
IL-1R1, and consequent interaction with the also transmembrane protein IL-1R3, with 
whom shares structural domains (240). Then MyD88 binds to the intracellular 
components of the heterodimer IL-1R1 / IL-1R3 and activates a strong proinflammatory 
signalling cascade that culminates with the activation of NF-kB. Therefore, IL-1 
signalling amplifies a robust proinflammatory response by potentiating an autocrine 
positive feedback loop as well as paracrine activation. 
 
Although IL-1a is constitutively expressed in many cell types whereas IL-1b expression 
is generally induced in response to a trigger, their biological functions are similar and 
key in promoting local and systemic inflammation (242). Besides being active signalling 
molecules in both innate and adaptive immunity, IL-1a and IL-1b are also signal 




indirectly mediated by IL-1 include: recruitment of immune cells to local sites of 
inflammation, partly due to the induction of the expression of adhesion molecules on 
endothelial cells; fever, caused by circulating IL-1b reaching the brain; and regulation 
of T cell polarization, for instance, by co-induction of IL-17 production (244-246). 
 
Because overproduction of activated IL-1b can have detrimental effects (204), caspase-
1 activity is tightly regulated. For example, in some cases, canonical inflammasome 
activation is regulated by a two-step mechanism. A first signal, also called priming, is 
required to boost the expression of the involved players and increase the pool of 
available proteins in the cytoplasm, such as proIL-1b or inflammasome components. 
This process is generally activated by transmembrane PRRs, such as the toll-like 
receptors (TLR), and results in the transcriptional activation of genes controlled by NF-
KB. In these cases, the priming is followed by a second signal which induces the 




Figure 1.9 A two-step process regulates the activation of some inflammasomes 
Priming (1) through PRRs activates the transcription of NF-kB target genes; in this diagram the 
recognition of extracellular lipopolysaccharide (LPS) by TLR-4 is depicted as an example. A 
second signal (2) contributes to the assembly of the canonical inflammasome. Activated 





Moreover, inflammasome activity is also intensively regulated, both positively and 
negatively, by other mechanisms, such as the interplay with autophagy, post-
translational modifications (such as phosphorylation) of inflammasome components, 
and interaction with CARD-only proteins (COPs) and Pyrin-only proteins (POPs) (231, 
234, 235, 247). Intriguingly, COPs and POPs encode genes that are present in humans 
and some primates but absent in mice, suggesting a further host specific difference in 
caspase-related mechanisms (248). 
 
1.2.2.2 The canonical inflammasome and IL-1 signalling in disease 
 
Although inflammasomes are crucial in the host’s defence against infection, sterile 
immunity and general homeostasis, their dysregulation is linked to several diseases 
(249). A reason for this is that IL-1b overproduction is highly detrimental and can 
preclude its beneficial effects; hence IL-1b production is strictly controlled. 
Uncontrolled excessive IL-1b production drives inflammatory syndromes. In fact, 
mutations in inflammasome components, such as the PRRs, are the established cause 
of some autoinflammatory diseases (230, 250-252). For instance, in patients with 
cryopyrin-associated periodic syndromes (CAPS), the origin of the hereditary disease 
has been identified as gain-of-function mutations in the NRLP3 gene that render 
hyperactivation of NLRP3 inflammasome activity. CAPS and other autoinflammatory 
diseases are now effectively treated by FDA-approved IL-1 blocking agents, such as IL-
1R1 pharmacological inhibitors or anti-IL-1b monoclonal antibodies (253-255). 
  
Besides its prominent role in autoinflammatory syndromes, acute or low-chronic IL-1 
due to aberrant inflammasome activation is also observed in other diseases with an 
inflammatory component, such as type 2 diabetes, rheumatoid arthritis or 
cardiovascular disease (246, 256, 257). Of interest, senescence has been associated with 
many of these sterile inflammatory diseases. Recent and on-going clinical trials are 
evaluating the outcome of therapeutic IL-1 blockade in these contexts: in general, when 
IL-1 is central to the aetiology of the disease, IL-1 blockade is efficient; otherwise, the 





In cancer research, both beneficial and detrimental functions have been attributed to 
IL-1 signalling: on the one hand, IL-1 mediates the induction of antitumour adaptive 
immune responses; on the other hand, tumour angiogenesis, induction of an 
immunosuppressed environment and chronic inflammation are mechanisms by which 
IL-1 contributes to tumour progression and metastasis (259-261). Studies using mouse 
models have tried to further elucidate the role of the inflammasome proteins in cancer 
(262). For instance, in a murine model of colitis-associated colorectal cancer, depletion 
of some specific inflammasome components, including caspase-1, enhances 
tumorigenesis, suggesting a protective role for the inflammasome (263). In contrast, 
some other studies have shown that caspase-1 knock-out mice are less susceptible to 
specific models of skin and breast cancer (263). Except for the few cases in which 
mutations in an inflammasome component have been functionally linked to cancer 
susceptibility (252, 264), there is no universal mechanism of action for the 
inflammasome in cancer but the existence of different activated inflammasome 
pathways, and the outcome of their signalling depends on the cell type, tissue and 
cancer stage among other factors (265). It is clear that an improvement in our current 
knowledge regarding the molecular mechanisms that involve the inflammasomes 
would be beneficial for the design of tailored therapeutic strategies (262, 263). 
 
Clinically, high IL1B mRNA expression has been associated with poor prognosis in some 
tumours (261). A recent study, emerging from a clinical trial with more than 10.00o 
enrolled patients and originally designed to evaluate the outcome of anti-IL-1b 
treatment in high risk atherosclerosis patients, found that administration of an anti-IL-
1b antibody reduces lung cancer incidence and mortality (266). The underlying 
mechanism that supports these results is still to be characterized, but it is thought that 
IL-1b blockade might have inhibited tumour progression and induced its clearance 
(267). IL-1 targeting clinical trials for the treatment of multiple myeloma and advanced 
colorectal cancer have shown promising results (258, 268). Moreover, IL-1b production 
is commonly observed after administration of some chemotherapy drugs; however, 
although combined IL-1 blockade and chemotherapy has been proposed, preclinical 
studies in mice show controversial results (259, 261). IL-1 blockade is also under 
investigation to treat cytokine release syndrome (CRS), the most prevalent secondary 





Overall, because inflammation, and in particular IL-1 signalling, is linked to many 
conditions, from autoinflammatory disorders to cancer, its targeting is of therapeutic 
interest. Although IL-1 blockade is approved for the treatment of some diseases (mainly 
those where IL-1 is clearly linked to the aetiology of the disease), the clinical benefit of 
IL-1 inhibition remains unclear for others (258). A better understanding of the context-
specific molecular complexity of IL-1 signalling, including the inflammasome, is 
essential to [1] assess the specific contribution of IL-1 signalling in distinct phenotypes 
and [2] identify potential selective novel therapeutic targets for each scenario (235, 253). 
 
 
1.2.3 The non-canonical inflammasome 
 
1.2.3.1 The non-canonical inflammasome: description 
 
Caspase-4 and -5, principal constituents of the non-canonical inflammasome, interplay 
with the canonical inflammasome during inflammatory responses (175). Although 
caspase-4 and -5 have an almost imperceptible ability to cleave proIL-1b in vitro 
compared to caspase-1 (270), absence of caspase-4 or -5 limits NLRP3 inflammasome-
mediated IL-1b processing and release in response to microbial infections (218, 271-275), 
suggesting a role for caspase-4 and -5 as upstream regulators of the canonical 
inflammasome. Moreover, when co-overexpressed, direct interaction between caspase-
1 and caspase-4 or -5 has also been reported (229, 271, 272). This has contributed to the 
hypothesis that a physical interaction between caspase-1 and caspase-4/-5 is required; 
however, the exact mechanism by which the non-canonical inflammasome exerts 
control over caspase-1-dependent IL-1b processing remains unclear. In mice, caspase-1 
activity is regulated by caspase-11 (213, 276, 277). Besides regulating IL-1b processing and 
secretion, caspase-4 and -5 can also regulate the cellular release of other proteins, 
including IL-1a (218, 273). 
 
Nonetheless, caspase-4, -5, and their murine counterpart caspase-11, have gained much 
relevance since the discovery over the last years of their functional role as key mediators 




regulated cell death with distinctive morphology, caused by the formation of pores in 
the plasma membrane, and linked to innate immunity mechanisms (177). Although 
pyroptosis was identified as a distinct type of cell death more than 15 years ago (278), 
recent developments in its research have led to a much better understanding of its 
mechanism and biological relevance. 
 
An initial ground-breaking study revisiting the function of caspase-11 (see section 1.2.1.2 
Inflammatory caspases) reported that, when challenged with a lethal LPS dose, caspase-
11 deficient mice showed a significant increased survival rate compared to wild-type or 
caspase-1 knock-out mice (213). Subsequent independent studies revealed that 
resistance to LPS challenge was mediated by caspase-4 in humans (272). In 2013, two 
research groups described an exciting novel finding: LPS-induced lethality depends on 
intracellular LPS recognition by the non-canonical inflammasome (279, 280), in 
contrast to the previous thought that this pathway was activated by extracellular 
sensing of LPS by TLR4 (281). 
 
Importantly, a further key study described that the lipid A of cytosolic LPS directly 
binds to the CARD domain of caspase-4, -5 or -11 (193); hence caspase-4, -5, -11 are PRRs 
themselves, unlike caspase-1. Binding of LPS induces oligomerization of caspase-4 or -
11, indispensable for its catalytic activation (193) (Figure 1.10). Although caspase-5 also 
binds LPS in vitro, the authors observed that the loss of cell viability following LPS 
transfection in human cell lines (including epithelial cells and keratinocytes) was 
exclusively dependent on the presence of endogenous caspase-4 (193). In a different 
study, caspase-5 did not mediate cell death or IL-1b production in response to LPS 
transfection; however, caspase-5 was required for the death of human macrophages 
following infection with Salmonella typhimurium (274). Altogether, these and other 
studies (272, 275) suggest that caspase-5 does not participate in engaging pyroptosis 
after intracellular LPS transfection challenge but might be an essential part of the 







Following the seminal findings by Shi et al. (193), three studies reported the 
downstream mechanism by which activation of caspase-4, -5 or -11 leads to pyroptosis: 
inflammatory caspases cleave gasdermin-D into two fragments and the liberated N-
terminal domain is the executioner of pyroptosis (283-285). After cleavage, the 
unleashed N-terminal domain of gasdermin-D binds to specific membrane lipids and 




Figure 1.10 The roles of canonical and non-canonical inflammasome activation in IL-1 
signalling 
LPS binding to the CARD domain of caspase-4, -5 or-11 induces their oligomerization, activation 
and gasdermin-D cleavage. The liberated N-terminal fragment of gasdermin-D translocates to 
the plasma membrane, where it forms pores that can cause pyroptotic cell death. Activated 
caspase-1, due to the assembly of the canonical inflammasome, can also cleave gasdermin-D. 
The prototypical NLRP3 canonical inflammasome is depicted. Dashed lines represent processes 
which remain unclear: how the non-canonical inflammasome, both through and independently 







Release of IL-1b into the extracellular space during cell death is a hallmark of pyroptosis 
(282, 291). Lack of gasdermin-D blocks IL-1b secretion in response to canonical 
inflammasome activation by diverse stimuli (283-285). In fact, it has been proposed 
that, besides mediating pyroptosis, transmembrane gasdermin-D pores also function 
as channels through which IL-1b is released (292, 293). IL-1b secretion can happen 
before pyroptosis or even in the absence of pyroptosis (294-298), which might be 
explained by a gradual concentration or a smaller number of gasdermin-D pores in the 
plasma membrane, respectively (299). Overall, the mechanisms that facilitate IL-1b 
secretion during pyroptosis, including the strict requirement for gasdermin-D pores, 
remain obscure. At a different IL-1 regulating level, it has also been suggested that the 
potassium efflux generated by gasdermin-D pores in the cell membrane might 
mechanistically explain how the non-canonical inflammasome can activate the NLRP3 
canonical inflammasome (281). 
 
Importantly, gasdermin-D is also cleaved by active caspase-1 and hence pyroptosis is 
not an exclusive function of the non-canonical inflammasome (205, 283-285). However, 
there are several differences regarding how the canonical and the non-canonical 
inflammasome induce pyroptosis. Of note, whereas caspase-1 activation depends on 
the previous assembly of the canonical inflammasome (and therefore the recruitment 
of mediator proteins), caspase-4 activation is prompted by the direct binding to its 
ligand. Nonetheless, whereas caspase-4,-5 and -11 trigger pyroptosis exclusively through 
gasdermin-D cleavage, caspase-1 activation can induce a different slower type of 
pyroptosis in the absence of gasdermin-D, suggesting a gasdermin-D independent 
pyroptotic mechanism downstream of caspase-1 activation (281, 284). A potential 
explanation to this evidence is that, in contrast to caspase-1, caspase-11 shows a much 
more limited substrate specificity (208). Finally, both the cell type and the specific 
trigger greatly influence whether gasdermin-D is cleaved by caspase-1, -4 or -5 (or a 
synergistic combination of more than one of them) and its outcome (cell death, IL-1b 
release or both). 
 
Although most attention has focused on LPS, at least one endogenous lipid species can 
bind caspase-4 and -11: the oxidized phospholipid oxPAPC (oxidized 1-palmitoyl-2-




caspase’s catalytic domain instead of the CARD (300). Paradoxically, oxPAPC has 
opposing roles regarding IL-1 secretion. On the one hand, oxPAPC binds caspase-11 
specifically in dendritic cells and induces the release of IL-1b in the absence of 
pyroptotic cell death (300). On the other hand, oxPAPC blocks IL-1b release and 
pyroptosis in macrophages by preventing LPS binding to caspase-4 or -11 (301). 
 
Besides regulating IL-1b cleavage indirectly and cleaving gasdermin-D, other biological 
functions have been attributed to caspase-4, -5, -11. For instance, caspase-11 interacts via 
its CARD domain with the actin-interacting protein 1 (AIP1) promoting cofilin-
mediated depolymerisation (302). Furthermore, a role for caspase-4 in endoplasmatic 
reticulum-stress cell death has also been proposed (303, 304). Nonetheless, these and 
other caspase-4, -5, -11 biological functions remain to be further elucidated, especially 
in non-infectious settings. 
 
1.2.3.2 The non-canonical inflammasome in health and disease 
 
The non-canonical inflammasome plays a role in antimicrobial defence, particularly 
against Gram-negative bacteria as caspase-4, -5 and 11 directly sense LPS (305). 
Intracellular LPS activates caspase-4, -5 or 11, which in turn can, through gasdermin-D 
dependent and independent mechanisms, [1] stimulate the canonical inflammasome 
(and thus induce IL-1b cleavage) and [2] mediate IL-1b release, altogether promoting a 
pro-inflammatory response (281). 
 
Moreover, caspase-4, -5 and -11, as well as caspase-1, can induce pyroptosis,  eliminating 
the intracellular pathogen’s replicative niche and allowing their release and exposure 
to immune antimicrobial clearance (299, 306). However, excessive pyroptosis 
activation can lead to unresolved damaged and eventual lethal sepsis. In mice models, 
caspase-11 or gasdermin-D deletion confers protection to endotoxic shock (213, 284). 
Therefore, gasdermin-D inhibitors are being developed and tested for the treatment of 






Although caspase-4, -5 and -11 have been much less investigated than caspase-1, these 
caspases have also been associated to sterile damage. For instance, caspase-4 and -11 
have been linked to the pathogenesis of some neurological disorders, such as multiple 
sclerosis or Alzheimer’s disease (309, 310). Nonetheless, how caspase-4, -5 or -11 
mechanistically function in these diseases is unclear. 
 
In particular, whether the non-canonical inflammasome has a role in cancer has also 
been poorly investigated. Caspase-11 contributes to the intestinal homeostasis 
protecting against colitis-associated colorectal cancer (311, 312). In humans, CASP4 
downregulated expression as well as infrequent loss-of function mutations have been 
described in some specific tumours, suggesting CASP4 is a tumour-suppressor gene 
(313, 314). Nonetheless, caspase-4 has also been positively correlated with malignancy: 
increased caspase-4 levels within intestinal epithelial cells or serum have been 
proposed as potential biomarkers for the diagnosis of colorectal and non-small cell lung 
cancer, respectively (315, 316). In all the aforementioned cancer-related studies, 
whether CASP4’s association with a protective or malignant role was mechanistically 
related to IL-1b regulation was unexplored. 
 
The role of pyroptosis in tumorigenesis has not yet been investigated (263). 
Interestingly, Val-boroPro, a potential anticancer agent that has reached Phase III 
trials, induces pyroptosis by indirectly activating caspase-1-dependent gasdermin-D 
(317, 318). Moreover, Wang et al. have recently described that chemotherapy drugs 
induce caspase-3 activation and cleavage of gasdermin-E, suggesting key roles for 

















1.3 Rationale, hypothesis and aims 
 
The role of the SASP remains controversial in cancer and mechanistically ill-defined in 
ageing, two of the key pathophysiological contexts where senescence has been 
extensively investigated. Moreover, recent evidence proposes that different triggers 
might induce distinctive SASP subsets with concrete functions. Nonetheless, the SASP 
has started to arise interest as a potential therapeutic target in disease. Altogether, a 
better understanding of the molecular machinery scaffolding the SASP complexity is 
needed. 
 
The canonical inflammasome is critical to the essence of the SASP (80).  On the other 
hand, innate immunity research has unveiled an unexpected crucial role for the non-
canonical inflammasome. Thus, we hypothesize that investigating caspase-4 may not 
only evidence and unreported role for the non-canonical inflammasome in senescence 
but also reveal functions that might be relevant beyond the senescence field.  
 
In this line, and given the previous published evidence, several questions arise: 
 
- Does the non-canonical inflammasome regulate the SASP in senescence? 
- Does gasdermin-D have a functional role in senescence? 
- Do inflammasomes have a broader role in senescence beyond cytokine 
regulation? 
- What are the mechanisms by which inflammatory caspases might be activated 
in senescence?  
 
Overall, this thesis aims to better understand the roles of inflammatory caspases in 
oncogene-induced senescence and, particularly, to explore, for the first time, the role 



















Phosphate-buffered saline (PBS) Dulbecco’s tablets + dH2O  
Tris-buffered saline (TBS) 25 mM Tris-HCl + 137 mM NaCl + 2.7 mM KCl, pH7.4  
TBS-Tweem (TBS-T) TBS + 0.05% Tween 20  
Tris-acetate EDTA (TAE) 40 mM Tris, 0.1% glacial acetic acid, 1 mM EDTA  
Immunofluorescence blocking buffer PBS + 1% Bovine Serum Albumin + 0.2% Fish Gelatin  
L-Agar 10 g/L tryptone, 5 g/L yeast extract, 10 g/L NaCl and 
15 g/L agar 
L-Broth 10 g/L tryptone, 5 g/L yeast extract, 10 g/L NaCl and   
1 g/L glucose 
 
Table 2.1 Regularly used solutions 
 
All other reagents were purchased from the indicated suppliers. 
 
2.2 Cell culture 
 
2.2.1 Cell lines and maintenance 
 
IMR90 and 293T cell lines were obtained from ATCC. All cells were routinely 




supplemented with 10% Fetal Bovine Serum (FBS) (ThermoFisher, SV30180.03) and 1% 
antibiotic-antimycotic (ThermoFisher, 15240062), referred as standard media.  
 
To induced oncogene-induced senescence, an inducible 4-hydroxy-tamoxifen (4-OHT) 
RASG12V in IMR90 cells model was used (320).  For a detailed explanation of this system, 
see section 3.1.2. ER:STOP and ER:RAS cells were produced, expanded and froze by Dr 
Juan-Carlos Acosta. For the experiments included in this thesis, IMR90 ER:STOP and 
ER:RAS were thawed as routinely and maintained in standard media supplemented 
with geneticin (ThermoFisher, 10131-027) at a 200 μg/ml final concentration. For 
induction of senescence, cells were cultured with standard media supplemented with 
200 μg/ml geneticin and 100 nM 4-hydroxytamoxifen (4OHT; Sigma, H7904). 
 
All cell lines were incubated at 37°C with 5% CO2 and tested for mycoplasma on a 
regular basis. Cells were cultured in 100 mm diameter round dishes as well as 6-well, 
24-well and 96-well plates (Sigma, 430167, 657160, 662160 and 167008, respectively). To 
further subculture, per each 100 mm diameter dish cells were detached by washing once 
the attached monolayer with 3 mL of PBS before adding 1.5 mL of trypsin 
(ThermoFisher, 25300-054) for 5 min at 37 ºC. 8.5 mL of standard media was added to 
fully detached cells and these were pelleted by centrifugation at 1000 rpm for 5 min. 
The supernatant was discarded and 4 mL of standard media were added to the cells. 
After careful resuspension, 1 mL was transferred to each new dish already containing 9 
mL of fresh standard media (split 1:4). Volumes were scaled down appropriately for 
smaller culture sizes. 
 
2.2.2 Cell counting and viability 
 
To determine cell concentration of cultures, after detached cells were collected by 
centrifugation, 50 uL of cells resuspended in standard media were added to 350 uL of 
Muse Count & Viability Reagent (Merck Millipore, MCH100102). After a 5 min 
incubation, cells were counted using the Muse Cell Analyzer (Merck Millipore), 





To determine cell viability, culture supernatants and attached cells were pooled 
together before centrifugation at 1000 rpm for 5 min. Pellets were resuspended in 50 uL 
of Muse Count & Viability Reagent (Merck Millipore, MCH100102) and further diluted 
1:4. After a 5 min incubation, cells were counted using the Muse Cell Analyzer (Merck 
Millipore), following manufacturer’s instructions. The Muse Count & Viability Reagent 
contains two dyes with differential permeability, one of which stains all cells whereas 
the other stains only nucleated (i.e. alive) cells. This system allows both the 
quantification and viability determination of the cell culture.  
 
2.2.3 Freezing and thawing of cells 
 
To freeze cells, cells were detached as explained in section 2.2.1. After centrifugation, 
the supernatant was discarded and cells were resuspended in 1 mL of 50% DMEM, 40% 
FBS, 10% DMSO per each 100 mm diameter dish, transferred to a cryogenic vial (Sigma, 
V7634), directly placed on dry ice and stored at -80 ºC. Cell stocks were stored in liquid 
nitrogen. 
 
To thaw cells, frozen cryogenic vials were incubated 1-2 min in a pre-warmed 37 ºC 
water bath. The vial content was then transferred to a 15 mL tube containing 9 mL of 
media. Cells were pelleted by centrifugation at 1000 rpm 5 min and further resuspended 
in 1 mL of standard media before transferring to a 100 mm diameter dish containing 9 
mL of fresh standard media. 
 
2.2.4 Cell harvest 
 
Cells were detached as explained in section 2.2.1. After centrifugation, pelleted cells 
were wash once with cold PBS and centrifuged 3 min at 3600 rpm in a bench-top 
centrifuge at 4 ºC. PBS was carefully removed and, if pellets were not immediately used, 










Pam2CSk4 (Tocris, 4637), Pam3CSK4 (Tocris, 4633), ultrapure lipopolysaccharide (LPS) 
from E. coli 111:B4 (Invovigen, tlrl-3pelps) and muramyldipeptide (MDP) (Tocris, tlrl-
mdp) were reconstituted following manufacturer’s instructions and stored at -20 ºC. 
Stock solutions were further diluted as needed for final concentration use on the day 
of the experiment. For inflammasome priming experiments, media was removed from 
cells and substituted with standard media supplemented with Pam2CSK4, Pam3CSk4, 
LPS and MDP at a final concentration of 0.05, 0.5, 1 and 1 µg/ml, respectively. For 
transfection experiments, LPS and MDP were used as explained in subheading 2.5. 
 
2.3 Production of stable cell lines 
 
2.3.1 Production of retroviral particles and infection of target cells 
 
All viral work was performed using Category 2 cell culture facilities and good practices. 
The 293T packaging cell line was routinely used to produce both retroviral and 
lentiviral particles to stable infect IMR90. Common steps shared among both protocols 
are shown in figure 2.1.  
 
Figure 2.1 Stable cell line generation using retroviral or lentiviral particles 
Schematic diagram showing the common steps of the protocols used to establish stable IMR90 
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To stably overexpress or knockdown the expression of genes of interest, IMR90 cells 
were infected using retroviral particles. On the day prior to transfection, 293T cells were 
split 1:4 to achieve 85% cell confluency at the moment of transfection. On day 0, to co-
transfect the required vectors into 293T cells, 2,5 µg of pCMV-VSVG, 7,5 µg of pUMVC3-
gag-pol and 20 µg of the chosen plasmid were vortexed and incubated 10 min at room 
temperature in 0.5 mL of DMEM (Sigma, D5796) per each 10 cm dish to be transfected. 
During incubation, a separate mastermix containing polyethyleneimine (PEI) (Alfa 
Aesar, 43896) was prepared by adding 75 µl PEI (1 mg/mL stock concentration) to 425 
uL of DMEM per each dish to be transfected. 0.5 mL of PEI mastermix vortexed solution 
were added to each tube containing the plasmids to be co-transfected. Each tube 
containing the transfection mix was gently vortexed and incubated 10 min at room 
temperature. Each transfection mix was carefully added drop by drop on each dish 
containing 293T. The following day (day 1), media was changed to all dishes. To check 
for transfection efficiency, a control dish was routinely transfected with a GFP-
expressing plasmid. On day 1, IMR90s cells to be infected the next day were split 1:4.  
 
On day 2, infections were performed. To perform infections, each viral supernatant was 
filtered using a 0,45 µm pore size filter (ThermoFisher, 15216869) into a 15 mL sterile 
Falcon tube. Each filtered media was complemented with polybrene (Sigma, H9268) to 
a final concentration of 4 µg/mL. Media on IMR90s was then substituted with the 
retroviral-containing supernatant and 6 mL of fresh standard media were added to the 
293Ts cells. Infections were performed again, using the same procedure, 3 and 6 h after 
the first round. During the second and third rounds, filtered retroviral supernatants 
supplemented with polybrene were added to IMR90 cells without prior removal of 
media. 9 h after the first infection, supernatants on IMR90 cells were carefully aspirated 
and fresh standard media was added. 
 
On day 4, infection efficiency was checked in IMR90 cells infected with a GFP-
expressing plasmid. On day 4, cells were split 1:3 and cultured in standard media 
supplemented with 1μg/mL puromycin (ThermoFisher, A11138). A control dish was 
infected with a non-containing selection marker vector. Media was changed every 2-3 
days with fresh standard media supplemented with the selection agent for over a week 




2.3.2 Production of lentiviral particles and infection of target cells 
 
To stably knockdown the expression of genes of interest, IMR90 cells were infected 
using lentiviral particles. On the day prior to transfection, 293T cells were split 1:4 to 
achieve 85% cell confluency at the moment of transfection. On day 0, to co-transfect 
the required vectors into 293T cells, 2,5 µg of pCMV-VSVG, 7,5 µg of psPAX2 and 10 µg 
of the chosen plasmid were vortexed and incubated 10 min at room temperature in 0.5 
mL of DMEM (Sigma, D5796) per each 10 cm dish to be transfected. Co-transfection of 
plasmids was performed as when producing retroviral particles, explained in section 
2.3.1. On day 1, media was changed to all dishes and transfection efficiency was checked 
using a control dish transfected with a GFP-expressing plasmid. On day 1, IMR90s cells 
to be infected the following day were split 1:4.  
 
On day 2, infections were performed. To perform infections, each viral supernatant was 
filtered using a 0,45 µm pore size filter (ThermoFisher, 15216869) into a 15 mL sterile 
Falcon tube. A separate mastermix was prepared containing standard media 
supplemented with polybrene (Sigma, H9268) at a final concentration of 4 µg/mL. 
Media on IMR90 was aspirated and 5 mL of polybrene-containing media were added to 
each dish. On top, 1 mL of filtered lentivirus-containing supernatant was added drop 
by drop carefully to each dish. After 3 h, media from IMR90 cells was aspirated and 10 
mL of fresh standard media were added per dish. Infection efficiency and selection with 
puromycin were conducted as when performing retroviral infections (see section 2.3.2). 
Doxycyline was used for the inducible expression of pLVX-Tet-On vector constructs. 
 
2.4 Short interfering RNA (siRNA) 
 
2.4.1 siRNA sequences 
 
siRNA technology was used to transiently knock-down the expression of a target gene. 
All siRNA reagents were ON-TARGETplus siRNA products (Dharmacon). Tubes 
containing siRNA were resuspended to 100 µM stocks following manufacturer’s 
instructions. Stocks were further diluted to 10 µM and aliquoted in 50 µL tubes to avoid 




siRNA Buffer (Dharmacon, B-002000-UB-100) diluted in ultrapure DNase/RNase-free 
distilled water (ThermoFisher, 10977049). siRNA was stored at -20 ºC. Table 2.2 
includes a list of the siRNA used to target the expression of human genes. 
 













Non-target control-1 UAGCGACUAAACACAUCAA 
Non-target control-2 UAAGGCUAUGAAGAGAUAC 
Non-target control-3 AUGUAUUGGCCUGUAUUAG 















CYCS -3 GAUUAGACUUCGUUAGUAA 





Table 2.2 List of siRNA sequences 





2.4.2 siRNA transfection 
 
siRNA was transfected into cells either by forward or reverse transfection, always using 
Dharmafect 1 (Dharmacon, T-2001) as the transfection agent and 30 nM final 
concentration of siRNA. A Dharmafect mix was obtained by diluting Dharmafect 1 in 
non-supplemented DMEM media (null media). 450 µL of 1x siRNA buffer were added 
to 50 µL of siRNA at 10 µM to obtain siRNA at 1 µM final concentration. Transfections 
were performed in 96-well or 6-well plates. IMR90 ER:STOP/ER:RAS cells were split 1:4 
3 days before day 0. On day 0, senescence was induced by the addition of 4-
hydroxytamoxifen and the first reverse transfection was performed. On day, 0 cells 
were also split and 200.000 cells / well were plated in 6-well plates. On day 3, cells were 
trypsinized, split 1:4 and reverse transfected. On day 5, cells were either harvest or fixed 




Figure 2.2 siRNA transfection protocol to transiently downregulate mRNA expression of 
target genes 
Schematic timeline of the different steps of the siRNA transfection protocol. ER:STOP and 






split & transfect split & transfect harvest/fix ortransfect harvest/fix




To reverse transfect cells (day 0 and day 3), the specified amounts of siRNA in table 2.3 
were added to each well. Next, the Dharmafect mix, prepared as specified in table 2.3, 
was added on top. Plates were incubated 1 h at room temperature. Meanwhile, cells 
were detached, counted and seeded, so that 100 µL or 2 mL final volume of cells were 
added to each siRNA:Dharmafect-containing well of a 96 or 6-well, respectively. 
 
 
Well size siRNA (1 µM) Dharmafect 1 mix 
96-well plate 3.6 µL 0.1 µL Dharmafect 1 + 17.4 µL null media 
6-well plate 72 µL 2 µL Dharmafect 1 + 348 µL null media 
 
Table 2.3 Reverse siRNA transfection specifications 
Indicated shown amounts refer to one single well. A master Dharmafect 1 mix solution was 
prepared before distribution. 
 
 
To forward transfect cells (day 5), solutions were prepared as indicated in table 2.4. 
siRNA and Dharmafect mix were incubated together for 20 min at room temperature. 
Then, standard media (when appropriate supplemented with 4-hydroxytamoxifen) was 
added and solutions were gently vortexed. Cell media was aspirated and substituted 










plate 3.6 µL 
0.1 µL Dharmafect 1 
+ 17.4 µL null media 20 min  
RT 
100 µL 121.1 µL 
6-well 
plate 72 µL 
2 µL Dharmafect 1 + 
348 µL null media 
2 mL 2.4 mL 
 
Table 2.4 Forward siRNA transfection specifications 
Indicated shown amounts refer to one single well. A master Dharmafect 1 mix solution and 









LPS (Invivogen, tlrl-3pelps) and MDP (Invivogen, tlrl-MDP) were reconstituted to 1 mg 
/mL following manufacturer’s instructions and stored at -20 °C. LPS and MDP were 
aliquoted in several Eppendorf tubes to avoid multiple thaw-freeze cycles. LPS and 
MDP were reconstituted and further diluted in ultrapure DNase/RNase-free distilled 
water (ThermoFisher, 10977049). 
 
2.5.2 Electroporation using the Neon Transfection System 
 
To transfect LPS or MDP, the Neon Transfection System (Invitrogen, MPK5000) and 
the Neon Transfection System 100 µL Kit (MPK10025) were used. In each 100 µL tip, 5 x 
10^5 cells were transfected with the indicated amount of PAMP (1, 0.1 or 0.01 µg). 
 
Cells were detached and counted as explained in sections 2.2.1 and 2.2.2. After counting, 
1,65 x 10^6 cells were washed once with PBS and resuspended in 315 µL of buffer R. 35 
µL of 10x concentrated LPS or MDP were added to the cells. Electroporation parameters 
were set at as indicated in table 2.5. 
 
Cell type Pulse voltage (v) Pulse width (ms) Pulse number 
293T 1100 20 2 
IMR90 1500 30 1 
Table 2.5 Selected parameters when using the Neon Transfection system 
 
Once electroporated, the tip content was unloaded into a clean Eppendorf tube. Tubes 
were centrifuged on a bench-top centrifuge at 3000 rpm 3 min. Supernatant was 
removed to avoid any traces of MDP or LPS in the extracellular media. Cells were 
resuspended in 500 µL of media and plated in 6-well, 24-well and 96-well plates 





Cell viability was determined as explained in section 2.2.2. For RNA extraction, SA-b-
galactosidase and immunofluorescence assays, cell media was removed 24h after 
transfection and fresh media was added. 
 
2.6 Senescence-associated b-galactosidase (SA-b-gal) 
activity assay 
 
To perform an SA-b-gal assay, 5 x 104 cells were seeded in each well of a 6-well plate. 
Four days later, cells were fixed. To fix cells, wells were first washed once carefully with 
PBS 1x at room temperature before adding 0,5 mL of 0.5% glutaraldehyde (Sigma, 
G5882) in PBS / well and incubating 10 min. Fixed cells were washed three times with 
PBS/1 mM MgCl2 pH 5.7, before incubating each well with 2 mLs of pre-warmed (37°C) 
X-Gal staining solution (2 mM MgCl2, 5 mM K4Fe(CN)6 • 3H2O, 5 mM K3Fe(CN)6, 1 
mg/mL X-Gal solution ready to use (ThermoFisher, R0941) in PBS). Plates were covered 
in aluminium foil and incubated for 2-24 h at 37 °C. 
 
2.7 Crystal-violet colony formation assay 
 
To perform a crystal-violet colony formation assay, equal amounts of cells (either 5 x 
104 or 1 x 105 cells) were seeded in 10 cm diameter dishes. Media was changed every three 
days and cells were fixed two weeks after initial seeding. To fix cells, dishes were first 
washed once carefully with PBS 1x at room temperature before adding 3 mL of 0.5% 
glutaraldehyde (Sigma, G5882) in PBS / dish for 20 min. Fixed dishes were washed two 
times with tap water and dried overnight. To stain the dishes, 4 mL 0.2% crystal violet 
staining solution were added to each dish and dishes were incubated on a rocker at 
room temperature. After 3 h, dishes were washed twice with tap water and dried. 
 
To quantify cellular mass, cell bound crystal violet was dissolved in 10% acetic acid. 
Equal amounts were transferred to a spectrophotometer-compatible 96-well plate and 







2.8.1 Cell lysis 
 
Cells were harvested as explained in section 2.2.4.  Samples were lysed in Cell Lysis 
Buffer (to prepare 2.5 mL: 250 µL 10x Cell Lysis Buffer (Cell Signalling, 9803), 100 µL 
cOmplete EDTA-free Protease Inhibitor Cocktail (Roche, 04693159001) and 2150 dH20). 
Cells were incubated on ice for 10 to 20 min and centrifuged 15 min at 10500 rpm at 4 
°C. Supernatants were transferred to new Eppendorf tubes. Protein was store at -80 °C. 
 
2.8.2 Determination of protein concentration 
 
Protein concentration was determined using the Bradford assay. The 5x Bradford 
reagent (Biorad, 500-0006) was diluted 1:5 in dH20. 2 µL of bovine serum albumin (BSA) 
pre-set standards (ThermoFisher, 23208) and samples were mixed with 198 µL of 1x 
Bradford reagent. Absorbance was measured at 595 nm using an iMark microplate 
reader (Biorad). BSA and unknown-concentrated samples were measured in triplicated. 
BSA samples were used to construct a standard curve and the derived regression 
formula was used to calculate the concentration of remaining samples. 
 
2.8.3 SDS-PAGE electrophoresis 
 
To prepare samples for sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE), 15 µg of protein were mixed with 6 µL 6x Laemmli SDS sample buffer, 
reducing (Alfa Aesar, J61337) in a final volume of 36 µL. Samples were boiled 5 min at 
95 °C. Samples were loaded in pre-cast Novex Tris-Glycine gels (Invitrogen). To 
determine protein size, a broad range colour pre-stained protein standard (NEB, P7712) 
was used. Different range or fix-concentrated gels were used depending on the 
molecular sizes of the proteins ot be detected. Pre-cast gels were run in am XCell 
SureLock™ Mini-Cell Electrophoresis tank (ThermoFisher). Tanks were filled with 
Novex Tris-Glycine SDS Running Buffer (10x) (ThermoFisher, LC2675) diluted 1:10 in 




2.8.4 iBlot dry transfer 
 
Samples were transferred into nitrocellulose membranes using the iBlot Gel Transfer 
Device (ThermoFisher) and nitrocellulose transfer stacks (Invitrogen, IB301002), 
following manufacturer’s conditions. Transfer conditions were routinely set to 7 min at 
20 V.  
 
2.8.5 Antibody probing 
 
After transferring, membranes were blocked in TBS supplemented with 5% non-fat 
milk (Marvel) (TBS-milk) 1 h at room temperature on a rocking shaker. Membranes 
were washed with TBS-T and primary antibodies were added. Used antibody 
concentrations are shown in table 2.6. All antibodies were diluted in TBS-milk. 
Membranes were incubated with primary antibodies overnight at 4 C. Membranes were 
then washed 10 times with TBS-T (x3 times) at room temperature on a rocking shaker.  
 
Target Host Supplier  Dilution 
Caspase-4 Mouse Santa Cruz, 4B9 1:1000 
Caspase-1 Mouse Adipogen, Bally-1 1:1000 
Gasdermin-D Rabbit Novus Biologicals, NBP2-33422 1:500 
IL-1b Mouse R&D, MAB201 1:100 – 1:10000 
IL-6 Goat R&D, AF206NA 1:500 
IL-8 Mouse R&D MAB208 1:500 
p53 Mouse Santa Cruz, DO-1 1:1000 
pRb Mouse BD Pharmigen, 554136 1:1000 
p16 Mouse  Santa Cruz, JC-8 1:3000 
b-Actin Goat Santa Cruz, I-19 1:5000 
Table 2.6 Primary antibodies used for immunoblotting procedures 
 
Next, membranes were incubated with secondary antibodies 1 h at room temperature 
on a rocking shaker. The secondary antibodies used are shown in table 2.7. Secondary 





Target Supplier  
Mouse-HRP Sigma, A2554 
Rabbit-HRP Sigma, A0545 
Goat-HRP Santa Cruz, 2020 
Table 2.7 Secondary antibodies used for immunoblotting procedures 
 
After incubation with the secondary antibody, membranes were washed 10 times with 
TBS-T (x3 times) at room temperature on a rocking shaker. Membranes were incubated 
during 2 min with 1:1 solution of A:B pre-mixed enhanced chemiluminescence solution 
(GE Healthcare, RPN2209). To visualize, bands, membranes were exposed to X-ray 





2.9.1 BrdU labelling 
 
BrdU (Sigma, 858811) was added the day before cells were fixed. Briefly, a mastermix 
BrdU solution was prepared by adding 100 µL of 10 mM BrdU stock solution to 10 mL 
of null media. 10 µL of the mastermix BrdU solution were added to each well of a 96-
well plate already containing 100 µL of media (50µM final BrdU concentration / well). 
Plates were placed back in the incubator for 16-18 h, after which, plates were fixed.  
 
2.9.2 Staining protocol 
 
To fix plates, plates were first washed once with 100 µL / well PBS, and then 30 µL of 
4% paraformaldehyde in PBS (FD NeuroTech, PF101) were added to each well. Cells 
were fixed during 45 min at room temperature in a fume hood. Next, plates were 
washed with 100 µL / well PBS (x3 times). To permeabilise cells, 30 μL 0.2% Triton-X100 
/ PBS were added to each well and plates were incubated for 10 min on an orbital shaker 
at room temperature. Next, plates were washed with 100 µL / well PBS (x3 times). Cells 




shaker at room temperature. Next, the immunofluorescence blocking buffer was 
removed and 30 µL / well primary antibody were added. Plates were then incubated for 
1h on an orbital shaker at room temperature. Primary antibodies were diluted in 
immunofluorescence blocking buffer and used as detailed in table 2.8. In addition, the 
anti-BrdU-containing solution was supplemented with 0.5 U / µL DNAse (SIGMA 
D4527) and 1 mM MgCl2 to improve anti-BrdU access DNA-bound BrdU. Wells were 
incubated with anti-BrdU antibody 30 min on an orbital shaker at room temperature. 
 
Target Host Supplier  Dilution 
Caspase-4 Mouse Santa Cruz, 4B9 1:100 
BrdU Mouse BD Biosciences, 555627 1:2000 
IL-1a Mouse R&D, MAB200 1:100 
IL-1b Mouse R&D, MAB201 1:100 
IL-6 Goat R&D, AF206NA 1:100 
IL-8 Mouse R&D MAB208 1:100 
p53 Mouse Santa Cruz, DO-1 1:100 
p21 Mouse Sigma, P1484 1:200 
p16 Rabbit ProteinTech, 10883-1-AP 1:400 
Table 2.8 Primary antibodies used for immunofluorescence procedures 
 
After incubation with the primary antibody, plates were washed with 100 µL / well PBS 
(x3 times). Secondary antibodies, detailed in table 2.9, were diluted 1:1000 in 
immunofluorescence blocking buffer. Secondary antibodies were added (30 µL / well) 
and plates were immediately covered in aluminium foil and incubated for 45 min on an 
orbital shaker at room temperature.  
 
Target Supplier  
Mouse-Alexa Fluor 488 ThermoFisher, A-11029 
Rabbit-Alexa Fluor 594 ThermoFisher, A-11037 
Goat-Alexa Fluor 594 ThermoFisher, A-11058 





After incubation with the secondary antibody, plates were washed with 100 µL / well 
PBS (x3 times). Next, nuclei were stained with 4ʹ,6-diamidino-2-phenylindole (DAPI) 
(Molecular Probes, D1306). To do so, 30 µL / well DAPI (1 µg/mL in PBS) were added 
and plates were incubated for 45 min on an orbital shaker at room temperature covered 
in aluminium foil. After incubation, plates were washed with 100 µL / well PBS (x3 
times).  
 
2.9.3 High-content microscopy 
 
Immunofluorescence was visualized using the high-content microscopy ImageXpress 
Micro XLS High-Content Analysis System (Molecular devices), following 
manufacturer’s instructions. Images were acquired at 10x magnification. Multi-
wavelength cell scoring analysis on acquired data were performed using the 
MetaXpress High-Content Image Acquisition and Analysis software (Molecular 
devices). Thresholds were carefully manually set for positive scoring. DAPI detection 
was used to quantify total cell counts. Exported one-wavelength images of the same 
frame were merged using the software Fiji (ImageJ). 
 
2.10 Enzyme-linked immunosorbent assay (ELISA) 
 
2.10.1 Secreted IL-1b quantification 
 
Detection of secreted IL-1b by ELISA was performed as previously described (321). 
Conditioned media was collected, centrifuged 10 min at 1000 rpm at 4 °C, transferred 
to a new tube and immediately stored at -80 °C. Detection of IL-1b was performed 
following the manufacturer’s instructions of the Human IL-1 beta ELISA Ready-Set-Go! 
Kit (ThermoFisher, 15581087). GraphPad Prism software was used to generate a four-
parameter logistic (4-PL) curve fit and create a standard curve using absorbance values 
of IL-1b standards. Concentrations of unknown samples were then deducted by 





2.11 Caspase-4 fluorometric activity assay 
 
2.11.1 LEVD-AFC cleavage detection 
 
To measure LEVD-AFC cleavage, the Caspase 4 Assay kit (Fluorometric) (Abcam, 
ab65658) was used following manufacturer’s instructions. Briefly, cultured IMR90 
ER:STOP and ER:RAS cells were counted and 2 x 10^6 cells were lysed in 50 µL cell lysis 
buffer and transferred to each well of a black sterile 96-well polystyrene plate 
(ThermoFisher, 137101). After a 10 min incubation on ice, 50 µL of DTT-containing 
reaction buffer was added to each well. 5 µl of 1 mM LEVD-AFC substrate were added 
to each well and the plate was covered with aluminium foil and incubated at 37 °C. 
Fluorescence was measured (excitation filter: 400 nm; emission filter: 505 nm) using 
the Infinite® 200 PRO (Tecan) plate reader. For the time-course experiments, induction 
with 4-hydroxytamoxifen was performed 8 and 4 days before LEVD-AFC cleavage 
detection so that all samples were subject to LEVD-AFC cleavage analysis using the 
same microplate on day 0. 
 
2.12 Detection of caspase-4 oligomerization 
 
2.12.1 Disuccinimidyl suberate (DSS) cross-linking 
 
2 T-6 well / condition were pelleted as explained in section 2.2.4. Fresh pellets were 
resuspended in 0.5 ml of ice-cold buffer A (20 mM HEPES-KOH, pH 7.5; 10 mM KCl; 1.5 
mM MgCl2; 1 mM EDTA; 1 mM EGTA; 320 mM sucrose) and lysed by shearing 10 times 
through a 25-gauge needle in microcentrifuge tubes. Lysates were centrifuged for 8 min 
at 1.800 g at 4 °C and supernatants were transferred to new tubes. At this step, 30 μL of 
lysates were kept as input controls. Remaining supernatants were diluted with 1 volume 
of CHAPS buffer (20 mM HEPES-KOH, pH 7.5; 5 mM MgCl2; 0.5 mM EGTA; 0.1 mM 
PMSF; 0.1% CHAPS) and centrifuged at 5,000 x g for 8 min. Supernatants were 
discarded and pellets resuspended in 50 μL of CHAPS buffer containing 4 mM of 
disuccinimidyl suberate and incubate for 30 min at room temperature to cross-link 




discarded and pellets resuspended in 60 μL of 2x protein loading buffer (2x loading 
buffer is prepared by diluting 4x protein loading buffer (50 mM Tris-HCl, pH 6.8; 2% 
SDS; 10% glycerol; 12.5 mM EDTA; 0.02% bromophenol blue) in dH20. Samples were 
then heated for 2 min at 90 °C. 18 μL of resuspended cross-linked pellets were loaded 
on 4-12% Tris-Glycine SDS-PAGE. Further immunodetection of caspase-4 in both cross-
linked and input samples was performed following standard procedures as described 
in section 2.8.3 – 2.8.5.  
 
2.13 Molecular cloning 
 
2.13.1 Plasmid constructs 
 
Retroviral vectors for gene overexpression were based on the (murine stem sell virus) 
(MSCV) retroviral expression system. The pMSCVpuro empty vector and pMSCVpuro-
HRASG12V were obtained from the laboratory stock plasmid collection. Human CASP1 
and CASP4 coding sequences (CDS) were cloned into the pMSCVpuro empty vector 
plasmid as explained in section 2.13.2 to obtain MSCVpuro-CASP1 and MSCVpuro-
CASp4 respectively. pMSCVpuro-CASP4 C258A for the overexpression of a mutant 
catalytic dead caspase-4 was generated using site-directed mutagenesis as explained in 
section 2.13.3.  
 
Short-hairpin RNA (shRNA) expression was used to stable silence target genes. The 
retroviral vectors pSUPER.retro.puro (pRS) empty backbone vector and pRS-shP53 
were obtained from the laboratory stock plasmid collection. pRS–shCASP4-1 and pRS-
shCASP4-2 were generated by Dr Andrea Quintanilla by inserting the oligonucleotides 
(+) GATCCCCCAACGTATGGCAGGACAAATTCAAGAGATTTGTCCTGCCATACGTTGTTTTTG and 
GATCCCCTAACATAGACCAAATATCCTTCAAGAGAGGATATTTGGTCTATGTTATTTTTG into the 
pRS empty backgone to generate pRS–shCASP4-1 and pRS-shCASP4-2 respectively, and 
according to the pSuper RNAi System manual (OligoEngine) instructions. 
 
To stably silence target genes through shRNA expression, lentiviral vectors belonging 




empty backbone, pGIPZ-shP53 and pGIPZ-shCASP1 (V3LHS_392179) were obtained 
from the laboratory stock plasmid collection. pGIPZ-shCASP4 (V3LHS_338745) was 
purchased from Dharmacon. 
 
pCMV-VSVG, pUMVC3-gag-pol, psPAX2, pBABE-GFP and pULTRA were obtained 
from the laboratory stock plasmid and used during the generation of stable cell lines 
by retroviral and lentiviral infections either because necessary for viral packaging 
(pCMV-VSVG, pUMVC3-gag-pol and psPAX2) or for infection control due to lack of 
puromycin resistance (pBABE-GFP and pULTRA). 
 
pLVX-Tet-On Advanced was obtained from the laboratory stock plasmid collection. 
pLVX-Tet-On-GSDMD-FL and pLVX-Tet-On-GSDMD-Nter were generated as 
explained in section 2.13.2. 
 
pQXCIN-BirA-Myc-C and pQXCIN-Myc-BirA-N were obtained from the laboratory 
stock plasmid collection. pQXCIN-CASP4-BirA-Myc-C, pQXCIN-Myc-BirA-CASP4-N 
and pQXCIN-Myc-BirA-CASP1-N were generated as explained in section 2.13.2. 
 
Plasmids were validated before use by Sanger sequencing using the in-house MRC HGU 
Technical Services. 
 
2.13.2 Coding sequence (CDS) amplification by polymerase chain 
reaction (PCR) 
 
Total RNA extracted from IMR90 cells was converted into cDNA generating a human 
coding sequence (CDS) library using standard retro-transcription procedures (see 
section 2.14.2). To clone into the pMSCVpuro empty vector, CASP1 and CASP4 CDS 
were amplified from the obtained CDS human library using customized primers with 
overhangs including recognition sites for selected restriction enzymes (table 2.10). The 
destination vector, pMSCVpuro, includes a modified multiple cloning site in which the 






For the biotin identification (BioID) proximity-labelling system experiments, CASP1 
and CASP4 CDS were cloned into the pQCXIN-BirA-Myc-C and pQCXIN-BirA-Myc-N. 
CASP1 and CASP4 CDS with customized overhangs (see table 2.x) were amplified from 
the pMSCVpuro-CASP1 and pMSCVpuro-CASP4 plasmids originally generated during 
this thesis and earlier mentioned. 
 
Full-length and the fragment coding for the N-terminal domain of GSDMD were cloned 
into the pLVX-Tet-On vector. CDS fragments were obtained from the human CDS 
library obtained from IMR90 cells as explained previously. 
 
Amplified DNA Destination vector 
Restriction 
enzymes Forward primer (5’ à 3’) Reverse primer (5’ à 3’) 
Human CASP1 












































pLVX-Tet-On EcoRI-BglII ATTTAGAATTCATGGGGTCGGCCTTTGA 
AACCAAGATCTCTAATCTGT
CAGGAAGTTGTGGAGG 
Table 2.10 Coding sequence (CDS) DNA fragments obtained by PCR 
The table shows a list of the amplified CDS fragments, their destination vector and the 
restriction enzymes used to ligate the inserts into the destination vector. 
 
 
PCR were performed using either Q5 high-fidelity DNA polymerase (New England 
Biolabs, M0491) or Phusion High-Fidelity PCR Master Mix with HF Buffer polymerase 
(New England Biolabs, M0531) using the SureCycler 8800 thermal cycler (Agilent); 







2.13.3 Site-directed mutagenesis by PCR 
 
The catalytically dead caspase-4 overexpressing retroviral vector pMSCVpuro-CASP4 
C258A was obtained through site-directed mutagenesis by PCR using the Q5 Site-
Directed Mutagenesis Kit (New England Biolabs, E0554S) and following manufacturer’s 
instructions. To perform the substitutional mutation (bases TGC to bases GCC at 
positions 772-774 of the 1134 bp CASP4CDS fragment), the NEBaseChanger online tool 
(New England Biolabs) was used and the following primers were picked: forward (5à3’) 
TGTCCAGGCCgccAGAGGTGCAA; reverse (5à3’) ATGATGACCTTGGGTTTG. The thermocycling 
conditions used to amplify the CDS fragment were: 30 s at 98 °C; 25 cycles of 10 s at 98 
°C, 30 s at 60 °C and 4 min and 30 s at 72 °C; 2 min at 72 °C.  
 
2.13.4 DNA digestion, ligation and bacterial methods 
 
DNA sizes (kb) were checked by agarose gel electrophoresis before digestion with 
selected restriction enzymes. All restriction enzymes used were purchased from New 
England Biolabs. Vectors were also linearized using chosen restriction enzymes. When 
two different enzymes were used, sequential digestion was performed if enzyme 
activities were not compatible in the same digestion buffer. 
 
Ligation was performed using the T4 DNA ligase (New England Biolabs, M0202S) 
following manufacturer’s instructions. Broadly, 50 ng of vector DNA were mixed with 
the insert DNA in a 3:1 insert:vector DNA molar ratio, reagents added and the mix 
incubated overnight at 16 °C. 
 
To transform bacteria, 5 µL of ligation product were added to 25 µl of 5-alpha 
competent Escherichia coli (New England Biolabs, C2987) and placed on ice for 15 min. 
Then, to heat-shock bacteria, tubes were incubated at 42 °C for 45 s and placed back on 
ice for 5 min. Next, 2-5 µL of bacteria were spread on L-Agar plates supplemented with 






 The following day, isolated colonies were picked and further grown in 120 mL of L-
Broth, supplemented with the antibiotic of choice, for 16 h. To generate glycerol 
plasmid stocks, the following day 10 mL of bacterial culture were centrifuged at 4.000 
rpm 15 min at 4 °C. Supernatant was discarded and the pellet was resuspended in 1 mL 
of a 50% LB/glycerol sterile solution. Glycerol stocks were stored at -80 °C.  
 
For plasmid extraction and purification, the the QIAGEN Plasmid Plus Midi Kit 
(Qiagen, 12945) was used following manufacturer’s instructions. DNA was quantified 
using a Nanodrop 2000C (Thermo Scientific) spectrophotometer and stored at – 20 °C 
until further use. 
 
2.14 Quantitative-reverse transcription polymerase 
chain reaction (qRT-PCR) 
 
2.14.1 RNA extraction 
 
Cells were harvested as explained in section 2.2.4. RNA was extracted using the RNeasy 
Plus Mini kit (Qiagen, 74134), following manufacturer’s instructions. During RNA 
extraction, cell lysates were homogenized using QIAshredder (Qiagen, 79654). RNA 
was eluted in ultrapure DNase/RNase-free distilled water (ThermoFisher, 10977049), 
quantified using a a Nanodrop 2000C (Thermo Scientific) spectrophotometer and 
stored at – 80 °C. 
 
2.14.2 Complementary DNA (cDNA) synthesis 
 
RNA was transformed into cDNA using qSscript cDNA Supermix (Quanta Biosciences, 
95048-100). Reactions were prepared in 0.2 mL 8-tube strips (Applied Biosystems, 
N8010580). 1 µg RNA was mixed with 4 µL of qScript cDNA SuperMix (5X) and topped 
to 20 µL final volume with ultrapure DNase/RNase-free distilled water (ThermoFisher, 
10977049). Samples were incubated sequentially 5 min at 25 °C, 30 min at 42 °C and 5 
min at 85ºC in a SureCycler 8800 thermal cycler (Agilent). cDNA was stored at -20 °C 




2.14.3 Quantitative PCR  
 
Primer sequences which were not already part of the laboratory primer stock collection 
were either retrieved from published data by others or newly designed. New primers 
were designed to have a length of 18-20 nucleotides and to amplify a DNA fragment 
between 120 and 180 nucleotides. Paired primers were designed to amplify a fragment 
containing an exon-exon junction to ensure only the CDS was amplified. Primer 
properties such as melting temperature or self-dimer and hetero-dimer tendencies 
were analysed using the online OligoAnalyzer Tool (Integrated DNA technologies). 
Primers were purchased from Sigma as dried DNA oligos in tubes. When received, 
primers were resuspended to 100 µM stock concentration. Intermediate 5 µM stocks 
were also prepared to avoid continuous thaw-freeze cycles of the 100 µM stocks. 
Primers were always resuspended and diluted in ultrapure DNase/RNase-free distilled 
water (ThermoFisher, 10977049). Primer sequences are shown in table 2.11.  
 
Reaction samples were loaded in triplicate in 96-well PCR plates (Starlab, E1403-7700). 
Each well contained: 1 µL of cDNA, 200 nM forward primer, 200 nM reverse primer, 1x 
SYBR Select Master Mix (Applied Biosystems, 4472908S) and up to 20 µL of ultrapure 
DNase/RNase-free distilled water (ThermoFisher, 10977049), except for reactions 
targeting the housekeeping gene (ACTB), where primers were added at a 100 nM final 
concentration instead of 200 nM. Plates were loaded into the StepOnePlus Real-Time 
PCR System (ThermoFisher, 4376600). The following PCR cycling parameters were 
used: 10 min at 95 °C; 40 cycles of 15 s at 95 °C, 30 s at 60 °C and 15 s at 72 °C; 15 s at 95 
°C. A ramp step (0.3 °C / 5 s) 60 °C to 95 °C was added immediately after the 
amplification stage to generate the melting curve. StepOnePlus Real-Time PCR System 
software was used to select PCR parameters and to analyse the quality of results once 
the qPCR was performed, including analysis of the melting curve and threshold cycle 
(Ct).  Data was analysed using the double Delta Ct method (322). ACTB mRNA 









Target Forward primer (5’ à 3’) Reverse primer (5’ à 3’) 
ACTB CATGTACGTTGCTATCCAGGC CTCCTTAATGTCACGCACGAT 
CASP1 CAACTACAGAAGAGTTTGAGG AACATTATCTGGTGTGGAAG 
CASP4 GAGAAGCAACGTATGGCAGG GGAATTCTTCATGAGGACAAAGC 
IL1B TGCACGCTCCGGGACTCACA CATGGAGAACACCACTTGTTGCTCC 
IL1A AGTGCTGCTGAAGGAGATGCCTGA CCCCTGCCAAGCACACCCAGTA 
IL6 CCAGGAGCCCAGCTATGAAC CCCAGGGAGAAGGCAACTG 
IL8 GAGTGGACCACACTGCGCCA TCCACAACCCTCTGCACCCAGT 
GSDMD ATGGATGGGCAGATACAGGG TGCTGCAGGACTTTGTGTTC 
CDKN1A CCTGTCACTGTCTTGTACCCT GCGTTTGGAGTGGTAGAAATCT 
CDKN2A CGGTCGGAGGCCGATCCAG GCGCCGTGGAGCAGCAGCAGCT 
CDK1 CTTGGCTTCAAAGCTGGCTC GGGTATGGTAGATCCCGGCT 
BUB1 ACACCATTCCACAAGCTT CGCCTGGGTACACTGTTT 
CDC6 GTTCAATTCTGTGCCCGCAA TAGCTCTCCTGCAAACATCCAG 
CCNA2 AGGAAAACTTCAGCTTGTGGG CACAAACTCTGCTACTTCTGGG 
CCNB1 TGTGTCAGGCTTTCTCTGATG TTGGTCTGACTGCTTGCTCT 
MCM2 GTGGATAAGGCTCGTCAGAT GTCGTGGCTGAACTTGTT 
SAA1 GAGCACACCAAGGAGTGATTT GAAGCTTCATGGTGCTCTCT 
SAA2 GCTGCAGAAGTGATCAGCAAT CAGCGAGTCCTCCGCAC 
APAF1 CTCTCATTTGCTGATGTCGC TCGAAATACCATGTTTGGTCA 
DIABLO AATGTGATTCCTGGCGGTTA AGCTGGAAACCACTTGGATG 
CYCS GGCTGCAGTGTAGCTGTGAT GATGGAGTTTCCTTTATCTGTTGC 
GBP1 GGTCCAGTTGCTGAAAGAGC CTTGGTTAGGGGTGACAGGA 
Table 2.11 Primers used for qPCR 











2.15.1 Ampliseq targeted RNA sequencing 
 
For Ampliseq targeted RNA sequencing, RNA was extracted as explained in section 
2.14.1. RNA quality control, reverse transcription, library preparation and sequencing 
were performed by the Wellcome Trust Clinical Research facility (WTCRF) as explained 
below. 
 
RNA samples were assessed for quality on the Bioanalyser 2100 Electrophoresis 
Instrument (Agilent, G2939AA) with the RNA 6000 Nano Kit (Agilent, 5067-1511), 
providing an RNA Integrity Number (RIN). Samples were quantified using the Qubit 
2.0 fluorometer (Q32866) and the Qubit RNA Broad Range assay (Q10210). 10 ng of RNA 
was reverse-transcribed to make cDNA, and then target genes were amplified for 12 
cycles of PCR using the Ion AmpliSeq Human Gene Expression Core Panel 
(Thermofisher, A26325). This panel contains a pool of 20,802 amplicons (41,604 
primers) of approximately 150 bases in length. Ion Torrent sequencing adapters and 
barcodes Ion XpressTM Barcode Adapters (Ion XpressTM Barcode Adapters, 4471250 
and 4468802) were ligated to the amplicons and adapter-ligated libraries were purified 
using AMPure XP beads. Libraries were quantified by qPCR and diluted to 100 pM 
before being combined in equimolar pools of 8 per each chip (ThermoScientfic, Ion PI 
Chip Kit v3). Sequencing was performed using the Ion PI Hi-Q Sequencing 200 Kit 
(ThermoFisher, A26433) and the Ion Proton platform (ThermoFisher, 2456290-0449).  
 
The WTCRF also conducted a first analysis of the Ion AmpliSeq Transcriptome 
libraries. Sequence reads were mapped to the 
hg19_AmpliSeq_Transcriptome_ERCC_v1.fasta reference. Next, matches per amplicon 
were quantified using defined amplicon regions from the 
hg19_AmpliSeq_Transcriptome_21K_v1.bed file. BAM files were generated using the 
Torrent Suite software v 5.2.0 (ThermoFisher). The ECRf provided the sequencing 






2.15.2 Differentially expressed gene (DEG) analysis 
 
DEG analysis was performed with the R Bioconductor package DESeq2 (323), using the 
matrix of read counts as input. Results tables with log2 fold changes, p values and 
adjusted p values were generated using the function results. Differential gene 
expression analysis results were explored using the plotMA function. Count data was 
transformed for clustering visualization using heatmaps and principal component 
analysis (PCA). 
 
2.15.3 Gene set enrichment analysis (GSEA) 
 
Gene Set Enrichment Analysis (GSEA) was performed using the Broad Institute GSEA 
software (324). The log2FC values obtained after the DEG analysis were used as inputs 
for the GSEA. Normalized Enrichment Scores (NES) were calculated for each of 50 
hallmark gene sets; each hallmark gene set being a specific well-characterized group of 
genes related to a biological process. A GSEA was also performed using the same input 
against a collection of 615 gene sets; each set contains a number of genes that share 
upstream cis-regulatory motifs which can function as potential transcription factor 
binding sites (325). 
 
2.16 Protein-protein interaction screening by 
proximity-labelling 
 
2.16.1 In situ proximal biotinylation 
 
Overexpression of the retroviral vectors encoding the fusion caspase-1/caspase-4-biotin 
ligase (BirA) proteins, as well as the BirA control, was performed as detailed in section 
2.3.1. Three days after the addition of 4-hydroxy-tamoxifen, biotin was added at a final 






2.16.2 Biotin-affinity capture 
 
22h after the addition of biotin, cells were collected as explained in section 2.2.1.  Each 
pellet was lysed in 400 µL of Cell Lysis Buffer (to prepare 2.5 mL: 250 µL 10x Cell Lysis 
Buffer (Cell Signalling, 9803), 100 µL cOmplete EDTA-free Protease Inhibitor Cocktail 
(Roche, 04693159001) and 2150 dH20). Cells were incubated on ice for 20 min and 
centrifuged 15 min at 14000 rpm at 4 °C. Supernatants were transferred to new 
Eppendorf tubes. 50 µl magnetic Myone Streptavidin Dynabeads (Thermo Fisher, 
65601) conjugated were added to approximately 350 µl lysate and samples were 
incubated overnight at 4 °C on a tube rotator. The following day samples were washed 
twice in ice-cold PBS and transferred to the IGMM Mass Spectrometry facilities. 
 
2.16.3 Mass spectrometry 
 
Sample preparation of mass spectrometry (MS) and MS were performed by the IGMM 
Mass Spectrometry facilities as explained next. Beads were incubated in 50 μL for 30 
minutes at 27°C with 0.3 μg trypsin in 2M urea, 50mM tris pH8, and the resulting 
supernatant transferred to a fresh tube.  Beads were washed in a further 50 μL of the 
same buffer with Dithiothreitol (DTT) added to 10 mM.  The wash was combined with 
the initial supernatant and incubated overnight at 37°C in a wet chamber.  
Iodoacetamide was added to 55 mM and after 30 minutes incubation at room 
temperature the solution was acidified by adding 8 μL of 10 % Trifluoroacetic acid 
(TFA). 50 μL of the resulting peptide solution was loaded onto an activated (20 µL 
methanol), equilibrated (50 µL 0.1% TFA) C18 Stage tip, and washed with 50 μL 0.1% 
TFA.  The bound peptides were eluted into a 96-well PCR plate (Axymat) with 40 μL 
80% Acetonitrile (ACN) 0.1% TFA and concentrated to less than 8 µL in a vacuum 
concentrator.  The final volume was adjusted to 15 uL with 0.1% TFA. Online LC was 
performed using a Dionex RSLC Nano (Thermo Scientific).  Following the C18 clean-
up, 5 µL peptides (~ a fifth of the beads input) were injected onto a home-pulled, home-
packed C18 analytical column over a gradient of 2%-40% ACN in 40 minutes, with 0.1% 
TFA throughout.  Eluting peptides were ionised at +2kV before data-dependent analysis 
on a Thermo Q-Exactive Plus (Thermo Scientific). First stage of MS (MS1) was acquired 




fragmentation with normalised collision energy of 30, and an exclusion window of 30 
seconds.  Second stage of MS (MS2) were collected with resolution 17,500. The AGC 
targets for MS1 and MS2 were 3e6 and 1e5 respectively, and all spectra were acquired 
without lockmass and 1 microscan. Finally, the data were analysed using MaxQuant 
(version MaxQuant_1.5.7.0). The IGMM Mass Spectrometry facilities provided logFC 
values for each protein in each sample. 
 
2.16.4 Data analysis 
 
Frequent contaminants in experiments using streptavidin pull-down approaches in 
Homo sapiens were discarded using data sets available at the contaminant repository 
for affinity purification website (www.crapome.org). A logFC value > 2.0 was 
estabishled as threshold for hit selection. To analyse subcellular localisation, a protein 
ID list of caspase-1 and caspase-4 interactor hits was used as input and submitted to 
gene ontology – cellular compartment analysis using the DAVID Bioinformatics 
Resources 6.8 online tool. To identify all CARD-containing proteins, the IPR001315 
CARD domain Homo sapiens list from the EMBL-EBI Interpro classification containing 
35 unique proteins was used. 
 
2.17 Statistical methods 
 
Experimental data were analysed as described in figure legends. Continuous variables 
were described as means and standard error of the mean (s.e.m). Categorical variables 
were described as frequencies and percentages. Normality of the residuals of the mixed 
models were assessed. In case of normal distribution, differences among study groups 
or times of assessments of continuous variables were analysed through one-way 
ANOVA. For each continuous variable, the overall F test was first assessed for 
significance. If it was significant, two-sided comparisons between each group and 
control were performed. Each pair-wise comparison was corrected using Bonferroni 
test, in order to control for the experiment-wise error rate. All statistical analyses were 
performed using GraphPad Prism version (version 7.0 for Mac GraphPad Software, La 





Chapter 3 - Caspase-4 is required for a complete 
SASP in OIS 
 
 
3.1  RASG12V-OIS as a model to study senescence 
 
3.1.1 Constitutive RASG12V overexpression drives OIS in IMR90 cells 
 
To model OIS, the overexpression of H-RASG12V (RASG12V from hereon) in IMR90 cells 
has been used throughout this thesis. To induce OIS by constitutive overexpression of 
RASG12V, IMR90 cells were infected with retroviral viruses carrying either a control or a 
RASG12V-encoding construct, as detailed in section 2.3.1 (Figure 3.1).  
 
 
Figure 3.1 Constitutive overexpression of RASG12V model 
Schematic representation of constitutively overexpressed RASG12V-driven OIS model in IMR90 
cells. 
 
Stably transfected cells were seeded at equal numbers prior to the assessment of 
senescence markers. RASG12V-overexpressing cells showed clear senescent features such 
as decreased BrdU incorporation or increased SA-b-galactosidase positive staining 



























































































Figure 3.2 Constitutive overexpression of RASG12V drives OIS in IMR90 cells 
Once IMR90 human fibroblasts infected with either the empty or the RASG12V overexpression 
vector were selected, cells were counted and equal numbers of cells were seeded. Quantification 
of BrdU incorporation and SA-b-galactosidase activity was performed four days after equal cell 
numbers were seeded. Representative pictures of the SA-b-galactosidase staining of one 




3.1.2 Inducible model of OIS in IMR90 cells: the ER:RAS system 
 
To exert a tight control on the onset of senescence, an inducible system extensively 
used to generate conditional forms of transcription factors and protein kinases (326) 
was used. This system is based on the use of a construct consisting of a mutant form of 
the estrogen receptor (ER) ligand-binding domain fused to the protein of interest, RAS, 
in cis (327). If no synthetic ER ligand 4-hydroxytamoxifen (4OHT) is added, the fused 
protein of interest remains complexed to inhibitory proteins. In contrast, addition of 
4-hydroxytamoxifen releases the fusion protein from the inhibitory proteins, allowing 
activation of the protein of interest (328). Using this system to generate an inducible 
OIS model, IMR90 human fibroblasts are stably modified to either express a control 
construct (the modified ER coupled to a stop codon, i.e. ER:STOP) or the ER fused to 





























































































Figure 3.3 Inducible activation of RASG12V drives OIS in IMR90 cells 
A. Schematic representation of the inducible ER:RAS OIS model in IMR90 cells. B. Equal 
amounts of cells were seeded; BrdU was quantified five days after the addition of 4OHT (upper 
left) and SA-b-galactosidase activity was quantified one week after the addition of 4OHT (lower 
left). Representative pictures of the SA-b-galactosidase staining are shown on the right.  
 Data shown as mean ± s.e.m of n=3 experiments, paired t test of each condition treated with 4-
hydroxytamoxifen compared to its non-treated counterpart, *=p<0.05, **=p<0.01, ns = non-
















































































3.2  Caspase-4 expression is increased in OIS 
 
A first approach towards investigating inflammatory caspases in senescence was 
conducted by studying the levels of caspase-1 and caspase-4 expression in RASG12V-
driven OIS. Furthermore, the proteolytic activity of caspase-4 in OIS was also 
investigated using a fluorometric assay based on cleavage specificity. Finally, the 
oligomeric state of caspase-4 was interrogated. 
 
3.2.1 Caspase-4 levels are increased in RASG12V-induced senescence 
 
To induce OIS, RASG12V was constitutively overexpressed in IMR90 fibroblasts. Cells 
infected with either a control empty vector or the RASG12V construct were analysed by 
RT-qPCR and immunofluorescence to study the levels of endogenous inflammatory 
caspases. In contrast to CASP1, CASP4 transcription was increased in OIS (Figure 3.4) 




Figure 3.4 CASP4 mRNA expression but not CASP1 is increased in RASG12V-OIS 
CDKN2A, CASP1 and CASP4 relative mRNA levels were quantified by RT-qPCR analysis after 
RNA extraction of control (empty vector) and RASG12V overexpressing IMR90 cells. Data shown 






























Figure 3.5 Caspase-4 protein levels are increased in RASG12V-OIS 
A. Quantification of BrdU incorporation and endogenous caspase-4 protein in IMR90 cells 
overexpressing the empty vector control or RASG12V using high-content analysis. B. 
Representative images of IMR90 cells stained for caspase-4 (FITC) and DAPI used for the 



































Next, CASP-1 and -4 expression was further analysed using the inducible RASG12V model. 
A time-course analysis of CASP1 and CASP4 mRNA expression every 48h until 8 days 
after the addition of 4-hydroxytamoxifen was performed. Interestingly, CASP4 but not 
CASP1 mRNA expression increased from the early stages after the induction of OIS, in 




Figure 3.6 CASP4 expression increases over time in an inducible model of RASG12V-OIS 
(A) CASP1, (B) CASP4 and (C) IL1B relative mRNA levels were quantified by RT-qPCR analysis 
after RNA extraction of ER:STOP and ER:RAS cells 0, 2, 4, 6 and 8 days after 4-hydroxytamoxifen 
addition. 





3.2.2 LEVD-AFC cleavage is increased in OIS 
 
Over the last 20 years, the substrate specificity of caspases has been investigated using 
different biochemical in vitro assays of varying complexity. Although there is some 
controversy regarding these studies (see section 1.2.1.1 Classification and function of 
caspases), researchers concluded that caspase-4 has preferential cleavage activity after 
the LEVD amino acid sequence. Consequently, specific probes have been designed for 
colorimetric and fluorometric detection of cleavage after the LEVD amino acid 
sequence. These probes are synthetic substrates containing the peptide sequence and 
a reporter. For instance, in a fluorometric assay, a fluorophore is used as a reporter 
A B C



































































































































































because its emitted fluorescence at a particular wavelength can be detected and 
quantified.  
 
To examine caspase-4 activity in senescence, the LEVD-AFC fluorogenic substrate was 
used as a readout for caspase-4 proteolytic activity. In this assay, upon protease 
cleavage of the substrate (LEVD-AFC), the fluorophore (AFC) is released and its 
emission spectra shifts, namely LEVD-bound AFC emits blue light whereas free AFC 
emits yellow-green fluorescence.  
 
LEVD-AFC cleavage was examined after 4 days of 4-hydroxytamoxifen in IMR90 
ER:STOP/ER:RAS cells cultured in two different serum percentages of cell media, 0.5% 
and 10% (Figure 3.7). Fluorescence values were recorded every 10 minutes during the 
incubation of the cell lysates with the fluorogenic substrates. To avoid a confounding 
factor due to potential different autofluorescence in control and senescent cells, 
absolute values of fluorescence intensity were corrected by autofluorescence values 
(fluorescence of cell lysates without substrate). An increase in fluorescence intensity in 
senescent cells was observed independent of the serum conditions in which cells were 
grown. Moreover, LEVD-AFC cleavage analysis in a RASG12V-OIS time-course revealed 
that senescent cells display approximately twice cleavage activity than proliferating 
cells 4 and 8 after 4-hydroxytamoxifen addition. In all, these experiments show an 







Figure 3.7 LEVD-AFC cleavage is increased in RASG12V-OIS 
LEVD-AFC cleavage was measured in IMR90 ER:STOP/ER:RAS cells cultured either in (A) low-
serum (0.5% FBS) or (B) normal serum (10% FBS) 4 days after 4-hydroxytamoxifen addition. Cell 
lysates were incubated with the fluorogenic substrate and fluorescence was measured every 10 
minutes. C. LEVD-AFC cleavage was measured in low serum (0.5% FBS) in a time-course 
experiment 4 and 8 days after 4-hydroxytamoxifen addition. Fluorescence was measured after 
100 min of incubation of the cell lysates with the fluorogenic substrate. To calculate relative 
fluorescence intensity values, all corrected absolute fluorescence intensity values were made 
relative to ER:STOP cells at 0 days of 4-hydroxytamoxifen addition.   
All data shown as mean ± s.e.m of n=3 experiments, multiple t tests, *=p<0.05. 4OHT = 4-
hydroxytamoxifen; a.u. = arbitrary units.  
 
 
3.2.3 Caspase-4 activity is increased in OIS 
 
Oligomerization of caspase-4 is essential for its activity (193). To further explore 
caspase-4 activation in senescence, an assay was performed to investigate whether 
caspase-4 is found in an oligomeric state in senescence. Disuccinimidyl suberate (DSS) 
was used to crosslink the samples previous to SDS-PAGE resolution. High molecular 
size bands appeared 3 days after 4-hydroxytamoxifen addition in senescent (ER:RAS) 





















































































Figure 3.8 Caspase-4 oligomerizes during OIS 
DSS-crosslinked samples were eluted in 2x loading buffer and loaded on a 10-20% 
gradient Tris-Glycine gel. After SDS-PAGE separation, both DSS-crosslinked samples 
and inputs (2.5%) were transferred to nitrocellulose membranes and probed for 
caspase-4 following regular western blot procedures. Blots belong to one representative 










































3.3 Transcriptomic analysis  
 
To further investigate the potential role of caspase-4 in RASG12V-OIS, whether global 
changes in mRNA expression would occur upon caspase-4 depletion was interrogated. 
Data mining of the transcriptomic results was conducted through differentially 
expressed gene (DEG) analysis and gene set enrichment analysis (GSEA).  
 
3.3.1 Experimental design and quality control  
 
siRNA technology was used to knock-down the target gene (CASP4). First, a pilot 
experiment was conducted to explore the efficiency of the knock-down. Targeting 
CASP4 with a pool of four different siRNA sequences (siCASP4) significantly reduced 
CASP4 mRNA expression, thus validating the use of these reagents for further 




Figure 3.9 SiRNA-mediated targeting of CASP4 effectively reduces the levels of CASP4 
mRNA 
ER:STOP and ER:RAS cells were transfected 0, 3 and 5 days after 4-hydroxytamoxifen addition 
with a pool of 4 control siRNAs with no target (non-target pool, NTP) or targeting CASP4. A. 
CASP4 mRNA expression 5 and 8 days after 4-hydroxytamoxifen addition was quantified by RT-
qPCR. B. Caspase-4 protein expression was analysed by western blotting 5 days after 4-
hydroxytamoxifen addition.  

















































Next, a transcriptomics experiment was performed to assess the effect of CASP4 knock-
down in OIS. ER:RAS cells were transfected with either a control non-targeting pool 
siRNA (siNTP) or a CASP4-targeting pool(siCASP4). ER:STOP cells were also 




Figure 3.10 Experimental design for the combined approach of transcriptomic analysis 
following siRNA-mediated targeting of CASP4 in RASG12V-OIS 
The diagram depicts the rationale and strategy supporting the transcriptomics experiment. 
4OHT = 4-hydroxytamoxifen; NTP = non-targeting pool. 
 
 
Because of the transient nature of siRNA, cells were transfected several times (day 0, 3 
and 5 after 4-hydroxytamoxifen addition) to maintain the knockdown effect. RNA was 
extracted 5 and 8 days after 4-hydroxytamoxifen addition. Three biological replicates 
of this experiment were performed. RNA quality control (QC), library preparation and 
sequencing using Ampliseq transcriptome technology were conducted by the WTCRF 
facilities at the Western General Hospital. RNA QC results showed optimal RNA 
quality, with all samples having and RNA Integrity number (RIN) > 9.0. Each library 
generated more than 11 x 10^6 reads and 95% valid reads per sample (above the expected 
for this sequencing technology). The WTCRF facilities conducted raw data processing, 
















































Figure 3.11 Schematic diagram of the experimental setup and  sequencing pipeline 
ER:STOP and ER:RAS cells were transfected with siRNA 0 and 3 days after 4-hydroxytamoxifen 
addition for day 5 cell harvest, or on day 0, 3 and 5 for day 8 cell harvest. Extracted RNA was 
submitted to Ampliseq sequencing. 4OHT = 4-hydroxytamoxifen.  
 
 
3.3.2 DEG analysis: exploration of results 
 
Differentially expressed gene (DEG) analysis was conducted using the DESeq2 package. 
Similarities between replicates and differential behaviour between conditions where 
confirmed by principal component analysis (PCA) visualization and heatmap sample 




Figure 3.12 PCA visualization of DEG analysis results 
PCA of variance stabilized transformed data using a parametric fit for the dispersion. Each dot 







































































































































































































































































































































































































































































































































































































































































































































































































(See previous page). Top: heatmap and hierarchical clustering of the sample-to-sample 
distances. Bottom: heatmap of the 30 genes with highest variance across all samples based on 
the total transformed data. Control = transfected with non-targeting siRNA; siC4 = transfected 
with CASP4-targeting siRNA; r1 = replicate 1; r2 = replicate 2; r3 = replicate 3. 
 
The DEG analysis identified 557 and 478 genes significantly differentially expressed (p-
adjusted <0.01) upon CASP4 targeting 5 and 8 days after 4-hydroxytamoxifen addition, 
respectively (Figure 3.14). 
 
Figure 3.14 DEG analysis after CASP4-targeting in ER:RAS 
Log2 fold expression changes over the mean of normalized gene counts of CASP4-knockdown 
ER:RAS samples compared to control ER:RAS samples after 5 days (A) or 8 days (B) of 4-
hydroxytamoxifen treatment. Each point represents a gene, which appears red-coloured when 
its adjusted p value is less than 0.01. Points which fall out of the window are plotted as triangles. 







































The top downregulated gene at day 5 and day 8 was CASP4, validating an efficient 
siRNA knockdown (Table 3.1). 
 
Day 5  Day 8 




GREM1 1.55E-12 CNN1 9.23E-19 
LARP1 6.66E-08 ACTG2 1.29E-18 
IL1A 1.31E-07 SERPINA9 2.61E-18 
VASN 6.34E-07 ANO4 1.14E-14 
 
Table 3.1 Top differentially expressed genes upon CASP4 targeting 
List of the top five differentially expressed genes upon between CASP4-knockdown ER:RAS and 
control ER:RAS five and eight days after 4-hydroxytamoxifen. p-adj = adjusted p-value.  
 
 
3.3.3 Gene Set Enrichment Analysis (GSEA) 
 
Next, a GSEA was performed and the Normalized Enriched Scores (NES), p-values and 
False Discovery Rate (FDR) q-values of different gene sets were examined. These 
statistics are defined as (324):  
• NES: the enrichment score for the gene set after it has been normalized across 
analysed genes sets 
• p-value: the statistical significance of the enrichment score 
• FDR q-value: the estimated probability that the normalized enrichment score 
represents a positive finding 
Importantly, whereas the FDR q-value is adjusted for gene size and multiple hypotheses 
testing, the p-value is not. Therefore, if a gene set has a small p-value but a high FDR 
q-value, it generally means that it is not as significant when compared with other gene 
sets in an empirical null distribution. 
 
NES obtained through GSEA of 50 hallmark gene sets showed a positive regulation of 
CASP4 in RASG12V-OIS of gene signatures related to inflammatory processes, including 
TNF-a signalling and interferon responses both 5 and 8 days after the addition of 4-






Table 3.2 GSEA identifies pathways regulated by CASP4 in RASG12V-OIS 
Normalized Enriched Scores (NES) of curated hallmark gene signatures were calculated based 
on the DEG analysis performed between control ER:RAS and CASP4-knockdown ER:RAS 
samples after 5 days or 8 days of 4-hydroxytamoxifen treatment. Gene sets with positive NES 
are positively regulated by CASP4 whereas gene sets with negative NES are negatively regulated 
by CASP4. FDR q-val = false discovery rate q-value. 
 
Gene set:
Day 5 Day 8
NES p-value FDR q-val NES p-value FDR q-val
TNFA SIGNALING VIA NFKB 1.845 <0.001 0.001 1.571 <0.001 0.054
INTERFERON GAMMA RESPONSE 1.574 <0.001 0.046 0.973 0.480 0.683
UV RESPONSE UP 1.439 0.004 0.132 1.041 0.354 0.562
APOPTOSIS 1.407 0.013 0.136 1.520 <0.001 0.055
CHOLESTEROL HOMEOSTASIS 1.354 0.029 0.188 0.985 0.467 0.709
INFLAMMATORY RESPONSE 1.336 0.023 0.184 1.607 <0.001 0.069
P53 PATHWAY 1.307 0.015 0.212 0.983 0.558 0.681
COMPLEMENT 1.300 0.022 0.198 1.250 0.077 0.312
PI3K AKT MTOR SIGNALING 1.268 0.074 0.234 -0.955 0.554 1.000
REACTIVE OXIGEN SPECIES PATHWAY 1.234 0.136 0.276 1.019 0.400 0.608
ESTROGEN RESPONSE LATE 1.231 0.040 0.259 -1.197 0.093 0.521
INTERFERON ALPHA RESPONSE 1.214 0.135 0.273 1.065 0.327 0.543
FATTY ACID METABOLISM 1.195 0.107 0.294 -0.787 0.949 1.000
IL6 JAK STAT3 SIGNALING 1.180 0.164 0.309 1.238 0.094 0.267
KRAS SIGNALING UP 1.173 0.125 0.305 -1.037 0.378 0.866
XENOBIOTIC METABOLISM 1.161 0.128 0.311 1.113 0.190 0.449
OXIDATIVE PHOSPHORYLATION 1.108 0.175 0.421 0.530 1.000 0.999
COAGULATION 1.086 0.245 0.467 1.103 0.247 0.452
HYPOXIA 1.080 0.262 0.458 1.044 0.329 0.583
NOTCH SIGNALING 1.074 0.334 0.455 1.178 0.212 0.390
ESTROGEN RESPONSE EARLY 0.950 0.571 0.875 -1.099 0.249 0.883
MTORC1 SIGNALING 0.886 0.809 1.000 -0.559 1.000 1.000
HEME METABOLISM 0.883 0.829 1.000 1.177 0.090 0.357
GLYCOLYSIS 0.863 0.860 1.000 0.744 0.998 1.000
APICAL SURFACE 0.854 0.727 1.000 0.933 0.568 0.796
ADIPOGENESIS 0.793 0.975 1.000 -0.596 1.000 1.000
TGF BETA SIGNALING 0.786 0.850 1.000 0.720 0.933 1.000
UNFOLDED PROTEIN RESPONSE 0.776 0.952 1.000 0.642 1.000 1.000
DNA REPAIR 0.722 0.998 1.000 0.823 0.913 1.000
MYC TARGETS V2 0.686 0.970 1.000 -0.631 0.992 1.000
ANDROGEN RESPONSE 0.665 0.998 1.000 1.122 0.223 0.453
MYC TARGETS V1 0.419 1.000 1.000 -0.326 1.000 1.000
UV RESPONSE DN -0.725 0.992 0.978 -0.797 0.930 1.000
WNT BETA CATENIN SIGNALING -0.739 0.916 1.000 1.144 0.254 0.419
PROTEIN SECRETION -0.789 0.930 1.000 -0.859 0.772 1.000
ANGIOGENESIS -0.869 0.688 0.948 -1.222 0.167 0.709
PEROXISOME -0.883 0.722 0.975 -0.772 0.923 1.000
IL2 STAT5 SIGNALING -0.957 0.586 0.768 1.257 0.060 0.341
PANCREAS BETA CELLS -1.022 0.428 0.590 1.435 0.061 0.097
ALLOGRAFT REJECTION -1.034 0.340 0.599 1.328 0.027 0.217
APICAL JUNCTION -1.036 0.352 0.652 -0.863 0.816 1.000
MITOTIC SPINDLE -1.074 0.270 0.577 -1.214 0.089 0.567
BILE ACID METABOLISM -1.094 0.262 0.566 0.736 0.948 1.000
MYOGENESIS -1.118 0.193 0.555 -0.847 0.863 1.000
KRAS SIGNALING -1.135 0.172 0.577 1.247 0.039 0.280
EPITHELIAL MESENCHYMAL TRANSITION -1.139 0.139 0.674 -0.873 0.811 1.000
SPERMATOGENESIS -1.166 0.180 0.694 -1.052 0.359 0.892
HEDGEHOG SIGNALING -1.303 0.114 0.298 -1.075 0.345 0.884
E2F TARGETS -1.513 0.002 0.050 -1.701 <0.001 0.010




Moreover, analysis of the enrichment of specific transcription factor target signatures 




Table 3.3 GSEA identifies specific transcription factor target signatures regulated by 
CASP4 in RASG12V-OIS 
Normalized Enriched Scores (NES) of transcription factor target signatures were calculated 
based on the DEG analysis performed between control ER:RAS and CASP4-knockdown ER:RAS 
samples after 5 days of 4-hydroxytamoxifen treatment. Gene sets with positive NES are 
positively regulated by CASP4 whereas gene sets with negative NES are negatively regulated by 
CASP4. For simplicity, this table only shows gene signatures with p-value <0.05. FDR q-val = 
false discovery rate q-value. 
 
 
A deeper exploration of the gene signature hallmark “INFLAMMATORY RESPONSE”, 
that showed both a small p-value and FDR q-value, (Table 3.2), was performed by 
plotting a heatmap of the log2FC values of control ER:STOP and CASP4-knockdown 
ER:RAS vs control ER:RAS of all genes included in this gene set (Figure 3.15). This 
analysis revealed a pattern by which the increased expression of inflammatory-related 
genes in senescence is abrogated if CASP4 is targeted, including SASP factors. Although 
transcriptomic data will be again gathered and discussed in subsequent chapters, the 
following subheadings of this chapter focus on the validation of the role of CASP4 in 
regulating the positive expression of inflammatory genes in OIS, including SASP 
factors.
Gene set NES p-value FDR q-val
EVI1_06 1.540 0.032 0.707
AP2REP_01 1.432 0.002 1.000
GGGNNTTTCC_NFKB_Q6_01 1.418 0.013 0.967
TAAWWATAG_RSRFC4_Q2 1.388 0.002 0.999
MEF2_01 1.365 0.021 1.000
NFKAPPAB_01 1.360 0.006 0.888
NFKAPPAB65_01 1.280 0.024 1.000
LEF1_Q6 1.277 0.031 1.000
GATA1_04 1.270 0.035 1.000
NFKB_Q6_01 1.240 0.048 1.000
AML_Q6 1.234 0.049 1.000
HNF1_01 -1.253 0.049 1.000
MEIS1BHOXA9_01 -1.335 0.033 1.000
E2F_01 -1.361 0.043 1.000





Figure 3.15 Gene expression of SASP factors is regulated by CASP4 in RASG12V-OIS  
Enrichment plot of the signature “INFLAMMATORY RESPONSE” upon CASP4 silencing in RASG12V –OIS 5 (A) and 8 days (B) after 4-hydroxytamoxifen 
addition. Each vertical black line below the enrichment plot corresponds to one specific gene, and its position –left to right- depends on whether its 
expression increases or decreases upon CASP4 targeting. C. Heatmap of the log2FC values of all genes included in the “INFLAMMATORY RESPONSE” GSEA 
gene set of control ER:STOP and CASP4–targeted ER:RAS compared to control ER:RAS after 5 days of  4-hydroxytamoxifen addition. A log2FC values colour 





























































































































































































































































































































































































































































































































































































































































































































































FDR q-val: 0.184 
NES: 1.607
p-value: <0.001







3.4 IL-1 signalling is impacted by caspase-4 targeting 
 
Analysis of transcriptomic data had revealed a role for CASP4 in regulating an 
inflammatory signature in OIS that included SASP factors. Next, mRNA expression 
changes were validated by RT-qPCR and the effect of CASP4 on IL-1 signalling was 
further investigated. 
 
3.4.1 Caspase-4 regulates the SASP 
 
Gene expression analysis by RT-qPCR confirmed the on-target effect of 2 individual 
CASP4-knockdown siRNA sequences (siCASP4-1 and siCASP4-2) and a pool of 4 
different CASP4-targeting sequences (siCASP4-p) (Figure 3.16A). CASP4 targeting did 
not affect CASP1 mRNA levels (Figure 3.16B). 
 
 
Figure 3.16 CASP1 and CASP4 mRNA expression after CASP4 siRNA-mediated targeting 
IMR90 ER:STOP/ER:RAS cells were transfected with control (NTP), CASP4-targeting or p53-
targeting siRNA. CASP4 was targeted by two individual siRNAs (CASP4-1 and CASP4-2) and a 
pool of four different siRNA sequences (CASP4-p). Senescence was induced by addition of 4-
hydroxytamoxifen. CASP1 (A) and CASP4 (B) mRNA expression was measured 5 and 8 days after 
the induction of senescence by RT-qPCR.  
All data shown as mean ± s.e.m of n=3 experiments, one-way ANOVA and post-hoc Bonferroni´s 
multiple comparisons comparing all conditions to ER:RAS +4OHT NTP, *=p<0.05, **=p<0.01, 























































































































































CASP4 knockdown in RASG12V-OIS resulted in reduced mRNA expression levels of SASP 
factors, such as IL1A, IL1B, IL8, IL6, SAA1 and SAA2 (330), compared to control 
senescence cells, in consonance with the transcriptomic data analysis (Figure 3.17). 
High-content analysis following immunofluorescence staining further confirmed that, 
upon CASP4 knockdown, the intracellular protein levels of IL1-a, IL-1b, IL-6 and IL-8 




Figure 3.17 mRNA expression of SASP factors is regulated by CASP4 
IMR90 ER:STOP/ER:RAS cells were transfected with control (NTP) or CASP4-targeting. CASP4 
was targeted by two individual siRNAs (CASP4-1 and CASP4-2) and a pool of four different 
siRNA sequences (CASP4-p). Senescence was induced by addition of 4-hydroxytamoxifen. All 
samples were treated with 4-hydroxytamoxifen. A. IL1A, IL1B and IL8 mRNA expression was 
measured 5 days after the induction of senescence by RT-qPCR. B. IL6, SAA1 and SAA2 mRNA 
expression was measured 8 days after the induction of senescence by RT-qPCR.  
All data are shown as mean ± s.e.m of n=3 experiments, one-way ANOVA and post-hoc 
Bonferroni´s multiple comparisons comparing all conditions to ER:RAS siNTP, *=p<0.05, 




























































Figure 3.18 Immunofluorescence detection of IL-1a, IL-1b, IL-6 and IL-8 confirms 
requirement of CASP1 and CASP4 for a full SASP activation in OIS 
IMR90 ER:STOP/ ER:RAS cells were transfected with control (NTP) siRNA or CASP4-targeting 
siRNA (either two individual sequences (siCASP4-1/siCASP4-2) or a pool of four different 
sequences (siCASP4-p). Cells were fixed 8 days after 4-hydroxytamoxifen addition and 
quantification of (A) IL-1a, (B) IL-1b and (C) IL-8 and IL-6 was performed using high-content 
analysis.  
All data are shown as mean ± s.e.m of n=3 experiments, t tests were performed comparing each 
CASP4-knockdown ER:RAS sample to the respective control senescent sample, *=p<0.05, 
**=p<0.01, ns=non-significant. NTP = non-targeting pool; 4OHT = 4-hydroxytamoxifen. 
 
 
Figure 3.19 Immunofluorescence detection of IL-1a, IL-1b, IL-6 and IL-8 confirms 
requirement of CASP1 and CASP4 for a full SASP activation in OIS  
See following page. IMR90 ER:STOP/ ER:RAS cells were transfected with control (NTP), CASP4-
targeting or CASP1-targeting siRNA. All samples were treated with 4-hydroxytamoxifen. IL-1a, 
IL-1b, IL-6 and IL-8 were quantified by high-content analysis 8 days after 4-hydroxytamoxifen 
addition. Representative images of the immunofluorescence staining are shown on the left side 
of each graph (top: IL-1a: FITC; middle: IL-1b: FITC, bottom: co-staining IL-6 and IL-8, TxRed 
and FITC respectively).  
All data are shown as mean ± s.e.m of n=3 experiments, t tests were performed comparing each 
CASP1- or CASP4-knockdown ER:RAS sample to the respective control senescent sample, 
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3.4.2 Mature IL-1b levels in RASG12V-OIS are impaired upon caspase-4 
targeting 
 
Because IL-1 signalling is a key component of the SASP and caspase-4 has been reported 
to modulate caspase-1 activity in other contexts (175), the role of caspase-4 in IL-1 
signalling in OIS was further explored. Analysis of IL-1b expression by western blotting 
allows the detection of both the full-length (31 kDa) and the mature active fragment (17 
KDa) which results from caspase-1 cleavage. CASP1 or CASP4 knockdown in RASG12V-
OIS resulted in decreased levels of full-length IL-1b (proIL-1b) and a reduction to a 





Figure 3.20 CASP4 targeting decreases the levels of intracellular mature IL-1b 
IMR90 ER:STOP/ER:RAS cells were transfected with control (NTP), CASP1- or CASP4-targeting 
pool siRNA. Cells were collected 8 days after addition of 4-hydroxytamoxifen, lysed and analysed 
by western blotting using the indicated antibodies. Data belong to one representative 
































Blot of d8 E39 and will also add quantification of Il1b and 





3.4.3 IL-1b secretion in RASG12V-OIS is controlled by caspase-4 
 
IL-1b is released from senescent cells into the extracellular space, where it can bind to 
membrane IL1-receptor (IL-1R), contributing to the SASP cascade amplification and 
paracrine senescence. Quantification of extracellular IL-1b by ELISA in CASP4-targeted 
RASG12V-OIS cells decreased the amount of IL-1b released (Figure 3.21).  
 
 
Figure 3.21 IL-1b release is impaired upon CASP4 targeting in RASG12V-OIS  
IMR90 ER:STOP/ER:RAS cells were transfected with control (NTP) siRNA or CASP4-targeting 
siRNA (either two individual sequences (siCASP4-1/siCASP4-2) or a pool of four different 
sequences (siCASP4-p)). Eight days after 4-hydroxytamoxifen addition, conditioned media was 
collected and IL-1b was quantified by ELISA. Data are shown as mean ± s.e.m of n=3 
experiments, one-way ANOVA and post-hoc Bonferroni´s multiple comparisons comparing all 
conditions to ER:RAS +4OHT NTP, *=p<0.05, **=p<0.01, ns=non-significant. NTP = non-
targeting pool; 4OHT = 4-hydroxytamoxifen. 
 
 
3.4.4 Induction of paracrine SASP is regulated by caspase-4 
 
Senescent cells can induce senescence in neighbouring non-senescent cells, a 
phenomenon termed paracrine senescence and that is mediated by soluble secreted 
factors by senescent cells among others (80). CASP4 knockdown in growing fibroblasts 
diminished the inflammatory response upon the induction of senescence by addition 
of senescent conditioned media (Figure 3.22). Remarkably, the paracrine upregulation 
of SASP factors such as IL1A, IL1B, Il6 or IL8 was independent of CASP1. 
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Figure 3.22 Regulation of paracrine SASP induction upon CASP4 knockdown 
Paracrine senescence experiments showed in this figure were performed by Dr Núria Tarrats. 
After 8 days of 4-hydroxytamoxifen treatment, conditioned media from ER:STOP or ER:RAS 
cells was collected an added on growing IMR90 cells. Concomitantly, IMR90 cells were 





































































































































































































































































































































































































































































































































































































































































transfected with the indicated siRNAs. A. Schematic diagram illustrating the experimental 
procedure. B. CASP1 and CASP4 mRNA expression was measured by RT-qPCR two days after 
the addition of conditioned media. C. IL1A, IL1B, IL8 and IL6 mRNA expression was measured 
by RT-qPCR two days after the addition of conditioned media. D. IL-1b, IL-6 and IL-8 were 
quantified using high-content analysis two days after the addition of conditioned media. 
All data are shown as mean ± s.e.m of n=3 experiments, t tests were performed comparing each 
CASP1- or CASP4-knockdown ER:RAS sample to the respective control senescent sample, 
*=p<0.05, **=p<0.01, where unstated non-significant. 4OHT = 4-hydroxytamoxifen; NTP = non-





























3.5 Exploring the role of gasdermin-D in OIS 
 
In recent years, gasdermin-D has gained major relevance as a target of inflammatory 
caspases in pyroptosis and it is currently the most well-characterized substrate of 
caspase-4. Therefore, gasdermin-D was studied as a potential downstream mechanism 
of inflammatory caspases in OIS. 
 
3.5.1 Gasdermin-D is cleaved in RASG12V-OIS 
 
Analysis of GSDMD mRNA relative expression in a RASG12V-OIS time-course did not 
show transcriptional regulation (Fig 3.23A). However, a key regulatory element of 
gasdermin-D activity is its cleavage (284, 285). Interestingly, gasdermin-D cleavage was 




Figure 3.23 Gasdermin-D cleavage in RASG12V-OIS 
A. GSDMD relative mRNA levels were quantified in a RASG12V-OIS time-course. Data are shown 
as mean ± s.e.m of n=3 experiments, paired t test, *=p<0.05. B. RASG12V, caspase-4 and caspase-1 
were overexpressed by retroviral infection in IMR90 cells and cell lysates were probed with the 
indicated antibodies following western blotting procedures. Infection with the empty retroviral 




































































blotting in a time-course of ER:STOP and ER:RAS cell lysates 0, 4 and 8 days after addition of 4-
hydroxytamoxifen. 4OHT = 4-hydroxytamoxifen; FL = full-length; NT = N-terminal domain. 
 
 
3.5.2 GSDMD knockdown has a limited impact on the SASP 
 
Because gasdermin-D is the key effector of inflammasome activation during pyroptosis, 
whether gasdermin-D is the downstream mediator of caspase-1/caspase-4-mediated 
SASP regulation in OIS was investigated.  
 
RT-qPCR confirmed the on–target effect of GSDMD targeting by siRNA (Figure 3.24A). 
GSDMD downregulation did not halt transcriptional activation of IL1A, IL1B and IL8 in 
OIS (Figure 3.24B). In line with the lack of transcriptional IL1B regulation, the amount 
of full-length IL-1b was not regulated by GSDMD siRNA-mediated targeting, although 
decreased levels of intracellular mature IL-1b were detected (Figure 3.24C, D). 
Importantly, recent studies have described that pores formed by gasdermin-D are 
essential for IL-1b release in some cell types (292). However, gasdermin-D 
downregulation in RASG12V-OIS did not affect secreted IL-1b, which was impaired when 
caspase-1 or caspase-4 was targeted (Figure 3.24E).  
 
These results show that downregulation of GSDMD has a limited effect on the 
transcription, translation or secretion of IL-1b compared to knockdown of CASP1 or 






Figure 3.24 GSDMD knockdown does not impact IL-1 signalling in RASG12V-OIS 
IMR90 ER:STOP/ER:RAS cells were transfected with the indicated pool siRNAs at day 0, 3 and 
5 after 4-hydroxytamoxifen addition. A. CASP1, CASP4 and GSDMD relative mRNA expression 
was quantified using RT-qPCR in cells treated 5 days with 4-hydroxytamoxifen. B. IL1A, IL1B and 
IL8 relative mRNA expression were quantified using RT-qPCR in cells treated 5 days with 4-
hydroxytamoxifen. C. and D. Protein expression in cell lysates was detected by western blotting 
using the indicated antibodies 5 and 8 days after 4-hydroxytamoxifen addition respectively. E. 
Released IL-1b was detected by ELISA 6, 7 and 8 days after 4-hydroxytamoxifen addition.  
Data in A, B and E are shown as mean ± s.e.m, n=3, one-way ANOVA and post-hoc Bonferroni´s 
multiple comparisons test, all samples compared to control cells, *=p<0.05, **=p<0.01, 
***=p<0.001, where unstated non-significant. NTP = non-target pool; 4OHT = 4-
hydroxytamoxifen. 
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In this chapter the expression of caspase-4 has been shown to increase 2-3 fold both at 
the mRNA and protein level in a well-characterized model of RASG12V-OIS. 
Simultaneously, during OIS caspase-4 oligomerizes and its cleavage activity is 
enhanced.  
 
CASP4 targeting by siRNA in RASG12V-OIS followed by transcriptomic analysis revealed 
that CASP4 regulates a subset of genes involved in inflammatory processes, including 
the SASP. A pattern could be identified for most of the genes of this specific 
inflammatory gene set: upregulated expression in RASG12V-OIS, compared to non-
senescent control, is halted upon CASP4 targeting. Changes in the mRNA expression 
of some of these genes were validated by RT-qPCR.  
 
Specifically, IL-1 signalling was further investigated, and, importantly, depletion of 
caspase-4 does not only affect overall levels of proIL-1b but also decreases the pool of 
intracellular cleaved mature IL-1b, as well as its release. Moreover, caspase-4 also 
mediates paracrine SASP signalling. 
 
Cleavage of endogenous gasdermin-D, an endogenous substrate of inflammatory 
caspases, was observed in RASG12V-OIS. However, GSDMD siRNA-mediated targeting 
did not impact the SASP at the same extent than CASP1 or CASP4, suggesting that IL-1 
regulation by inflammatory caspases is independent of gasdermin-D, and that IL-1b is 
released from senescent cells in a gasdermin-D independent manner. 
 
In all, these results demonstrate that both the canonical and non-canonical 
inflammasome regulate the SASP in OIS and reveal that caspase-4 is necessary for a full 






Figure 3.25 Caspase-4 regulates the SASP in OIS 
Senescent cells display increased proteins levels of caspase-4. In senescent cells, 
caspase-4 is necessary for a complete induction of the SASP and the secretion of IL-1b. 
Nonetheless, caspase-4 is also necessary for a full SASP induction in paracrine 
senescence. Altogether, caspase-4 plays a key role in the maintenance and 






























4.1 Caspase-1 and caspase-4 overexpression induces 
a phenotype with senescence features 
 
In the previous chapter, results regarding the role of caspase-4 regulating inflammatory 
features of OIS were presented. This chapter focuses on the potential role of 
inflammatory caspases regarding cellular proliferation. A first approach was conducted 
by overexpressing caspase-1 and caspase-4 in IMR90 cells. 
 
4.1.1 Overexpression of caspase-1 and caspase-4 reduces cell 
proliferation and increases SA-b-galactosidase activity 
 
Human CASP1 and CASP4 CDS were cloned into the retroviral MSCV vector and 
efficient caspase-1 and caspase-4 overexpression in IMR0 cells was confirmed by 
western blotting (Figure 4.1A). Phenotypical outcome of the overexpression of caspase-
1 and caspase-4 in IMR90 cells was then assessed, using the overexpression of the empty 
MSCV retroviral vector as negative control and the overexpression of RASG12V as a 
positive control for the induction of senescence.  
 
Both the overexpression of caspase-1 or caspase-4 reduced cell proliferation, measured 
by colony formation assay and 5-bromo-2-deoxyuridine (BrdU) incorporation (Figure 
4.1B, C). Senescence-associated b-galactosidase activity (SA-b-galactosidase activity) 
was also increased upon caspase-1 or caspase-4 overexpression, although only 






Figure 4.1 Caspase-1 and caspase-4 overexpression in human fibroblasts induce a 
senescent phenotype 
CASP1, CASP4 and RASG12V were overexpressed in IMR90 cells. IMR90 cells were also infected 
with the empty vector and used as negative control. A. Caspase-1 and caspase-4 detection in 
IMR90 lysates by western blotting four days after equal numbers of cells were seeded. B. BrdU 
incorporation was measured by high-content analysis four days after equal number of cells were 
B
D




























































































plated. Representative images of BrdU staining as detected by immunofluorescence and used 
for high-content analysis are shown below. C. Relative cell content quantification after 
performing a colony formation assay; representative images of crystal violet stained plates from 
one experiment are shown on the right. D. SA-b-galactosidase activity was quantified four days 
after equal number of cells were plated. Images of SA-b-galactosidase stained cells from one 
representative experiment are shown on the right.  
Data in A belongs to one representative experiment. Data in B, C and D are shown as mean ± 
s.e.m of n=3 experiments, paired t test, *=p<0.05, **=p<0.01, ***=p<0.001. ns = non-significant. 
 
 
4.1.2 Inflammasome priming is required to activate IL1B transcription 
 
Because depletion of either caspase-1 or caspase-4 impacted on IL-1 signalling in 
RASG12V-OIS (see section 3.4), whether the overexpression of caspase-1 or caspase-4 per 
se had an effect on endogenous levels of IL1A or IL1B was analysed. IL1A and IL1B mRNA 
expression were not increased upon caspase-1 or caspase-4 overexpression (Figure 
4.2A).  
 
Previous studies have described a two-step model for inflammasome activation in 
which a priming signal is followed by an activating stimulus (see Figure 1.9). 
Accordingly, addition of the synthetic lipopeptides Pam2CSK4 and Pam3CSK4 (TLR2/6 
and TLR1/2 agonists respectively) to IMR90 cells highly increased IL1B transcription 
(Figure 4.2B). Interestingly, addition of Pam2CSK4 also increased the levels of caspase-
4 in IMR90 cells (Figure 4.2C). When Pam2CSK4 or Pam3CSK4 were added on cells 
overexpressing caspase-1 or caspase-4, IL1B transcription was increased in a similar 
fashion to control cells. (Figure 4.2D).  
 
In all, these results suggest that the sole overexpression of an inflammatory caspase is 
not enough for transcriptional activation of IL1 genes, which depends on an external 









Figure 4.2 Activation of IL1B transcription requires inflammasome priming 
independently of caspase-1/caspase-4 overexpression 
A. IL1A and IL1B relative mRNA expression were quantified using RT-qPCR in control or CASP1-
, CASP4- or RASG12V-overexpressing IMR90 cells. (B) IL1B and (C) CASP4 mRNA relative 
expression were quantified by RT-qPCR in IMR90 cells treated with MDP, LPS, Pam2CSK4 or 
Pam3CSK4 as indicated. In B and C all data are relative to gene expression at t = 3 h in control 
(mock) cells. D. IL1B relative mRNA expression was quantified by RT-qPCR in control or CASP1-
, CASP4- or RASG12V-overexpressing IMR90 cells with the indicated TLR agonists for 3h; 
overexpression of RASG12V was used as a positive control for IL1B mRNA expression. In D all data 
are relative to IL1B mRNA relative expression in mock-treated empty vector overexpressing 
IMR90.  
Data in A are mean ± s.e.m, n=3, one-way ANOVA and post-hoc Bonferroni´s multiple 
comparisons test comparing all samples to control cells transfected with the empty vector 
(vector), **=p<0.01, where unstated non-significant. B, C and D show data of one representative 
experiment. Data in A, B and D are plotted in a logarithmic scale Y axis. MDP = muramyl 
dipeptide; LPS = lipopolysaccharide.  

































































































4.2 LPS-driven non-canonical inflammasome 
activation induces a caspase-4-dependent 
senescence response 
 
Because overexpression of caspase-4 and caspase-1 suggested a potential role for 
inflammatory caspases in cell proliferation, whether the non-canonical inflammasome 
is involved in cell proliferation was explored by targeting endogenous caspase-4. 
Elegant studies have thoroughly described the activation of the non-canonical 
inflammasome by intracellular LPS (193, 280) (see section 1.2.3 The non-canonical 
inflammasome). Therefore, this well-characterized non-canonical inflammasome 
activation system was used to investigate the potential effect of caspase-4 activation on 
cell proliferation in human fibroblasts.  
 
4.2.1 Intracellular LPS causes cell death in IMR90 cells  
 
To transfect LPS into IMR90 cells, the transfection protocol described by Shi et al. (193) 
was adapted. In their research, the authors described that the 293T cell line is resistant 
to cell death by LPS transfection due to lack of caspase-4 expression and this result was 
confirmed (Figure 4.3A). In contrast to 293T cells, IMR90 were sensitive to intracellular 
LPS (Figure 4.3A), like other human cells that express caspase-4 (193). Addition of LPS 
without electroporation did not result in cell death, confirming the requirement of 
intracellular location to elicit pyroptosis. Moreover, transfection with muramyl 
dipeptide (MDP), a bacterial cell wall component that activates the cytoplasmic 
receptor NOD2 generating a proinflammatory response (331), did not cause cell death, 
supporting the specificity of LPS in triggering pyroptosis (Figure 4.3B, C). Nonetheless, 











Figure 4.3 Intracellular LPS elicits cell death in IMR90 in a dose-dependent manner 
A. IMR90 or 293T were untransfected (control) or transfected with 1 µg LPS / 5 x 10^5 cells (LPS 
T). For further control, IMR90 were also treated with 1 µg LPS / 5 x 10^5 cells without subsequent 
transfection (LPS NT). Cell viability was measured 2.5 h after transfection. B. IMR90 cells were 
transfected with 1 µg MDP / 5 x 10^5 cells or with three different doses of LPS (0.01; 0.1 or 1 µg 
LPS / 5 x 10^5 cells). Cell viability was measured at different times after transfection. C. 
Representative images of IMR90 cells mock-transfected (left) or transfected with 0.1 µg LPS / 5 
x 10^5 cells (middle) or 1 µg LPS / 5 x 10^5 cells (right) under brightfield microscopy 4x (upper 
row) or 10x magnification (lower row) 24h after transfection. 
Data in A belong to one representative experiment. Data in B are shown as mean ± s.e.m, n=3, 
t-tests were performed at each time-point comparing each condition to control cells (mock), 













































Stable GSDMD knockdown in IMR90 cells before LPS transfection confirmed that LPS-
driven cell death was GSDMD-dependent (Figure 4.4A). Moreover, full-length and the 
N-terminal fragment of gasdermin-D were overexpressed using an inducible 
doxycycline-dependant system. Overexpression of the N-terminal gasdermin-D 
fragment but not the full-length protein resulted in cell death in IMR90 cells (Figure 
4.4B, C). 
 
Figure 4.4 Intracellular LPS elicits cell death in IMR90 in a GSDMD-dependent manner 
A. Stable GSDMD knockdown in IMR90 cells by lentiviral shRNA was followed by LPS 
transfection (0.1 µg LPS/transfection), and cell viability was measured 24 h after transfection B. 
Overexpression of full-length (FL) and the N-terminal (N-ter) fragment of gasdermin-D 
(GSDMD) in IMR90 cells was induced by addition of doxycycline after stable transfection with 
lentiviral vectors, and viability was measured 24 h after addition of doxycycline. Representative 
images of cells in culture 24 after doxycycline (DOX) addition (100 ng / mL) are shown in C. 
Data shown in A as mean ±  s.e.m of n =3, paired t test, **=p<0.01, ns=non-significant. Data 
shown in B are mean ± s.e.m of n =3, one-way ANOVA and post-hoc Bonferroni´s multiple 
comparisons test comparing all samples to 0 ng/mL doxycycline, *=p<0.1, **=p<0.01, where 
unstated non-significant. 

















































4.2.2 Intracellular LPS promotes a caspase-4 dependent senescence 
phenotype  
 
Cell death was detectable within the first hours after LPS transfection. However, the 
fraction of cells surviving cell death after these hours remained viable and this 
subpopulation was further studied. This subset of cells displayed decreased cell 
proliferation (measured by BrdU incorporation) in an LPS dose-dependent manner 
(Figure 4.5A) 48 h after transfection. Moreover, the reduction in cell proliferation was 
accompanied by an increase in the protein levels of caspase-4 as well as the cell cycle 
regulators p21 and p16 (Figure 4.5B, C, E). Quantification of SA-b-galactosidase positive 
cells 4 days after LPS transfection revealed an increase in SA-b-galactosidase activity in 
LPS transfected cells compared to control or MDP-transfected cells (Figure 4.5D, F). 
These results indicate that the portion of cells surviving cell death display senescent 
features, including reduced cell proliferation, increased levels of cell cycle regulators 
and enhanced SA-b-galactosidase activity.  
 
Next, we investigated the requirement of caspase-1 or/and caspase-4 for the acquisition 
of senescent features after LPS transfection. To stably knockdown CASP1 or CASP4, 
IMR90 cells were infected with lentiviral shRNAs targeting either CASP1 or CASP4. 
CASP4 knockdown but not CASP1 knockdown abrogated cell death following LPS 
transfection (Figure 4.6A). Interestingly, the decrease in cell proliferation after 
transfection with LPS was also rescued when CASP4 but not CASP1 was targeted (Figure 
4.6B). Both CASP1 and CASP4 knockdown were validated by RT-qPCR and 
immunofluorescence staining, respectively (Figure 4.6C, D). Concomitant to the 
decrease in BrdU incorporation, CASP4-dependent increase in the levels of the cell 
cycle regulators p53, p21 and p16 after LPS transfection was observed (Figure 4.6E, F). 
CASP4 knockdown did also prevent an increase in SA-b-galactosidase activity following 
LPS transfection (Figure 4.6G).  
 
Overall, these results suggest that the acquisition of a senescent phenotype following 






Figure 4.5 LPS transfection causes cell proliferation arrest  
IMR90 cells were transfected with 1 µg MDP / 5 x 10^5 cells or with increasing doses of LPS 
(0.01/0.1/1 µg / 5 x 10^5 cells). BrdU incorporation (A) and caspase-4 (B), p21 and p16 (C) protein 
levels were quantified by high content analysis 48 h after LPS transfection. D. Quantification of 
SA-b-galactosidase activity 4 days after transfection. E. Representative images used for p21 and 
p16 quantification (C).  F. Representative images used for the SA-b-gal quantification (D).  
All data are shown as mean ± s.e.m, n=3, one-way ANOVA and post-hoc Bonferroni´s multiple 
comparisons test, all samples compared to control cells, *=p<0.05, **=p<0.01, ***=p<0.001, 
where unstated non-significant.  





































































































Figure 4.6 Acquisition of a senescent phenotype following LPS transfection is caspase-
4-dependent but caspase-1-independent 
Stable CASP1 and CASP4 knockdown in IMR90 cells by lentiviral shRNA was followed by LPS 
transfection (0.1 µg LPS/transfection). A. Cell viability was measured 24 h after transfection 
(n=3, mean ± s.e.m, paired t test, **=p<0.01, ***p<0.001, ns=non-significant). B. BrdU 
incorporation was quantified 48 h after transfection (n=4, mean ± s.e.m, paired t test, 
***p<0.001, ns=non-significant). C. CASP1 mRNA expression was analysed 48 h after LPS 
transfection was performed by RT-qPCR (n=3, mean ± s.e.m, one-way ANOVA and post-hoc 

































































































































































































Bonferroni´s multiple comparisons test comparing all samples to control cells, ***p<0.001, 
where unstated non-significant) D. Caspase-4 protein levels were quantified 48 h after LPS 
transfection by high-content analysis (n=3, mean ± s.e.m, one-way ANOVA and post-hoc 
Bonferroni´s multiple comparisons test comparing all samples to control cells, *p<0.05, where 
unstated non-significant). E. p53, p21 and p16 levels were quantified by high-content analysis 
48h after LPS transfection (n= 4, mean ± s.e.m, paired t test comparing each transfected samples 
to the respective control, *p<0.05, **p<0.01, where unstated non-significant).  F. CDKN1A and 
CDKN1B mRNA expression analysis 48 h after LPS transfection was performed by RT-qPCR (n=3, 
mean ± s.e.m, unpaired t test comparing each transfected sample to the respective control, 
*p<0.05, **p<0.01, ***p<0.001, where unstated non-significant). G. Quantification of SA-b-
galactosidase activity 4 days after transfection (n=4, mean ± s.e.m, paired t test, **=p<0.01, 
**=p<0.01, ns=non-significant,); representative images of cells stained for SA-b-galactosidase 




Next, LPS was transfected into IMR90 cells constitutively overexpressing caspase-4. 
Transfection of LPS into caspase-4 overexpressing cells increased cell proliferation 
arrest compared to overexpression of caspase-4 alone (Figure 4.7A). Moreover, when 
transfected, overexpressing caspase-4 IMR90 cells incorporated less BrdU than control 
cells with endogenous caspase-4 levels. Interestingly, LPS-transfected caspase-4 
overexpressing cells proliferated at a similar rate than cells undergoing RASG12V-OIS. 
The levels of p21 and p16, which are not induced by caspase-4 overexpression alone, 
were increased after LPS transfection (Figure 4.7B, C). High levels of caspase-4 were 
still detectable in caspase-4-overexpressing cells surviving pyroptosis (Figure 4.7C). SA-
b-galactosidase activity was also enhanced in a dose-dependent manner when LPS was 
transfected into cells overexpressing caspase-4 (Figure 4.7D).  
 
These results suggest that the overexpression of caspase-4 enhances the acquisition of 






Figure 4.7 Overexpression of caspase-4 in IMR90 exacerbates the acquisition of a 
senescent phenotype following LPS transfection 
Caspase-4 was stably overexpressed in IMR90 cells previously to LPS transfection. Cells infected 
with the empty vector (vector) were used as negative control whereas overexpression of RASG12V 
was used as a positive control for the induction of senescence. A. BrdU incorporation was 
quantified 48 h after LPS transfection. B. p21 and p16 were quantified 48h after LPS transfection 
using high-content analysis. C. Caspase-4 and p16 protein levels were analysed by western 
blotting 48 h after LPS transfection. D. Quantification of SA-b-galactosidase activity 4 days after 
transfection with 0, 0.1 or 1 µg LPS/transfection; representative images of the SA-b-galactosidase 
staining are also shown on the right.  
Data in A, B and D are shown as mean ± s.e.m of n=3, one-way ANOVA and post-hoc 
Bonferroni´s multiple comparisons test comparing all samples to control cells, *=p<0.05, 
**p<0.01, ***p<0.01, where unstated non-significant. In A, an additional paired t-test was 
performed comparing LPS transfected caspase-4 overexpression and RasG12V-overexpression, 






















































































4.2.3 Role of p53 in the acquisition of a senescence phenotype following 
LPS transfection 
 
The tumour suppressor p53 has been shown to be a key mediator of senescence 
induction after telomere dysfunction and oncogene activation among others (4). To 
investigate whether the acquisition of senescent features following LPS transfection 
depends on p53, LPS was transfected into IMR90 cells where p53 expression is stably 




Cell death was not abrogated by P53 targeting, indicating that P53-knockdown cells are 
as sensitive to pyroptosis as control cells (Figure 4.8A). P53-knockdown in IMR90 cells 
without further treatment increased cellular proliferation compared to control cells as 
expected (Figure 4.8B). However, LPS transfection into P53-knockdown cells reduced 
cellular proliferation by approximately 50% compared to mock-transfected P53-
knockdown cells, proportionally similar to the decrease observed in control cells 
(Figure 48B). Furthermore, LPS-transfected P53-knockdown cells showed increased 
levels of caspase-4 and p16 (Figure 4.8C). On the other hand, LPS-transfected P53-
knockdown cells showed no activation of p21 (Figure 4.8C) and a mild increase in SA-
b-galactosidase activity (Figure 4.8D). Taken together, these results suggest that 
although p53 contributes to the acquisition of senescent features after LPS transfection 
together with p16 activation, activation of caspase-4 by intracellular LPS induces 













Figure 4.8 p53 contributes to the acquisition of an LPS-driven senescence phenotype  
Stable CASP4 and p53 knockdown in IMR90 cells by lentiviral shRNA was followed by LPS 
transfection (0.1 µg LPS/transfection). IMR90 cells were transfected with the empty vector for 
control (vector). A. Cell viability was measured 24 h after transfection. BrdU incorporation (B) 
and p53, p21, p16 and caspase-4 protein levels (C) were quantified by high-content analysis 48 h 
after LPS transfection. D. SA-b-galactosidase activity was quantified 4 days after transfection 
and representative pictures of cells stained for SA-b-galactosidase activity are shown in the right. 
Data in A and B are shown as mean ± s.e.m, of n=3, paired t-test, each transfected sample was 










































































































































D are shown as mean ± s.e.m of n=3, one-way ANOVA and post-hoc Bonferroni´s multiple 
comparisons test comparing all samples to empty vector control cells, *=p<0.05, **p<0.01, 
***p<0.01, where unstated non-significant. C = control; L = LPS. 
 
 
4.2.4 Inflammasome priming is not involved in LPS-driven cell 
proliferation arrest 
 
To investigate whether inflammasome priming is required for the acquisition of a 
senescent phenotype following transfection with LPS, cells were primed with Pam2csk4 
for 3 h. This stimulus was chosen because Pam2CSK4 had induced the highest IL1B 
transcription activation when added to IMR90 cells among the ones tested (Figure 4.2). 
Addition of Pam2CSK4 alone or followed by LPS transfection did not reduce cellular 
proliferation (Figure 4.9A) or alter SA-b-galactosidase activity (Figure 4.9B, C). 
Similarly, Pam2CSK4 did not enhance the acquisition of a senescent phenotype in cells 
overexpressing caspase-4, irrespectively of whether these were transfected with LPS 
(Figure 4.9B, C). 
 
Next, whether the acquisition of senescent features following LPS transfection was 
accompanied by an activation of IL-1 signalling was investigated. LPS transfection 
increased IL1B mRNA levels in a CASP4-dependent CASP1-independent manner 
(Figure 4.9E). Addition of Pam2CSK4 prior to LPS transfection further increased IL1B 
transcription (Figure 4.9D). Thus, although inflammasome priming can reinforce the 
transcriptional activation of IL1B, it is not involved in the acquisition of senescent 
features such as decreased cell proliferation and increased SA-b-galactosidase observed 
after activation of the non-canonical inflammasome activation by LPS transfection. 
 
Altogether, these results suggest that, in contrast to RASG12V-OIS, cell proliferation halt 
following LPS transfection is uncoupled from a strong IL-1 signalling transcriptional 
activation. Moreover, inflammasome priming does not impact on the acquisition of 
senescent features, such as cell proliferation arrest or enhanced SA-b-activity, following 
LPS transfection. In contrast, these results suggest that inflammasome priming is 





Figure 4.9 Inflammasome priming did not alter proliferation halt after LPS transfection 
For data shown in A-D, IMR90 cells were infected to constitutively overexpress caspase-4. Cells 
infected with the empty vector (vector) were used for negative control, whereas cells 
overexpressing RASG12V were used as a positive control for senescence induction. Control and 
caspase-4 overexpressing cells were treated for 3 h with Pam3CSK4 prior to LPS transfection (0.1 
µg/transfection). A. BrdU incorporation was quantified 48 h after LPS transfection. B. 
Quantification of SA-b-galactosidase activity 4 days after transfection C. Representative images 
of SA-b-galactosidase quantification (B). D. IL1B relative mRNA expression was quantified 
using RT-qPCR 48 h after LPS transfection. E. Cells were treated as explained in Figure 4.5. IL1B 
relative mRNA expression was quantified by RT-qPCR 48 h after LPS transfection. 
In A, B and D, data are shown as mean ± s.d, n=2, one-way ANOVA and post-hoc Bonferroni´s 
multiple comparisons test comparing all samples to control cells, *=p<0.05, **=p<0.01, 
***=p<0.001, where unstated non-significant. Data in E are shown as mean ± s.e.m, n=3, one-
way ANOVA and post-hoc Bonferroni´s multiple comparisons test comparing all samples to 
control cell, **=p<0.01, s.  C = control, L = LPS.  
mock Pam2CSK4




















































































































4.3 CASP4 knockdown partially bypasses cell 
proliferation arrest in RASG12V-OIS 
 
Data presented in the previous section show that activation of the non-canonical 
inflammasome by intracellular LPS results in the acquisition of senescent features, 
including cell proliferation arrest, in the fraction of cells surviving pyroptosis. Next, 
whether caspase-4 is involved in cellular proliferation in OIS was investigated. 
 
4.3.1 siRNA and shRNA-mediated CASP4 targeting results in a partial cell 
proliferation arrest bypass in RASG12V-OIS 
 
CASP4 knockdown by siRNA in RASG12V-OIS partially bypassed cell proliferation arrest; 





Figure 4.10 siRNA-targeted CASP4-knockdown causes partial cell proliferation arrest 
bypass in RASG12V-OIS 
IMR90 ER:STOP/ER:RAS cells were transfected with siRNA 0 and 3 days after 4-
hydroxytamoxifen addition and BrdU incorporation was measured 5 days after 4-
hydroxytamoxifen addition. In A, CASP4 expression was targeted with two individual sequences 
and a pool of 4 different siRNA sequences. In B, CASP1, CASP4 or GSDMD were targeted with a 
pool of 4 different siRNAs sequences/gene; all samples were treated with 4-hydroxytamoxifen.  
In A, data are shown as mean ± s.e.m, n=3, one-way ANOVA and post-hoc Bonferroni´s multiple 











































































































shown as  mean ± s.e.m, n=4, one-way ANOVA and post-hoc Bonferroni´s multiple comparisons 
test comparing the indicated samples, *p<0.1, ns = non-significant. NTP = non-targeting pool; 
4OHT = 4-hydroxytamoxifen. 
 
 
Moreover, targeting CASP4, but not CASP1, decreased SA-b-galactosidase activity in 
RASG12V-OIS (Figure 4.11). 
 
Figure 4.11 CASP4 downregulation reduces SA-b-galactosidase activity in RASG12V-OIS 
IMR90 ER:STOP/ER:RAS cells were transfected with the indicated siRNAs 0, 3 and 5 days after 
4-hydroxytamoxifen addition. Quantification of SA-b-galactosidase activity was performed 8 
days after 4-hydroxytamoxifen addition. Data are shown as mean ± s.e.m, n=3, one-way ANOVA 
and post-hoc Bonferroni´s multiple comparisons test comparing the indicated samples, *p<0.05, 
ns = non-significant).  Representative images of SA-b-galactosidase stained cells are also shown 
on the right. NTP = non-targeting pool; 4OHT = 4-hydroxytamoxifen. 
 
 
To confirm the aforementioned results, CASP4 was stably targeted by retroviral 
shRNAs. A colony formation assay confirmed that CASP4 knockdown by shRNA-
mediated targeting also resulted in a partial bypass of proliferation arrest in RASGI2V-
OIS (Figure 4.12). 
 
Altogether these results suggest that caspase-4 contributes to cellular proliferation 
arrest and enhanced SA-b-galactosidase in RASGI2V-OIS. 
 
ER:STOP siNTP ER:RAS siNTP
ER:RAS siCASP1 ER:RAS siCASP4





























Figure 4.12 shRNA-mediated CASP4-knockdown causes partial cell proliferation arrest 
bypass in RASG12V-OIS 
IMR90 ER:STOP/ERRAS cells were stably transfected using retroviral shRNA vectors. Infection 
with the empty vector was used as negative control and an shRNA targeting p53 was used as a 
positive control for bypass of cellular proliferation arrest. All conditions were treated with 4-
hydroxytamoxifen. IMR90 ER:RAS cells were infected with two different retroviral vectors 
targeting CASP4 and one targeting P53. After selection, equal number of cells were plated on 
day 0 and 4-hydroxytamoxifen was added to all conditions. 15 days after 4-hydroxytamoxifen 
addition, plates were fixed and stained with crystal violet. Crystal violet was extracted and used 
to quantify the cell content in each plate (n=3, ratio paired t test as indicated, *p<0.1, **p<0.01, 



























































4.3.2 Caspase-4 regulates cell proliferation in RASG12V-OIS through pRb 
 
Interestingly, among those hallmark gene sets analysed by GSEA in the transcriptomic 
analysis, the gene sets “G2M_CHECKPOINT” and “E2F_TARGETS” had the lowest 
Normalized Enriched Score (NES) when CASP4 was targeted by siRNA in RASG12V-OIS 
(Figure 4.13, Table 3.2). Moreover, the transcription factor E2F was also amongst the 




Figure 4.13 GSEA identifies “G2M Checkpoint” and “E2F targets” as gene sets regulated 
by CASP4 
Enrichment plots for “G2M CHECKPOINT” and “E2F TARGETS” hallmark gene sets comparing 
control ER:RAS and CASP4 knockdown ER:RAS 5 days after addition of 4-hydroxytamoxifen.  
 
 
The key mediator event leading to the irreversible implementation of cell senescence 
is the hypophosphorylation of pRb and subsequent silencing of E2F target genes (5, 
332). CASP4 knockdown in RASG12V-OIS resulted in impaired hypophosphorylation of 
pRb, (Figure 4.14A). In line with this finding, the reduced expression of E2F target genes 
in RASG12V-OIS was partially rescued upon CASP4 knockdown (Fig 4.14B). In this same 
context, CASP4 knockdown did not alter the levels of p53 and p21, (Fig. 4.15A, B), 













Nonetheless, there were no significant changes on p16 mRNA and proteins levels or CDKN2B 
mRNA levels upon caspase-4 targeting (Fig, 4.14A, 4.15A, 1.15B). Altogether, these results 
suggest that caspase-4, through a mechanism which is independent of p21 and p16 
mRNA and protein levels, regulates the phosphorylation state of pRb and, 
consequently, the transcription of E2F target genes and thus cell proliferation. 
 
Figure 4.14 CASP4 knockdown in RASG12V-OIS regulates phosphorylation of pRb 
IMR90 ER:STOP/ER:RAS cells were transfected with the indicated siRNAs at day 0 and 3 after 
4-hydroxytamoxifen addition (where unspecified, a pool of 4 different siRNA sequences was 
used). All samples were treated with 4-hydroxytamoxifen. A. Cells were pelleted on day 5 after 
4-hydroxytamoxifen addition and subjected to western blotting procedures using the indicated 
antibodies. An antibody that detects the different phosphorylated states of pRb was used. B. 
Relative mRNA expression of the indicated genes 5 days after 4-hydroxytamoxifen addition.  
Data in B  are shown as mean ± s.e.m, n=3, one-way ANOVA and post-hoc Bonferroni´s multiple 
comparisons test comparing all samples to ER:RAS siNTP, *p<0.05, **p<0.01, ***p<0.001, ns = 



































































Figure 4.15 CASP4 knockdown regulation of proliferation in RASG12V-OIS is independent 
of CDK2A, CDKN2B and CDKN1A and p53 levels 
IMR90 ER:STOP/ER:RAS cells were transfected with the indicated siRNAs at day 0 and 3 after 
4-hydroxytamoxifen addition (where unspecified, a pool of 4 different siRNA sequences was 
used). A. CDKN1A and CDKN2A mRNA expression levels were analysed 5 days after addition of 
4-hydroxytamoxifen B. Quantification of p16, p53 and p21 5 days after 4-hydroxytamoxifen 
addition by high-content analysis. In B,  all samples were treated with 4-hydroxytamoxifen. 
All data are shown as mean ± s.e.m, n=3, one-way ANOVA and post-hoc Bonferroni´s multiple 
comparisons test comparing all samples to ER:RAS siNTP, *p<0.05, **p<0.01, ***p<0.001, where 





















































































































































































































































































































































4.4 Caspase-4 regulation of cell proliferation is 
independent of its catalytic activity 
 
4.4.1 Overexpression of a catalytic dead mutant caspase-4 induces 
senescence to a similar extent than wild-type caspase-4 overexpression 
 
Caspases are cysteine-dependent proteases; hence their catalytic activity depends on a 
conserved cysteine residue. The active site of human caspase-4 has been well 
characterized and associated to residue C258 (Cysteine 258) and point mutations of this 
amino acid render the protein catalytically inactive (Figure 4.16). 
 
 
Figure 4.16 Schematic representation of caspase-4 
A schematic representation of caspase-4 is shown. C = cysteine; A =alanine; aa = amino acid. 
 
 
Catalytic dead CASP4 CDS (CASP4 C258A) was cloned into the retroviral MSCV vector 
using site-directed mutagenesis. Both wild-type (WT) and catalytic dead (C258A) 
caspase-4 were overexpressed in IMR90 cells and the phenotypical outcome was 
assessed. The overexpression of either construct induced similar levels of caspase-4 
expression (Figure 5.2A). Interestingly, the overexpression of caspase-4 C258A reduced 
cell proliferation and increased the levels of SA-b-galactosidase activity to a similar 
extent than caspase-4 WT overexpression (Figure 4.17). 
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Figure 4.17 Overexpression of C258A caspase-4 induces cell proliferation arrest and SA-
b-galactosidase activity  
WT or C258A caspase-4 were overexpressed in IMR90 cells. Overexpression of the empty MSCV 
retroviral vector was used as negative control, whereas overexpression of RASG12V was used as a 
positive control for the induction of senescence. A. BrdU incorporation, caspase-4, p21 and p16 
levels were quantified using high-content analysis 4 days after equal amounts of cells were 
plated. B. A colony formation assay was performed and crystal violet was extracted and used to 
quantify the cell content in each plate; representative images of stained plates of one experiment 
are also shown on the right. C. Quantification of SA-b-galactosidase activity 4 days after equal 
amounts of cells were plated; representative images of SA-b-galactosidase stained are also 
shown on the right.  
All data are shown as mean ± s.e.m, n=3, one-way ANOVA and post-hoc Bonferroni´s multiple 
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4.4.2 Overexpression of a catalytic dead mutant caspase-4 prior to LPS 
transfection rescues cell death but not acquisition of a senescence 
phenotype 
 
Assessment of the phenotypical outcome of the overexpression of caspase-4 C258A 
suggested that caspase-4’s regulation of cellular proliferation could be independent of 
its catalytic activity. To further investigate this hypothesis, LPS was transfected into 
IMR90 cells overexpressing either WT or C258A caspase-4. 
 
As expected, overexpression of caspase-4 C258A preceding LPS transfection prevented 
cell death (Figure 4.18A, B). However, caspase-4 C258A overexpression did not rescue 
the acquisition of senescent features such as reduced cell proliferation and increased 
SA-b-galactosidase (Figure 4.18C, D). Interestingly, pRb was majorly detected in its 
hypophosphorylated state in CASP4 C258A overexpressing IMR90 following LPS 
transfection compared to untransfected cells (Figure 4.18E).  
 
These results suggest that, although the catalytic activity is essential for pyroptosis, the 









Figure 4.18 Overexpression of a catalytic dead mutant caspase-4 before LPS transfection 
prevents cell death but not the acquisition of a senescence phenotype 
WT and a C258A caspase-4 were stably overexpressed in IMR90 cells and these were subjected 
to LPS transfection. Infection with the empty vector was used as a negative control whereas 
overexpression of RASG12V was used as positive control for the induction of senescence. A. Cell 
viability was measured 24 h after transfection (1 µg LPS transfected/ 5 x 10^5 cells). B. 
Representative bright-field pictures of cells in culture 24 h after LPS transfection (0.1 µg LPS 
transfected/ 5 x 10^5 cells). C. BrdU incorporation was quantified 48 h after LPS transfection (1 
µg LPS transfected/ 5 x 10^5 cells). D. SA-b-galactosidase activity was quantified 4 days after LPS 
transfection (1 µg LPS transfected/ 5 x 10^5 cells); representative pictures are also shown (right). 
E. Caspase-4 and pRb were analysed by western blotting 48 h after LPS transfection in cells 
overexpressing the catalytic dead caspase-4 (C258A caspase-4).  
Data in A, C, and D are shown as mean ± s.e.m, n=3, one-way ANOVA and post-hoc Bonferroni´s 
multiple comparisons comparing the indicated conditions, **p<0.01, ***p<0.001,  ns = non-
significant). C = control; L = LPS. 
























































































Overexpression of caspase-4 and caspase-1 in IMR90 cells resulted in cell proliferation 
arrest. Moreover, activation of the non-canonical inflammasome by intracellular LPS 
induced a senescence phenotype in the fraction of cells surviving pyroptosis (Figure 
4.19). shRNA-mediated endogenous CASP4 downregulation abrogated LPS-driven 
senescence features whereas overexpression of caspase-4 enhanced them, confirming 
that caspase-4 is the key mediator of the senescence phenotype acquisition following 
LPS transfection. In contrast, CASP1 knockdown prior to LPS transfection did not have 
the same effect, indicating that the acquisition of senescence features following LPS 
transfection is caspase-1 independent. P53 knockdown prior to LPS transfection mildly 
affected the acquisition of senescence features, suggesting that the p53-p21 axis 
contributes but is not solely responsible for the senescence response following caspase-
4 activation. 
 
Inflammasome priming by addition of Pam2CSK4 did not alter cell proliferation arrest. 
However, cell proliferation arrest after LPS transfection was accompanied by a mild 
activation of IL-1b mRNA expression, which was enhanced upon addition of 
Pam2CSK4. These results suggest that inflammasome priming is necessary to activate 
inflammatory components such as IL-1 signalling within a senescence response. 
 
CASP4 knockdown by siRNA or shRNA targeting partially bypassed cell proliferation 
arrest in RASG12V-OIS, suggesting caspase-4 regulates cell proliferation in OIS. 
Moreover, further exploration of the transcriptomic data earlier presented, suggested 
that caspase-4 regulates proliferation in RASG12V-OIS by controlling the 
phosphorylation state of pRb. Caspase-4 knockdown in RASG12V-OIS did not affect the 
levels of p53 or p21, suggesting that caspase-4 regulates pRb phosphorylation state 
downstream the p53-p21 axis, as in LPS-driven senescence. Nonetheless, CDKN2A and 




Finally, overexpression of a catalytic dead mutant caspase-4 induced a similar 
phenotype to the overexpression of wild-type caspase-4, including decreased cell 
proliferation and an increase in SA-b-galactosidase activity. Moreover, overexpression 
of the catalytic dead mutant caspase-4 prior to LPS transfection significantly abrogated 
cell death, suggesting a dominant negative effect. In contrast, analysis of senescence 
markers did not show differences between WT or C258 caspase-4 overexpression prior 
to LPS-driven activation of the non-canonical inflammasome. Altogether these results 
suggest that the catalytic activity of caspase-4 is dispensable for the acquisition of 
senescent features following LPS transfection. 
 
 
Figure 4.19 Caspase-4 activation by intracellular LPS induces the acquisition of a 
senescent phenotype 
Intracellular LPS activates caspase-4 and elicits a rapid pyroptotic response. Cells surviving 
pyroptosis present senescence features such as reduced cellular proliferation and increased SA-
b-galactosidase staining. Whereas pyroptosis depends on caspase-4 cleavage of  gasdermin-D, 
the experimental results presented in this chapter suggest that the acquisition of a senescence 




















Chapter 5 -  Identification of novel interactors of 
inflammatory caspases in OIS 
 
In this chapter, a protein-protein interaction screening was performed to identify novel 
interactors of inflammatory caspases in OIS. Selected candidate proteins were then 
targeted by siRNA in OIS, and their phenotypical impact was assessed in terms of cell 
proliferation and IL-1 signalling.   
 
5.1 Characterization of the inflammatory caspase 
interactome in OIS 
 
5.1.1 BioID: protein interactome discovery by proximity biotinylation  
 
The results presented in the previous chapter suggest a role for caspase-4 in regulating 
cell proliferation independent of its catalytic activity. With the aim of targeting 
potential non-proteolytic functions of inflammatory caspases, the BioID technique, 
which allows identification of protein-protein interactions in vivo by proximity 
biotinylation, was used. Briefly, in a BioID proteomic screening, the protein of interest 
is fused to a promiscuous biotin ligase (BirA) and overexpressed in vivo. After addition 
of the substrate (biotin), the ligase will biotinylate endogenous proteins in the 
proximity, which can then be pulled-down by biotin-affinity capture (333). 
 
With the aim of applying this technique to identify potential interactors of caspase-1 
and caspase-4 in OIS, caspase-4 or caspase-1 were fused to the biotin ligase (Figure 
5.1A). For further control, two caspase-4 expression constructs were generated, one 
with the biotin ligase located prior to caspase-4 N-terminus and another with the biotin 
ligase placed after caspase-4 C-terminus. Additionally, each construct was also fused to 




of the constructs, with fusion proteins having an approximate size of 80 kDa, in 
accordance with their predicted sizes (Figure 5.1B, C).  
 
Figure 5.1 Caspase-1-BirA and caspase-4-BirA fusion constructs generated to identify 
interacting proteins by proximity biotinylation 
A. Schematic representation of the three generated constructs: CASP1 CDS fused to the biotin 
ligase (BirA) (B-C1), CASP4 cDNA fused to the biotin ligase in its N-terminus (B-C4) and Casp4 
CDS fused to the biotin ligase in its C-terminus (C4-B). B. Table indicating the reference number 
of base pairs (bp) and amino acids (aa) relative to each component of the fusion proteins. C. 
Western blotting analysis using the indicated antibodies for caspase-1 and caspase-4 detection 
in 293T cell lysates 48 h after transfection with the indicated constructs.  
 
 
5.1.2 BioID screening results  
 
IMR90 ER:STOP and ER:RAS cells were transfected with each of the three constructs 
described in the previous subheading and the empty vector control by retroviral 
infection. Three days after the addition of 4-hydroxytamoxifen, biotin was added. The 
following day, biotinylated proteins were pulled-down using streptavidin-coupled 
beads. Attached proteins were sent to the Mass Spectrometry IGMM Facility where 
identification of the biotinylated proteins was performed using mass spectrometry (Fig 
5.2). Downstream analysis was performed with the label-free quantification (LFQ) 












































































Figure 5.2 Schematic diagram of the streptavidin pull-down followed by MS analysis 
approach to detect potential inflammatory caspase interactors in OIS 
On top, a schematic representation of the screening performed to identify potential interactors 
of caspase-1 and caspase-4 in OIS. Below, IMR90 ER:STOP/ER:RAS  cells had been infected with 
the indicated vectors. 4 days after the addition of 4-hydroxytamoxifen and 22 h after biotin 
addition, cells were lysed and biotinylated proteins were pull-down with streptavidin beads. 
Western blotting was performed using the indicated antibodies for caspase-1 and caspase-4 
detection in streptavidin-pulldown samples. 
MS = Mass Spectrometry; 4OHT = 4-hydroxytamoxifen. 
 
 
To identify candidate interactors in OIS, we calculated logFC values using LFQ 
intensity values of ER:RAS + caspase-1-BirA or ER:RAS + caspase-4-BirA samples 
relative to ER:RAS + empty vector control. The same analysis was performed in non-
senescent (ER:STOP) samples. Potential interactors for each caspase were considered 
as those with logFC>2 in senescent but logFC<2 in non-senescent cells. For a more 
stringent analysis, only proteins that were enriched in both caspase-4-BirA samples 




















































































Using this approach, 83 and 72 proteins were identified as potential interactors of 
caspase-4 and caspase-1 respectively in OIS (Figure 5.3). Interestingly, there was a 
significant overlap among caspase-1 and caspase-4 potential interactors in OIS (41 
identified proteins were common candidates). For further exploration, potential 
caspase-1 and caspase-4 interactors in OIS were classified into categorical cellular 
component terms using the DAVID Bioinformatics Resources 6.8 (334). (Table 5.1). 
Both caspase-1 and caspase-4 potential interactors were mostly found in the cytosol. 
 
 
Figure 5.3 Potential interactors of caspase-1 and/or caspase-4 in OIS 
Above, a Venn diagram of the identified potential interactors of caspase-1, caspase-4 or both in 
OIS is shown. A heatmap of the logFC values of the potential candidate interactors of caspase-1 





Table 5.1 Cellular component enrichment analysis of potential interactors of caspase-1 
or caspase-4 in OIS 
The 83 and 72 respectively identified caspase-1 or caspase-4 interactor candidates in OIS were 








Cellular component enrichment analysis of caspase-4 candidate interactors in OIS:
Term Count p-value Bonferroni Benjamini FDR
GO:0005829~cytosol 45 3.0E-11 4.13E-09 4.13E-09 3.54E-08
GO:0070062~extracellular exosome 38 3.9E-09 5.30E-07 2.65E-07 4.55E-06
GO:0045335~phagocytic vesicle 4 9.4E-04 0.12 0.04 1.10
GO:0042470~melanosome 5 1.6E-03 0.19 0.05 1.84
GO:0005737~cytoplasm 39 4.0E-03 0.42 0.10 4.57
GO:0035145~exon-exon junction complex 3 5.2E-03 0.51 0.11 5.97
GO:0005739~mitochondrion 15 5.5E-03 0.53 0.10 6.31
Cellular component enrichment analysis of caspase-1 candidate interactors in OIS:
Term Count p-value Bonferroni Benjamini FDR
GO:0005829~cytosol 23 1.47E-03 0.15 0.15 1.65






















































































































































5.2 siRNA targeting of selected BioID candidates in 
OIS 
 
5.2.1 Selection of candidates from the BioID screening results  
 
In the process of canonical inflammasome activation, a key upstream signalling event 
is the interaction of caspase-1 with other proteins through the caspase recruitment 
domain (CARD) (see section 1.2.1.1). These CARD-CARD interactions occur between 
the CARD motif of caspase-1 and the CARD motif of the binding protein.  
Seven proteins with a CARD domain were identified in the mass spectrometry results 
generated from the BioID screening. Strikingly, the only CARD-containing protein 
identified as a potential interactor of both caspase-1 and caspase-4 in OIS was the 
apoptotic peptidase activating factor 1 (Apaf-1) (Figure 5.4). 
 
 
Figure 5.4 CARD-containing proteins identified in the BioID screening results analysis  
Heatmap of the logFC values of the potential candidate interactors of caspase-1 and caspase-4 
containing a CARD domain. All proteins identified by mass spectrometry were screened for 
human proteins containing a CARD domain (IPR001315; list accessible at:  
http://www.ebi.ac.uk/interpro/entry/IPR001315/taxonomy). C4-B, B-C4 and B-C1 refer to the 


























Apaf-1 is a master signalling protein of apoptosis: after detecting cytochrome C released 
from mitochondria, it forms a multimeric protein cytosolic complex called the 
apoptosome, which recruits and activates caspase-9 through CARD domain homotypic 
interactions between Apaf-1 and caspase-9 (335). Caspase-9 then activates the effector 
caspase-3, which cleaves many substrates, ultimately leading to apoptotic cell death.   
Interestingly, analysis of the BioID screening data also revealed significant potential 
interaction of cytochrome C with caspase-1 in proliferating cells and with caspase-4 in 
both proliferating and senescent cells (see Appendix). Moreover, Smac/DIABLO 
(hereafter referred as DIABLO), which promotes apoptosis by blocking the inhibitors 
of apoptosis (IAPs) proteins (336), was also detected in the screen as a candidate 
interactor protein with both caspases in OIS (Figure 5.3).  
Of note, CARD16 was enriched in caspase-1 and caspase-4 pull-down samples in 
ER:STOP samples but not in ER:RAS samples (Figure 5.4), suggesting that a potential 
interaction between CARD16 and inflammatory caspases is lost in OIS. Interestingly, 
CARD16 is a CARD-only protein (COP) that acts a negative regulator of caspase-1 and 
caspase-4 activity and inhibits IL-1b release from LPS-stimulated monocytes as well as 
prevents inflammatory caspase-mediated cell death in non-immune cells (337-339). 
The guanylate-binding protein 1 (GBP1), a protein involved in host defence, was another 
candidate interactor protein of both caspase-1 and caspase-4 identified in the BioID 
screening (Figure 5.3). Of note, GBP1 can be cleaved by caspase-1 and secreted in a 
caspase-1 dependent manner (340), is necessary for caspase-11 LPS-driven pyroptosis in 
some infection models (341) and causes mitochondrial dysfunction and senescence in 
macrophages (342). 
In light of their previously described functions, a targeted approach was conducted 
towards the potential role of Apaf-1, DIABLO, cytochrome C and GBP1 in OIS using 
siRNA. The effect of the knockdown of these genes was assessed in terms of 






5.2.2 APAF-1 regulates IL-1 signalling in OIS 
 
Efficiency of the siRNA-mediated knockdown targeting of candidates was validated by 
mRNA expression. All siRNA significantly decreased the mRNA levels of their target 
genes (Figure 5.5A).  
 
 
Figure 5.5 siRNA-targeting of APAF1, DIABLO, CYCS and GBP1 does not bypass 
proliferation arrest in OIS 
IMR90 ER:STOP/ER:RAS cells were transfected with the indicated siRNAs 0 and 3 days after 4-
hydroxytamoxifen addition. All samples were treated with 4-hydroxytamoxifen. A. APAF1, 
DIABLO, CYCS and GBP1 mRNA expression was quantified 5 days after addition of 4-
hydroxytamoxifen. Dara are shown as mean ± s.e.m, n=3, one-way ANOVA and post-hoc 
Bonferroni´s multiple comparisons test comparing to ER:STOP NTP, *p<0.05, **p<0.01, 
***p<0.01, where unstated non-significant. Data obtained in collaboration with Dr Fraser Millar. 
B. Caspase-4 was quantified 5 days after the addition of 4-hydroxytamoxifen by high-content 
analysis. Data are shown as mean ± s.e.m, n=3, one-way ANOVA and post-hoc Bonferroni´s 
multiple comparisons comparing senescent samples to ER:RAS NTP, *p<0.05, **p<0.01, 
***p<0.01, where unstated non-significant. C. BrdU incorporation was quantified 5 days after 



















































































































































the addition of 4-hydroxytamoxifen. Data are shown as mean ± s.e.m, n=3, one-way ANOVA 
and post-hoc Bonferroni´s multiple comparisons comparing senescent samples to ER:RAS NTP,  
***p<0.01, where unstated non-significant,.  
NTP = non-targeting pool. Where asterisks are not shown, comparisons are non-significant.  
 
APAF1, DIABLO, CYCS and GBP1 knockdown slightly decreased the levels of caspase-4 
in senescence (Figure 5.5B). Measurement of BrdU incorporation five days after the 
addition of 4-hydroxytamoxifen showed only a marginal increase in cellular 
proliferation when targeting APAF1 and no difference when targeting the other 
candidates. (Figure 5.5C).  
Notably, downregulation of APAF1 (but not CYCS or DIABLO) significantly decreased 
the levels of IL1A, IL1B, IL8 and IL6 mRNA expression compared to control senescent 
cells (Figure 5.6A). These substantial changes were also observed by 
immunofluorescence staining of IL-1a and IL-1b (Figure 5.7).  
 
 
Figure 5.6 IL-1 signalling is controlled by APAF1 in RASG12V-induced senescence in human 
fibroblasts 
IMR90 ER:STOP/ER:RAS cells were transfected with the indicated siRNAs 0 and 3 days after 4-
hydroxytamoxifen addition. All samples were treated with 4-hydroxytamoxifen. A. IL1A, IL1B, 
IL8 and IL6 mRNA expression was quantified 5 days after addition of 4-hydroxytamoxifen. Dar 
are shown as mean ± s.e.m, ratio paired t tests were performed comparing ER:RAS samples to 
ER:RAS NTP control, n=3, *p<0.1, **p<0.05, where unstated non-significant, Data obtained in 
collaboration with Dr Fraser Millar.  
















































































































































































Figure 5.7 IL-1a and IL-1b protein levels are significantly decreased after APAF1-targeting 
in RASG12V-OIS 
See previous page. IL-1a and IL-1b proteins levels were quantified 8 days after 4-
hydroxytamoxifen addition by high-content analysis. Data are shown as mean ± s.e.m, n=3, one-
way ANOVA and post-hoc Bonferroni´s multiple comparisons test comparing all senescent 
samples to ER:RAS NTP, *p<0.05, **p<0.01, where unstated non-significant. NTP = non-target 
pool. 
Importantly, the secretion of IL-1b was also impaired to a similar extent when knocking 
down either APAF1 of CASP1 (Figure 5.8). In all, these results suggest a prominent role 
for Apaf-1 in mediating SASP signalling independently of cytochrome C or Diablo. 
 
 
Figure 5.8 IL-1b secretion is significantly impaired after APAF1-targeting in RASG12V-OIS 
Released IL-1b was detected by ELISA 8 days after 4-hydroxytamoxifen addition. Data are shown 
as mean ± s.e.m, n=3, one-way ANOVA and post-hoc Bonferroni’s multiple comparisons 




In contrast to APAF1, GBP1 knockdown increased the mRNA levels of IL1A, IL1B, IL8 
and IL6 in OIS, suggesting that GBP1 may be a negative regulator of IL-1 signalling in 
OIS (Figure 5.6).  However, the effect of the increased translation of these genes was 
not observed at the protein level, as there were no significant changes in the protein 




























































Using a BioID proteomic approach coupled to mass spectrometry downstream analysis, 
a screening for potential interacting proteins with caspase-1 and caspase-4 in OIS was 
performed. 41 proteins were identified as potential interactors of both caspase-1 and 
caspase-4 in OIS. Moreover, 31 and 42 proteins were identified as candidate interactors 
of caspase-1 or caspase-4 respectively. Of note, there was a significant overlap among 
the identified candidate interactors of both inflammatory caspases.  
A functional validation of selected hits was conducted. SiRNA-mediated knockdown in 
OIS of selected candidates from the BioID screening results (APAF1, DIABLO, CYCS 
and GBP1) was performed and BrdU incorporation as well as SASP quantification were 
used as readouts. Although none of the targeted genes had a remarkable effect on the 
bypass of cell proliferation, strikingly, APAF1 downregulation significantly decreased 
the mRNA levels of some key SASP factors to a similar extent than CASP1 knockdown. 
Moreover, APAF1 targeting did also reduce the levels of intracellular IL-1a and IL-1b as 
well as significantly impair IL-1b release. Importantly, Apaf-1 was the only protein 
containing a CARD domain identified as a potential interactor of caspase-1 and caspase-
4 in OIS. 
In all, these results suggest a potential interaction between inflammatory caspases and 













Chapter 6 - Discussion 
 
6.1 Caspase-4 and IL-1 signalling in OIS 
 
IL-1 proinflammatory cytokines (IL-1a and IL-1b) are key apical SASP components and 
master regulators of inflammation in senescent cells (80, 100). A previous study had 
shown that IL-1 signalling and the SASP are controlled by caspase-1 in OIS (80). 
However, in this thesis, the role of caspase-4 in senescence has been investigated for 
the first time. 
 
The results here presented have unveiled a new role for caspase-4 in regulating IL-1 
signalling in a sterile context. First, a transcriptomic approach was conducted to 
interrogate the role of caspase-4 in OIS. Downstream analysis of the obtained 
transcriptomic data revealed that downregulation of caspase-4 in OIS attenuates the 
inflammatory response. A deeper exploration of these results showed that caspase-4 
targeting directly impacted on the mRNA and protein levels of different SASP 
components and, in particular, the exponential increase of IL-1b in OIS was halted. 
Nonetheless, both mature intracellular IL-1b and released IL-1b were reduced to a 
similar extent when targeting either caspase-1 or caspase-4. Altogether, these results 
suggest that the roles of the canonical and non-canonical inflammasome in regulating 
IL-1 signalling in OIS are critical and non-redundant (Figure 6.1). 
 
Caspase-4 limited the induction of the SASP in non-senescent cells to which 
conditioned media was added to a greater extent than caspase-1. This suggests 
differential roles for caspase-1 and caspase-4 in regulating the SASP. However, the 
addition of conditioned media to simulate paracrine senescence has two important 
limitations: [1] SASP content changes over time and conditioned media collected at day 
8 does not reflect earlier stage of senescence (82) and [2] addition of concentrated 
conditioned media at a certain point might overstimulate proliferating cells. To better 




perform true co-culture experiments, in which senescent and non-senescent cells are 
cultured together, either by using trans-well chambers that prevent direct contact 
between cells or fluorescent markers that allow to distinguish different cellular 
populations in co-culture (80).  
 
Noteworthy, a key mediator for the maintenance of SASP signalling is IL-1R (80), which 
recognizes both IL-1b and IL-1a. In contrast to IL-1b, IL-1a secretion has been described 
to be caspase-1 independent (273). Of note, in a model of Francisella novicida infected 
human macrophages, IL-1a release was shown to be caspase-4 dependent and caspase-
1 independent (217). It would be interesting to investigate whether caspase-4 and 
caspase-1 have a similar effect on the amount of IL-1a released from senescent cells. 
Moreover, because the SASP is a highly heterogenous phenotype (24), hypothetically, 
caspase-4 may be regulating a partially different SASP subset. In this sense, comparing 
the proteome of conditioned media of caspase-1 and caspase-4 depleted senescent cells 
could be informative.  
 
In contrast to caspase-1, caspase-4 does not cleave IL-1b directly (270). How caspase-4 
regulates IL-1b post-translationally is still under debate. It has been suggested that 
caspase-4 is an upstream regulator of caspase-1 and that direct interaction between 
caspase-1 and caspase-4 is involved in the regulatory mechanism (229, 271, 272). 
However, the results of the BioID experimental approach suggest no robust interaction 
between caspase-1 and caspase-4 in senescence (Figure 5.4), suggesting that 
inflammasome platforms that contain caspase-1 do not recruit caspase-4 and vice versa. 
 
 To date, the better characterized caspase-4 downstream mechanisms involve the direct 
cleavage of  a substrate. However, the absence of highly specific caspase inhibitors is a 
substantial limitation when investigating the role of a caspase catalytic activity, 
specially, when trying to depict the effect of a particular caspase (see section 1.2.1.1). 
One way to circumvent this obstacle involves direct targeting of the identified 
substrates. In particular, because recent discoveries have brought to light an 
indisputable key role for gasdermin-D downstream inflammatory caspases in 
pyroptosis (283-285), gasdermin-D was investigated as a potential downstream effector 




thesis shows that inflammatory caspase activity in OIS is accompanied by the cleavage 
of gasdermin-D; however, pyroptosis is not present during OIS. Taking into account 
that apoptosis resistance is one of the hallmarks of senescence, could there also exist 
mechanisms that prevent pyroptosis during senescence? Exploiting apoptosis 
resistance has been key in the development of senolytics. Therefore, it is possible that 
understanding a potential pyroptotic resistance mechanism could contribute to the 
development of new senolytic strategies. Furthermore, downregulation of gasdermin-
D in OIS marginally decreased IL-1b secretion, suggesting that IL-1b is not released 
from senescent cells through gasdermin-D-formed membrane pores, but by 
gasdermin-D independent mechanisms. 
 
Besides gasdermin-D, the other key caspase-4 substrate with a well-described role is 
the  cGMP-AMP (cGAMP) synthase (cGAS). Inflammatory caspases cleave cGAS in 
response to viral DNA and dampen cGAS-STING IFN production (209). Recently, a key 
role has also been describe for the innate immune DNA sensor cGAS in senescence: 
cGAS detects cytosolic DNA fragments in senescent cells and activates the production 
of SASP factors through the cGAS-STING pathway (97-99). Noteworthy, cGAS has been 
described to activate the non-canonical inflammasome in age-related macular 
degeneration (343). Further research on the role of cGAS both upstream and 
downstream caspase-4 activation might provide insights into non-canonical 
inflammasome signalling in senescence. 
 
Activation of caspase-1 occurs upon recruitment to a cytosolic multiprotein complex 
through CARD-CARD domain homotypic interactions (175). In contrast, caspase-4 is 
activated in the cytosol by specific lipid species (193). During this thesis research, a 
proteomic screening was conducted to identify potential inflammatory caspase 
interactors in OIS by proximity biotinylation. None of the previously described CARD-
containing caspase-1 recruiters in canonical inflammasome assembly were identified 
when analysing the list of hits of potential interactors of inflammatory caspases in OIS. 
However, one CARD-containing protein, Apaf-1, was found to be a potential interactor 
of both caspase-1 and caspase-4 specifically in OIS. Intriguingly, resembling 
inflammasome formation, Apaf-1 also forms a cytoplasmic oligomeric complex and 




Downregulation of endogenous APAF-1 in OIS resulted in a strong inhibition of the 
expression of some SASP factors and, in particular, of IL-1b levels and cellular release. 
Altogether, these results suggest that Apaf-1 interacts with caspase-1 and caspase-4 in 
OIS and activates their respective inflammasomes, thus regulating IL-1 signalling. How 
Apaf-1 is activated in OIS should be further investigated. Apoptosome formation is 
initiated by cytochrome C release from mitochondria (335); however, cytochrome C 
targeting in RASG12V did not recapitulate the regulation of IL-1 signalling observed upon 
Apaf-1 targeting. Moreover, the role of Apaf-1 in non-cell autonomous signalling has 
not been investigated in this thesis. Co-culture experiments targeting Apaf-1 could 
provide insights into whether Apaf-1 mediates non-cell autonomous senescence. 
 
 
Figure 6.1 Model for the mechanism by which inflammatory caspases regulate IL-1 
signalling in OIS 
In this hypothetical model, Apaf-1 binds either caspase-1 or caspase-4 through the homotypic 
interaction of their CARD domains. Consequently, caspase-1 and caspase-4 are activated and 
proIL-1b cleaved and released from senescent cells, together with other SASP factors that induce 
autocrine and paracrine effects. A potential role for caspase-4 in the release of IL-1a is also 



















A limitation of this study is that the potential interaction between caspase-1 or caspase-
4 and Apaf-1 in OIS has not been validated. It would be very interesting to validate the 
physical Apaf-1+caspase-1 or Apaf-1+caspase-4 interaction by means of an appropriate 
technique, for instance, a co-immunoprecipitation assay. Nonetheless, two 
independent strategies conducted in this thesis (interactome analysis by BioID + APAF-
1 siRNA-mediated targeting) support a role for Apaf-1 in regulating IL-1 signalling in 
OIS. Moreover, caspase-1, caspase-4 and Apaf-1 bear CARD domains, and these have 
been strongly linked to their interaction with other proteins and functional role in all 
cases. Finally, caspase-4 and Apaf-1 interaction has been described once previously. Hu 
et al. co-transfected 293T with different plasmids to overexpress Apaf-1 and other 
CARD-containing proteins; interestingly, caspase-4 and caspase-9 were co-
immunoprecipitated with Apaf-1, in contrast to caspase-3 (344). 
 
From a more conceptual point of view, these results suggest that an Apaf-1 – 
inflammatory caspase axis regulates an inflammatory process, and hence the classic 
apoptotic vs inflammatory functional division does not only misrepresent caspase 
functions but also other proteins in their signalling pathways. Indeed, it would be 
intriguing to explore the role of Apaf-1 in other inflammatory settings. Noteworthy, the 
apoptotic caspase-8, which has a key described role in apoptosis, can also be recruited 
to canonical inflammasomes, regulate caspase-1 activity and even, in some scenarios, 
directly cleave proIL-1b (175). Therefore caspase-4 might, in a similar way to caspase-8, 
be involved in both inflammatory and cell death processes.  
 
Two potential novel negative regulators of the SASP can be proposed from the data 
presented in Chapter 5. On the one hand, the CARD-containing protein CARD16 was 
identified as a potential interactor of caspase-1 and caspase-4 only in proliferating but 
not the counterpart senescent samples and, interestingly, several studies have 
described an inhibitory caspase-1 function for CARD16 (337, 338). On the other hand, 
GBP1, which has also been functionally linked to inflammatory caspases by others (340-
342), was identified as a potential interactor of both caspase-1 and caspase-4 only in 
senescent cells. Further GBP1 siRNA-mediated targeting in OIS resulted in increased 





































6.2 The role of caspase-4 in senescence beyond IL-1 
signalling 
 
Importantly, activation of the non-canonical inflammasome by intracellular LPS 
challenge resulted in reduced cellular proliferation whereas caspase-4 targeting in OIS 
partially bypassed cell proliferation arrest. Hence, several questions arise from the fact 
that caspase-4 regulates cell proliferation. Which is the upstream stimulus that induces 
caspase-4-dependent cell proliferation arrest? The results presented in this thesis 
suggest, that, in contrast to IL-1 signalling, APAF-1 and caspase-1 do not regulate cellular 
proliferation. Intracellular LPS in itself, which directly binds caspase-4, causes caspase-
4-dependent proliferation arrest. Noteworthy, senescent cells present an altered 
lipidome (44). An exciting hypothesis is that the change in lipid content propitiates 
specific contacts between certain endogenous lipid species and caspase-4, activating 
the non-canonical inflammasome towards proliferation regulation in OIS (Figure 6.3). 
It will be interesting to see whether in the near future novel functional interactions 
between lipids, specially of endogenous origin, and inflammatory caspases are 
described. 
 
The experimental data included in this thesis suggests that caspase-4 catalytic activity 
is not involve in the regulation of cell proliferation and its effect may be limited (if any) 
to the regulation of the SASP. Mechanistically, the data presented in this thesis shows 
that caspase-4 can partially control cell proliferation in senescence through the 
regulation of the phosphorylation state of pRb and hence the transcription of E2F target 
genes, necessary for cell cycle progression. In senescence, hypophosphorylation of pRb 
has been classically described as a downstream signalling event of the stabilization of 
p53, following DDR activation, or p16 upregulation due to INK4-ARF locus de-
repression. However, the results here presented suggest that caspase-4 regulation of 
pRb phosphorylation state is independent of the mRNA and protein levels of p53, p21 







How caspase-4 contributes to pRb hypophosphorylation requires  further research. The 
activity of CDK–cyclin complexes is necessary to phosphorylate and inactivate pRb 
(345). In senescence, a number of CDKi have been described to inhibit the activity of 
CDK-cyclin complexes (24). TGF-b has been suggested to both upregulate the mRNA 
levels of CDKN2B and promote protein stabilization of the cell cycle inhibitor p15, 
consequently preventing CDK4-cyclin D association in senescence (346). Although 
caspase-4 targeting in RASG12V-OIS did not affect the mRNA levels of CDKN2A, the 
levels of p15 protein were not analysed. Therefore, it is not possible to rule out the 
implication of p15 downstream caspase-4 (Figure 6.2).  
 
 
Figure 6.2 Potential mechanisms by which caspase-4 regulates pRb phosphorylation in 
senescence 
Caspase-4 regulates proliferation downstream p53, p21, p16 protein levels. Of note, cyclin D was 
identified as a potential interactor of caspase-4 exclusively in senescence. Therefore, one 
hypothesis is that, caspase-4 might function as a CDKi itself preventing CDK4/6-cyclin D 
association/activity. Nonetheless, caspase-4 might be regulating pRb phosphorylation by other 










Whereas p21 binds CDK-cyclin complexes, p16 prevents the association of CDK4/6 and 
cyclin D by binding  exclusively to CDK4/6 (347). Interestingly, G1/S-specific cyclin D1 
was identified as a potential interactor of caspase-4 specifically in OIS (Figure 5.3).  
Therefore, one hypothetical mechanism could be that, similarly to p16 binding to 
CDK4/6, caspase-4 sequesters cyclin-D and therefore prevents its binding to 
CDK4/CDK6 (Figure 6.2). Further studies that confirm the potential interaction of 
caspase-4 and cyclin D in senescence could provide insights into the validity of this 
hypothesis. Alternatively, the non-canonical inflammasome might regulate 
phosphorylation of pRb through an unexplored pathway during this thesis’ research 

























6.3 Concluding remarks 
 
In summary, the results described throughout this thesis suggest that caspase-4 is at 
the crossroads of cellular inflammation and cellular proliferation in senescence. 
Inflammatory caspases, potentially activated through the homotypic interaction of 
their CARD domains with Apaf-1, regulate IL-1 signalling in OIS. Nonetheless, 
intracellular LPS alone is able to elicit a senescence response through the activation of 
caspase-4. Remarkably, in both LPS-driven senescence and OIS models, caspase-4 
mediates cellular proliferation arrest through the regulation of the phosphorylation of 
pRb (Figure 6.3).  
 
 
Figure 6.3 The dual role of caspase-4 in OIS  
Schematic diagram of the model proposed for caspase-4 in senescence in regulating both IL-1 







Given the current excitement in therapeutic strategies based on senescence targeting, 
a better understanding of the complexity entailed in senescence might contribute to 
the development of therapies. In particular, elucidating the mechanisms that govern 
the SASP might be critical to the development of therapeutic strategies focused on the 
selective depletion of the SASP (161). At present, SASP targeting remains elusive 
because of the off-target effects of current SASP-targeting approaches (142, 162). Here, 
not only new insights are provided into inflammasome signalling in senescence but also 
novel SASP regulators, such as Apaf-1 have been identified. 
 
Nonetheless, recent insights into the role of caspase-4 in various cellular processes, 
including now senescence, reveal an indisputable role for this protein in numerous 
contexts that might have previously been overlooked or unexplored. The results here 
presented contribute to expand our knowledge of the non-canonical inflammasome 
and provide new insights into the biology of inflammasomes which might be relevant 
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Appendix – BioID interactome analysis 
 supplemental data 
 
Heatmap of the identified potential interactors of caspase-1 and/or caspase 4 
irrespective of RASG12V. The last two columns show cells which are coloured in green if 
a protein is considered a potential interactor of caspase-4 or caspase-1, respectively, in 
this analysis.  
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